



Australian Government

Department of Health and Ageing
Therapeutic Goods Administration

POISONS STANDARD 2007

The National Drugs and Poisons Schedule Committee, acting in accordance with their power under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989* (the Act), prepares this new Poisons Standard under the Act, in substitution for the current Poisons Standard.

Signed

DR ROHAN HAMMETT
CHAIR
NATIONAL DRUGS AND POISONS SCHEDULE COMMITTEE

Dated this 14th day of December 2007

1. Citation

This instrument is the *Poisons Standard 2007*.

2. The New Poisons Standard

(1) The Poisons Standard 2007 prepared by the National Drugs and Poisons Schedule Committee (the Committee) consists of the following:

- (a) Part 1- Standard for the Uniform Scheduling of Drugs and Poisons No. 22, published by the Committee in 2007; and
- (b) Part 2 – Standard for the Uniform Scheduling of Drugs and Poisons No. 22, Consolidated Amendment.

3. Commencement

- (1) Subject to subsection (2), the Poisons Standard 2007 commences on 1 January 2008.
- (2) Part D of Part 2 – Standard for the Uniform Scheduling of Drugs and Poisons No. 22, Consolidated Amendment, commences on 1 January 2009.

**Part 1- Standard for the
Uniform Scheduling of Drugs
and Poisons No. 22 published
by the Committee in 2007**

**STANDARD FOR THE UNIFORM SCHEDULING OF
DRUGS AND POISONS
No. 22**

Effective Date – 1 June 2007

© Commonwealth of Australia 2007

ISBN

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Australian Government available from the Attorney-General's Department. Requests and inquiries concerning reproduction and rights should be addressed to the:

Commonwealth Copyright Administration
Copyright Law Branch
Attorney-General's Department
Robert Garran Offices
National Circuit
BARTON ACT 2600

or at <http://www.ag.gov.au/cca>

Published by the Australian Government under the *Therapeutic Goods Act 1989*.

Publication approval number:

This publication is a consolidation of the amendments resulting from decisions made at meetings of the National Drugs and Poisons Schedule Committee (NDPSC) up to and including the October 2006 meeting. The basis of these amendments can be found in the 'Record of the Reasons', which can be accessed from the NDPSC website:

www.tga.gov.au/ndpsc

Further inquiries should be directed to:

The Secretary
National Drugs and Poisons Schedule Committee
PO Box 100
WODEN ACT 2606

Or by email: NDPSC@health.gov.au

Media Liaison Unit
Australian Government Department of Health and Ageing

CONTENTS

PREFACE	v
INTRODUCTION	vii
Classification	vii
Principles of Scheduling	ix
Reading the Schedules	ix
PART 1 INTERPRETATION	1
PART 2 LABELS AND CONTAINERS	10
LABELS	10
General requirements	10
Immediate wrapper	10
Primary packs and immediate containers	11
Statements of quantity, proportion or strength	18
Exemptions	20
Selected containers and measure packs	20
Ampoules, pre-filled syringes and injection vials	20
Transport containers and wrappings	21
Dispensary, industrial, laboratory and manufacturing poisons	21
Dispensed medicines	22
Gas cylinders	22
Paints	22
Camphor and naphthalene	23
Prohibitions	23
CONTAINERS	24
Containers for poisons other than Schedule 5 poisons	24
Containers for Schedule 5 poisons	25
Approved containers	26
Child-resistant closures	26
Schedule 8 poisons	29
Exemptions	29
Camphor and naphthalene	30
Prohibitions	30
PART 3 MISCELLANEOUS REGULATIONS	31
Advertising	31
Sale or supply	31
Schedule 2 poisons	31
Schedule 3 poisons	31
Schedule 4 poisons	32
Schedule 7 poisons	32
Prohibitions on sale, prescribing and possession	33
Storage	33
Dispensed medicines	33

PART 4 THE SCHEDULES	35
• Schedule 1	36
• Schedule 2	37
• Schedule 3	56
• Schedule 4	63
• Schedule 5	152
• Schedule 6	188
• Schedule 7	233
• Schedule 8	245
• Schedule 9	249
 PART 5 APPENDICES	 255
• Appendix A - General Exemptions	256
• Appendix B - Substances considered not to require control by scheduling	259
• Appendix C - Substances other than those included in Schedule 9, of such danger to health as to warrant prohibition of sale, supply and use	269
• Appendix D - Additional controls on possession or supply of poisons included in Schedule 4 or 8	272
• Appendix E - First Aid Instructions	275
• Appendix F - Warning Statements and general safety directions for poisons	294
• Appendix G - Dilute Preparations	324
• Appendix H - Schedule 3 poisons permitted to be advertised	326
• Appendix I - Uniform Paint Standard	327
• Appendix J - Conditions for availability and use of Schedule 7 poisons	329
• Appendix K - Drugs required to be labelled with a sedation warning	334
 INDEX	 337

PREFACE

The Standard for the Uniform Scheduling of Drugs and Poisons is the decisions of the National Drugs and Poisons Schedule Committee, regarding classification of drugs and poisons into Schedules for inclusion in the relevant legislation of the States and Territories. It also includes model provisions about containers and labels, and recommendations about other controls on drugs and poisons.

This document is presented with a view to promoting uniform scheduling of substances and uniform labelling and packaging requirements throughout Australia. It has no legal standing other than that given to it by relevant legislation.

INTRODUCTION

CLASSIFICATION

Drugs and poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with the relevant State or Territory Authority.

Schedule 1. [This Schedule is intentionally blank.]

Schedule 2. Pharmacy Medicine – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.

Schedule 3. Pharmacist Only Medicine – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.

Schedule 4. Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.

Schedule 5. Caution – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.

Schedule 6. Poison – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.

Schedule 7. Dangerous Poison – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply.

Schedule 8. Controlled Drug – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.

Schedule 9. Prohibited Substance – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

Availability of drugs and poisons

The purpose of classification is to group drugs and poisons into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain drugs and poisons that may be obsolete for various reasons. Also as part of the move to harmonise the Australian and New Zealand classifications many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a drug or poison in a Schedule indicates the degree of control required if it is marketed. It does not indicate:

- that the drug or poison is available; nor
- that it has been approved or is efficacious for any use that may be specified in a Schedule,

nor does it negate any obligation for registration of a therapeutic good or an agricultural or veterinary chemical containing that drug or poison.

Preparations containing poisons listed in two or more schedules.

If a preparation contains two or more poisons, the provisions relating to each of the Schedules in which those poisons are included apply.

Where it is not possible to comply both with a provision relating to one of those Schedules and with a provision relating to another of those Schedules, the provision of the more restrictive Schedule applies, unless a contrary intention is indicated in the Schedules or relevant legislation.

The Schedules listed in order of greatest to least restriction are 9, 8, 4, 7, 3, 2, 6, 5. Schedule 1 is not currently in use.

PRINCIPLES OF SCHEDULING

PRINCIPLES OF SCHEDULING

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This Standard now lists poisons in nine Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (drugs) are included in Schedules 2, 3, 4 and 8 with progression through these schedules signifying increasingly strict controls.

For agricultural, domestic and industrial poisons Schedules 5, 6 and 7 represent increasingly strict container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State/Territory Health Authorities. Although appearing as a Schedule in this Standard the method by which it is implemented in the States/Territories may vary.

Substances in products which have been considered for scheduling but have been exempted from this standard may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

Appendix C contains a list of substances or preparations, the sale, supply or use of which should be prohibited because of their known dangerous properties. It is recommended that provisions of this appendix be put into effect through inclusion of the substances in appropriate State and Territory legislation.

READING THE SCHEDULES

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are now scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are being revised and replaced by individual entries as time permits although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry these have been emphasised by printing the word “except” in bold type.

Where the schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation such as pesticide registration may apply.

Where a poison has been included in more than one Schedule the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Interpretation PART 1 [paragraph 1(2)]).

Finally, when using the Standard to determine the scheduling status of a poison it may be necessary to search each relevant Schedule as well as Appendices A, B and C and the Index. In this process if the poison is not found under its “approved name” it may be shown under a group term such as:

Group	Example
the parent acid of salts	“oxalic acid” to find sodium oxalate
the radical of a salt	“chromates” to find potassium chromate
the element	“arsenic” to find arsenic trioxide
a chemical group with similar toxicological or pharmacological activity	“hydrocarbons, liquid” to find kerosene
a pharmacological group	“anabolic steroidal agents” to find “androsterone”

PART 1 INTERPRETATION

1. (1) In this Standard, unless the contrary intention appears —

“**Animal feed premix**” means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.

“**Appropriate authority**” means:

- (a) in the Australian Capital Territory, ACT Health;
- (b) in New South Wales, the Director-General of New South Wales Health;
- (c) in Northern Territory, the Chief Health Officer of the Department of Health and Community Services;
- (d) in Queensland, the Chief Executive of Queensland Health;
- (e) in South Australia, the Chief Executive of the Department of Health;
- (f) in Tasmania, the Secretary of the Department of Health and Human Services;
- (g) in Victoria, Secretary to the Department of Human Services;
- (h) in Western Australia, the Chief Executive Officer, Department of Health.

“**Approved name**” means:

- (a) in relation to a poison that is for therapeutic use -
 - (i) the Australian Approved Name for the poison, not including synonyms, as listed in the publication entitled “Therapeutic Goods Administration Approved Terminology for Medicines”, July 1999, or its successor, published by the Therapeutic Goods Administration, Canberra; or, if the poison is not listed in that publication,
 - (ii) the international non-proprietary name recommended for the poison by the World Health Organisation; or, if no such name is recommended,
 - (iii) the English name, not including synonyms, by which the poison is described in the British Pharmacopoeia, the British Pharmaceutical Codex, the Australian Pharmaceutical Formulary and Handbook or the British Pharmacopoeia (Veterinary); or, if the poison is not described in any of those publications,

- (iv) the approved name given to the poison by the Medicines Commission of Great Britain; or, if no such name is given,
 - (v) the accepted scientific name or the name descriptive of the true nature and origin of the poison;
- (b) in relation to a poison that is not for therapeutic use
- (i) the English name recommended by the Standards Association of Australia as the common name for the poison; or, if no such name is recommended,
 - (ii) the English name given to the poison by the International Organisation for Standardisation; or, if no such name is given,
 - (iii) the English name given to the poison by the British Standards Institution; or, if no such name is given,
 - (iv) the Australian Approved Name for the poison, not including synonyms, as listed in the publication entitled “Therapeutic Goods Administration Approved Terminology for Drugs”, January 1993 (ISBN 0 644 28628 8), or its successor, published by the Australian Government Publishing Service; or, if the poison is not listed in that publication,
 - (v) the English name, not including synonyms, by which the poison is described in the British Pharmacopoeia, the British Pharmaceutical Codex, the Australian Pharmaceutical Formulary and Handbook or the British Pharmacopoeia (Veterinary); or, if the poison is not described in any of those publications,
 - (vi) the approved name given to the poison by the Medicines Commission of Great Britain; or, if no such name is given,
 - (vii) the international non-proprietary name recommended for the poison by the World Health Organisation; or, if no such name is recommended,
 - (viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

“Blood” means whole blood extracted from human donors.

“Blood components” means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

“Child-resistant closure” means:

- (a) a closure that complies with the requirements for a child-resistant closure in the Australian Standard AS1928-2001 entitled *Child-resistant packages* as specified or amended from time to time;
- (b) a closure approved by any order made under section 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or
- (c) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”.

“Child-resistant packaging” means packaging that:

- (a) complies with the requirements of the Australian Standard AS1928-2001 entitled *Child-resistant packages* as specified or amended from time to time;
- (b) is reclosable and complies with the requirements of at least one of the following standards as specified or amended from time to time.
 - (i) the International Organization for Standardization Standard ISO 8317:1989 entitled *Child-resistant packaging - Requirements and testing procedures for reclosable packages*;
 - (ii) the British Standards Institution Standard BS EN 28317:1993 entitled *Child-resistant packaging - Requirements and testing procedures for reclosable packages*;
 - (iii) the Canadian Standards Association Standard CSA Z76.1-99 entitled *Reclosable Child-Resistant Packages*;
 - (iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled *Poison prevention packaging standards* and Section 1700.20, entitled *Testing procedure for special packaging*;
- (c) is approved as child-resistant by any order made under section 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or
- (d) is in the form of blister or strip packaging in which a unit of use is individually protected until the time of release and that complies with Section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001 *Child-resistant packages*.

“Compounded” in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

“Debitterised neem seed oil” means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

“Dermal use” means application to the skin primarily for localised effect.

“Designated solvent” means the following:

acetone
 dimethylformamide
 N-(N-dodecyl)-2-pyrrolidone
 hydrocarbons, liquid
 methanol when included in Schedule 5
 methyl ethyl ketone
 methyl isoamyl ketone
 methyl isobutyl ketone
 N-methyl-2-pyrrolidone
 N-(N-octyl)-2- pyrrolidone
 phenyl methyl ketone
 styrene
 tetrachloroethylene
 1,1,1-trichloroethane

“Distributor” means a person who imports, sells or otherwise supplies a poison.

“Divided preparation” means a preparation manufactured and packed as discrete pre-measured dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

“Dosage unit” means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

“Drug” means a poison intended for human or animal therapeutic use.

“Essential oils” means products obtained from natural raw materials either by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation. For scheduling purposes it also means:

- (a) oils of equivalent composition derived through synthetic means; or
- (b) prepared mixtures of oils of equivalent composition comprising a mixture of synthetic and natural components.

“External” in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

“First Schedule Paint” means a paint containing the specified proportion of any substance in the First Schedule to Appendix I of this Standard.

“Graphic material” means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

“Height” in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

“Hemp seed oil” means the oil obtained by cold expression from the ripened fruits (seeds) of *Cannabis sativa*.

“Immediate container” includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

“Immediate wrapper” means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

“Internal use” means administration:

- (a) orally, except for topical effect in the mouth; or
- (b) for absorption and the production of a systemic effect,
 - (i) by way of a body orifice other than the mouth; or
 - (ii) parenterally, other than by application to unbroken skin.

“Label” means a statement in writing on a container of a poison.

“Main label” means, where there are two or more labels on a container or a label is divided into two or more portions:

- (a) that label or portion of the label on which the name of the product is most prominently shown and which is primarily designed to attract attention; or

- (b) where the name of the product is equally prominent on two or more labels or portions of a label, each of those labels or portions of the label on which the name of the product is equally prominent.

“Manufacturer” means a person who manufactures, produces, or packs a poison.

“Measure pack” means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

“Name and address” means the name and address, in Australia, of the manufacturer or distributor of a poison but does not include a post office, cable, telegraphic or code address. Where such manufacturer or distributor is a company incorporated in accordance with the appropriate law of any State or Territory of the Commonwealth of Australia or a firm registered under the Business Names Act of any State or Territory, the inclusion in the label of the registered name of the corporation or firm or its branch or its division and the city or town in which a registered office is situated shall be deemed to comply with the requirements.

“Non-access packaging” is packaging that complies with the requirements of Australian Standard AS4710-2001 entitled *Packages for chemicals not intended for access or contact with their contents by humans*, in relation to products that are not intended for human therapeutic use.

“Non-volatile content” in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580.

“Paint”, without limiting the ordinary meaning, includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material.

“Pesticide” means any substance or mixture of substances used or intended to be used:

- (a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or
- (b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

“Poison” means any substance or preparation included in a Schedule to this Standard.

“Primary pack” means the pack in which a poison and its immediate container or immediate wrapper or measure pack are presented for sale or supply.

“Required Advisory Statements for Medicine Labels” means the document of that name published by the Therapeutic Goods Administration on 1 July 2004, as in force from time to time.

“Restricted flow insert” means a restriction fitted, or moulded, in the neck of a container which:

- (a) cannot readily be removed from the container by manual force; and
- (b) limits the delivery of the contents to drops each of which is not more than 200 microlitres.

“Second Schedule Paint” means a paint containing the specified proportion of any substance in the Second Schedule to Appendix I of this Standard.

“Selected container” means:

- (a) an injection vial having a nominal capacity of ten millilitres or less;
- (b) a single use syringe; or
- (c) any other container for substances for therapeutic use having a nominal capacity of ten millilitres or less.

“Solid” is considered to include “powder” for the purposes of scheduling.

“Therapeutic use” means use in or in connection with:

- (a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals;
- (b) influencing, inhibiting or modifying a physiological process in human beings or animals; or
- (c) testing the susceptibility of human beings or animals to a disease or ailment.

“Third Schedule Paint” means a paint containing the specified proportion of any substance in the Third Schedule to Appendix I of this Standard.

“Tinter” means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

“Topical use” means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

“Toy” means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of fourteen years.

“Transdermal use” means application to the skin primarily for systemic effect.

“Writing” includes the visible representation or reproduction of words or figures in any form, and “to write” and “written” have corresponding meanings.

- (2) Unless the contrary intention appears a reference to a substance in a schedule or an appendix to this Standard includes:
- (a) that substance prepared from natural sources or artificially; and
 - (b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that plant or any part of that plant when packed or prepared for therapeutic use; and
 - (c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; and
 - (d) every alkaloid of the substance and every salt of such an alkaloid; and
 - (e) except where the substance is levomethorphan or levorphanol, every stereoisomer of the substance and every salt of such a stereoisomer; and
 - (f) every recombinant form of the substance; and
 - (g) a preparation or admixture containing any proportion of the substance,
- but does not include:
- (h) a preparation or product included in Appendix A, or a substance and the reason for its entry in Appendix B; or

- (i) a substance included in Appendix G at a concentration not exceeding the concentration specified in column 2 of that Appendix in respect of that substance; or
 - (j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; or
 - (k) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the current version of the *Minimum Compositional Standards (MCS) for Active Constituents* or its successor, as published by the Australian Pesticides and Veterinary Medicines Authority.
- (3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a schedule or an appendix to this Standard in respect of a substance:
- (a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and
 - (b) the expression “one per cent” means:
 - (i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or
 - (ii) in the case of a solid or semi-solid preparation, 1 gram of the substance per 100 grams of the preparation; and
 - (iii) any expression of greater or lesser percentages shall have a corresponding meaning; and
 - (c) in the case of codeine such concentration, strength or quantity is calculated as anhydrous codeine.
- (4) A reference to a boiling or distillation temperature in the schedules means that temperature at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).

PART 2

LABELS AND CONTAINERS

LABELS

2. A person must not sell or supply a poison unless it is labelled in accordance with paragraphs 3 to 19 of this Standard.

General requirements

3. Any word, expression or statement required by this Standard to be written on a label or container must be written:
 - (1) on the outside face of the label or container; and
 - (2) in the English language; and
 - (3) in durable characters; and
 - (4) in a colour or colours to provide a distinct contrast to the background colour; and
 - (5) in letters at least 1.5 millimetres in height.
4. Sub-paragraph 3(5) does not apply to a word, expression or statement on a container which has a capacity of 20 millilitres or less, or on the label of such a container if:
 - (1) an appropriate authority approves the use of smaller letters; and
 - (2) the letters are at least 1 millimetre in height.
5. The label must be printed on, or securely attached to:
 - (1) the outside of the immediate container; and
 - (2) if the immediate container is enclosed in a primary pack, the outside of that primary pack.

Immediate wrapper

6. (1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in accordance with paragraph 7 of this Standard; and
 - (2) the immediate wrapper must be conspicuously labelled with:
 - (a) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and

- (b) the approved name of the poison; and
- (c) a statement of the quantity or strength of the poison in accordance with paragraph 8.

Primary packs and immediate containers

7. (1) The primary pack and immediate container of a poison must be labelled as follows:

- (a) with the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the following table:

Schedule	Purpose	Signal words required
2	for any purpose	PHARMACY MEDICINE
3	for any purpose	PHARMACIST ONLY MEDICINE
4	for human use	PRESCRIPTION ONLY MEDICINE
4	for animal use	PRESCRIPTION ANIMAL
REMEDY		
5	for any purpose	CAUTION
6	for any purpose	POISON
7	for any purpose	DANGEROUS POISON
8	for any purpose	CONTROLLED DRUG

written:

- (i) on the first line or lines of the main label; and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least half the height of the largest letter or numeral on the label but need not be larger than:
 - (A) 6 millimetres on labels for packages having a nominal capacity of 2 litres or less; or
 - (B) 15 millimetres on labels for packages having a nominal capacity of more than 2 litres; and

(iv) if the poison:

(A) is a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail* or a statement of the principal hazard of the poison, written on that line; or

(B) is not a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on that line;

(b) if the poison is a Schedule 8 poison, with the cautionary statement –

POSSESSION WITHOUT AUTHORITY ILLEGAL

written:

(i) on a separate line or lines immediately below the signal words required by sub-paragraph 7(1)(a); and

(ii) in bold-face sanserif capital letters of uniform thickness; and

(iii) in letters at least four tenths the height of the letters used for the signal words; and

(iv) with no other statement written on the same line;

(c) with the cautionary statement –

KEEP OUT OF REACH OF CHILDREN

written:

(i) on a separate line or lines:

(A) immediately below the signal word or words required by sub-paragraph 7(1)(a); or

(B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by sub-paragraph 7(1)(b), on the line immediately below that statement; and

(ii) in bold-face sanserif capital letters of uniform thickness; and

(iii) in letters at least four tenths the height of the letters used for the signal word or words; and

- (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;
- (d) if the poison is a dry chlorinating compound containing more than 10 per cent of available chlorine, **except** for preparations certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances), with the cautionary statement –

FIRE AND EXPLOSION HAZARD

written:

- (i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least four tenths the height of the letters used for the signal word or words; and
- (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;
- (e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary statement –

BURNS SKIN AND THROAT

written:

- (i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); and
- (ii) in bold-face sanserif capital letters of uniform thickness; and
- (iii) in letters at least four tenths the height of the letters used for the signal word; and
- (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line of the main label;

- (f) if the poison is an aqueous solution of paraquat, with the cautionary statements –

**CAN KILL IF SWALLOWED
DO NOT PUT IN DRINK BOTTLES
KEEP LOCKED UP**

written:

- (i) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); and
 - (ii) in bold-face sanserif capital letters of uniform thickness; and
 - (iii) in letters at least four tenths the height of the letters used for the signal words; and
 - (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same lines of the main label;
- (g) if safety directions are required on the label by sub-paragraph 7(1)(n), with the cautionary statement –

**READ SAFETY DIRECTIONS BEFORE OPENING
OR USING**

or with the cautionary statement –

READ SAFETY DIRECTIONS

written:

- (i) on a separate line or lines;
 - (A) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by sub-paragraph 7(1)(c); or
 - (B) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and
- (ii) in bold-face sanserif capital letters of uniform thickness; and

- (iii) in letters at least four tenths the height of the letters used for the signal word or words; and
 - (iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;
- (h) if the poison meets the criteria for a ‘flammable liquid’ in the *Australian Code for the Transport of Dangerous Goods by Road or Rail*, as in force at the commencement of this Standard and as amended from time to time, with the cautionary statement –

FLAMMABLE

written on the main label in bold-face sanserif capital letters of uniform thickness, unless already present in accordance with the requirements of the *Australian Code for the Transport of Dangerous Goods by Road or Rail*;

- (i) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written on the main label in bold-face sanserif capital letters of uniform thickness;

- (j) if the poison is a Schedule 5 poison intended for any purpose other than internal or pesticidal use, with the cautionary statement –

DO NOT SWALLOW

written in sanserif capital letters on the main label or as part of the directions for use;

- (k) with the approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with paragraph 8:
 - (i) if the poison is for human therapeutic use, written in accordance with orders made under section 10(3) of the *Commonwealth Therapeutic Goods Act, 1989*; or
 - (ii) if the poison is not for human therapeutic use, written in bold-face sanserif capital letters on the main label, unless:
 - (A) a list of approved names is required; and

- (B) it is impractical to include the list on the main label; and
- (C) an appropriate authority has authorised its inclusion on another part of the label; or
- (iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table the appropriate name opposite thereto in column 2 may be used as the approved name:

TABLE

Column 1	Column 2
Alkaline salts	Alkaline salts
Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules)	Aliphatic amines or aromatic amines
Epoxy resins, liquid	Liquid epoxy resins
Hydrocarbons, liquid	Liquid hydrocarbons
Quaternary ammonium compounds	Quaternary ammonium compound(s)

- (iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25 per cent, the approved names of those solvents may be expressed as follows:
- (A) where the designated solvent is a liquid hydrocarbon as “liquid hydrocarbons”; or
- (B) where the designated solvent is a ketone as “ketones”; or
- (C) in any other case as “solvents” or “other solvents”;
- (l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, with the following expression written immediately below the approved name or the list of declared contents –

AN ANTICHOLINESTERASE COMPOUND

- (i) the requirements of sub-paragraph 7(1)(l) do not apply to:
 - (A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or
 - (B) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or
 - (C) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use;
- (m) if the poison is prepared, packed or sold for a specific purpose, with clear and adequate directions for use unless:
 - (i) the poison is included in Schedule 4 or Schedule 8; or
 - (ii) it is impractical to include such directions on the label and:
 - (A) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; and
 - (B) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; and
 - (C) the insert is enclosed in the primary pack;
- (n) if use of the poison may be harmful to the user, with appropriate safety directions (see Appendix F), grouped together as a distinct section of the label and prefaced by the words –

SAFETY DIRECTIONS

written in bold-face capital letters;

- (o) if any warning statement or statements are required for the poison (see Appendix F), with that warning statement or those statements grouped together:
 - (i) if safety directions are included on the label, immediately after the words “SAFETY DIRECTIONS”; or
 - (ii) if there are no safety directions, immediately preceding the directions for use;

(p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or Schedule 8 poison, with appropriate first aid instructions (see Appendix E):

(i) grouped together and prefaced by the words –

FIRST AID

written in bold-face capital letters; or

(ii) if a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(A) written on each immediate container as specified in sub-paragraph 7(1)(p)(i); and

(B) replaced on the primary pack with the statement –

FIRST AID: See inner packs;

(q) with the name and address of the manufacturer or distributor.

(2) For the purposes of sub-paragraph 7(1)(a)(iii) the term “largest letter or numeral” does not include:

(a) a single letter or numeral which is larger than other lettering on the label; or

(b) an affix forming part of the trade name; or

(c) in the case of a poison for therapeutic use, numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

Statements of quantity, proportion or strength

8. The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

(1) if the poison is for human therapeutic use, in the manner prescribed by orders made under section 10(3) of the Commonwealth *Therapeutic Goods Act, 1989*;

- (2) if the poison is for a purpose or purposes other than human therapeutic use and:
- (a) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;
 - (b) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;
 - (c) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;
 - (d) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
 - (e) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;
 - (f) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
 - (g) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;
- (3) if the poison is a solution of a mineral acid, the proportion of the acid may be expressed as the mass of the acid per stated mass of the preparation;
- (4) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:
- contains not more than 10 per cent (*name of the metal*); or
 - contains not more than 30 per cent (*name of the metal*); or
 - contains more than 30 per cent of (*name of the metal*);
- (5) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5 per cent of the product;
- (6) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;

- (7) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.
- (8) For the purposes of sub-paragraph 8(7) “derivative” includes alkaloid.

Exemptions

Selected containers and measure packs

9. The requirements of paragraph 7 do not apply to an immediate container that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which paragraphs 10 or 11 apply) when:
- (1) packed in a primary pack labelled in accordance with paragraph 7; and
 - (2) labelled with:
 - (a) the signal word or words, relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the table to sub-paragraph 7(1)(a); and
 - (b) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and
 - (c) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and
 - (d) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sanserif capital letters.

Ampoules, pre-filled syringes and injection vials

10. The requirements of paragraph 7 do not apply to a selected container, or an ampoule (other than an ampoule to which paragraph 11 applies) when:
- (1) packed in a primary pack labelled in accordance with paragraph 7; and
 - (2) labelled with:
 - (a) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and

(b) with the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(c) if the poison is for the treatment of animals, with the cautionary statement

—

FOR ANIMAL TREATMENT ONLY

written in sanserif capital letters.

11. The requirements of paragraph 7 do not apply to a selected container that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:

(1) packed in a primary pack labelled in accordance with paragraph 7; and

(2) the strip is labelled in accordance with paragraph 10; and

(3) the ampoule is labelled with:

(a) the approved name of the poison or the trade name of the product; and

(b) the quantity, proportion or strength of the poison in accordance with paragraph 8.

Transport containers and wrappings

12. The labelling requirements of this Standard do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

Dispensary, industrial, laboratory and manufacturing poisons

13. The labelling requirements of this Standard do not apply to a poison that:

(1) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and

(2) is labelled in accordance with the National Occupational Health and Safety Commission's *National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012 (1994)] or its successors.

Dispensed medicines

- 14.** Unless otherwise specified by regulation, the labelling requirements of this Standard do not apply to a poison for therapeutic use that:
- (1) is supplied by a medical, dental or veterinary practitioner in the ordinary course of their professional practice; or
 - (2) is supplied on and in accordance with a prescription written by a medical, dental or veterinary practitioner or any other person authorised to prescribe drugs and poisons; or
 - (3) is prepared and supplied by a pharmacist for an individual patient.

Gas cylinders

- 15.** The requirements of sub-paragraphs 7(1)(a)(iv), 7(1)(c)(iv), and 7(1)(g)(iv) do not apply to a cylinder containing a poison that is a compressed gas.

Paints

- 16.** The requirements of paragraph 7 do not apply to:
- (1) paint (other than a paint for therapeutic or cosmetic use) which:
 - (a) contains only Schedule 5 poisons; or
 - (b) is a First Schedule, Second Schedule or Third Schedule paint, that is labelled with:
 - (i) the word “WARNING”, written in bold-face sanserif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and
 - (ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sanserif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and
 - (iii) the appropriate warnings specified for the paint in Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and
 - (vi) the name and proportion of the First Schedule, Second Schedule or Third Schedule poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint.

- (2) a tinter which contains:
- (a) only Schedule 5 poisons; or
 - (b) a poison included in the First Schedule, Second Schedule or Third Schedule to Appendix I, provided that it is labelled with:
 - (i) the name and proportion of that poison, and where the poison is a metal or metal salt, the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”; and
 - (ii) if it contains more than 0.1 per cent of lead in the non-volatile content of the tinter, with:
 - (A) the word “WARNING”, written in bold-face sanserif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and
 - (B) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sanserif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and
 - (C) the warnings specified for tinters in Appendix F (see paint), written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”.

Camphor and naphthalene

- 17.** The labelling requirements of sub-paragraph 3(4) and paragraph 7 do not apply to a device that contains camphor or naphthalene in block, ball, disc or pellet form if the device:
- (1) complies with paragraph 28; and
 - (2) is sold or supplied in a primary pack labelled in accordance with paragraphs 3 and 7.

Prohibitions

- 18.** A label used in connection with any poison must not include:
- (1) any reference to this Standard, or any comment on, reference to, or explanation of any expression required by this Standard that directly or by implication contradicts, qualifies or modifies such expression; or

- (2) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by the Government or any government authority unless required by legislation; or
- (3) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or
- (4) any trade name or description that:
 - (a) represents any single constituent of a compound preparation; or
 - (b) misrepresents the composition or any property or quality of the poison; or
 - (c) gives any false or misleading indication of origin or place of manufacture of the poison.

19. A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure:

- (1) any expression required by this Standard to be written or embossed on the container or pack; or
- (2) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as appropriate.

CONTAINERS

20. A person must not sell or supply a poison unless the immediate container complies with the requirements of paragraphs 21 to 28 of this Standard.

Containers for poisons other than Schedule 5 poisons

21. If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of 2 litres or less, the container must comply with Australian Standard AS 2216 – 1997, *Packaging for Poisonous Substances* (ISBN 0 7337 1176 6) as published by Standards Australia.

21a. Notwithstanding subparagraph 21, a poison which is in Schedule 6 and is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of the Australian Standard if:

- (1) the other safety factors are not diminished; and
- (2) the container has a restricted flow insert and a child-resistant closure.

22. If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of more than 2 litres, the container must:
- (1) comply with sub-section 1.4 (General Requirements) of Australian Standard AS 2216 – 1997; and
 - (2) have the word “POISON”:
- (a) in sanserif capital letters the height of which is at least one thirty second part of the length, height or width of the container, whichever is the greatest:
 - (i) embossed; or
 - (ii) indelibly written in a colour in distinct contrast to the background colour;
 - (b) on the side or shoulder of the container.

Containers for Schedule 5 poisons

23. (1) The container in which any Schedule 5 poison is sold or supplied must:
- (a) comply with the container requirements of paragraph 21 or paragraph 22; or
 - (b) be readily distinguishable from a container in which food, wine or other beverage is sold; and
 - (i) comply with sub-section 1.4 (General Requirements) of Australian Standard AS 2216 – 1997 excluding paragraph 1.4.3;
 - (ii) be securely closed and, except when containing a preparation for use on one occasion only, be capable of being re-closed to prevent spillage of its contents; and
 - (iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.
- (2) Notwithstanding sub-paragraph 23(1), the following Schedule 5 poisons namely:
- (a) methylated spirit(s);
 - (b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;

- (c) petrol;
- (d) toluene; or
- (e) xylene,

must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less, unless the immediate container complies with the container requirements specified in paragraph 21.

Approved containers

- 24.** Notwithstanding sub-paragraphs 21, 22 and 23 a poison may be packed in a container that does not comply with the tactile identification requirements of the Australian Standard or the requirements of paragraphs 22(2) or 23(1)(iii) if:
- (1) the other safety factors are not diminished;
 - (2) the container is for a specific purpose; and
 - (3) an appropriate authority has approved the use of the container for that purpose.

Child-resistant closures

- 25.** (1) If a poison listed in column 1 of the following table is sold or supplied in a container having a nominal capacity specified for that poison in column 2 it must be closed with a child-resistant closure.

TABLE	
Column 1	Column 2
Name of the poison	Nominal capacity
Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets.	All sizes
Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels.	5 litres / kilograms or less
Alkaline salts included in Schedule 5, when packed and labelled as a food additive.	2.5 litres or less

TABLE

Column 1 Name of the poison	Column 2 Nominal capacity
Anise oil when included in Schedule 5.	200 millilitres or less
Basil oil when included in Schedule 5.	200 millilitres or less
Bay oil when included in Schedule 6.	200 millilitres or less
Cajuput oil when included in Schedule 6.	200 millilitres or less
Cassia oil when included in Schedule 5.	200 millilitres or less
Cineole when included in Schedule 6.	2 litres or less
Cinnamon bark oil when included in Schedule 5.	200 millilitres or less
Cinnamon leaf oil when included in Schedule 6.	200 millilitres or less
Clove oil when included in Schedule 6.	200 millilitres or less
Essential oils when included in Schedule 6 because of their natural camphor component.	200 millilitres or less
Ethylene glycol when included in Schedule 6.	5 litres or less
Ethylene glycol when included in Schedule 5 in preparations containing more than 50 per cent of ethylene glycol.	5 litres or less
Eucalyptus oil when included in Schedule 6.	2 litres or less
Eugenol when included in Schedule 6.	200 millilitres or less
Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid.	5 litres or less
Hydrochloric acid when included in Schedule 6.	5 litres or less

TABLE

Column 1 Name of the poison	Column 2 Nominal capacity
Marjoram oil when included in Schedule 5.	200 millilitres or less
Melaleuca oil (tea-tree oil) when included in Schedule 6.	200 millilitres or less
Methylated spirit excluding preparations or admixtures.	5 litres or less
Methyl salicylate and preparations containing more than 50 per cent of methyl salicylate.	200 millilitres or less
Nutmeg oil when included in Schedule 5.	200 millilitres or less
Oil of turpentine.	5 litres or less
Pennyroyal oil when included in Schedule 6.	200 millilitres or less
Potassium hydroxide as such.	2.5 litres or less
Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs.	5 litres or less
d-Pulegone when included in Schedule 6.	200 millilitres or less
Sage oil (Dalmatian) when included in Schedule 6.	200 millilitres or less
Sodium hydroxide as such.	2.5 litres or less
Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs.	5 litres or less
Thujone when included in Schedule 6.	200 millilitres or less
Thyme oil when included in Schedule 5.	200 millilitres or less

- (2) The manufacturer or packer of a poison must ensure that the child-resistant closure is appropriate for the container and the poison and that it retains its child-resistant properties for the expected life of the poison.

Schedule 8 poisons

25A. (1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

- (2) This paragraph does not apply to the supply of a Schedule 8 poison by a:
- (a) medical practitioner, dentist or veterinary surgeon in the practice of his or her profession;
 - (b) pharmacist on the prescription of a medical practitioner, dentist or veterinary surgeon;
 - (c) pharmacist employed at a hospital, on the written requisition of a medical practitioner, a dentist or the nurse in charge of the ward in which the Schedule 8 poison is to be used or stored; or
 - (d) nurse on the direction in writing of a medical practitioner or dentist.

Exemptions

- 26.** (1) Paragraphs 21, 22 and 23 do not apply to the immediate container of a poison prepared, packed and sold:
- (a) for human internal or animal internal use; or
 - (b) as a solid or semi-solid preparation for human external or animal external use; or
 - (c) as a paint, other than a paint for therapeutic or cosmetic use; or
 - (d) in containers having a nominal capacity of 15 millilitres or less; or
 - (e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or
 - (f) solely for dispensary, industrial, laboratory or manufacturing purposes.
- (2) Paragraph 25 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.

27. The tactile identification or embossing required by paragraphs 21, 22 or 23 of this Standard or Australian Standard AS 2216 – 1997 do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

Camphor and naphthalene

28. The container requirements of paragraph 21 do not apply to a device that contains only camphor or naphthalene in block, ball, disc or pellet form for domestic use, if the device:
- (1) in normal use, prevents removal or ingestion of its contents; and
 - (2) is incapable of reacting with the poison; and
 - (3) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and
 - (4) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.

Prohibitions

29. A person must not sell or supply camphor or naphthalene in ball, block, disc or pellet form for domestic use unless the balls, blocks, discs or pellets are enclosed in a device which prevents removal or ingestion of its contents.
30. A person must not sell or supply a poison in a container which has the name of another poison embossed or indelibly marked thereon.
31. A person must not sell any poison, drug or medicine which is for internal use or any food, drink or condiment in a container prescribed by paragraphs 21, 22 or 23 of this Standard.

PART 3

MISCELLANEOUS REGULATIONS

(It is recommended that the States and Territories implement regulations which provide controls similar to those included in this Part of the Standard.)

ADVERTISING

32. A person must not include any reference to a poison included in:

- (a) Schedule 3 unless included in Appendix H; or
- (b) Schedule 4 or Schedule 8,

of this Standard in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

33. A person must not include any reference to a substance included in Schedule 9 of this Standard in any advertisement.

SALE OR SUPPLY

Schedule 2 poisons

34. A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a medical, dental or veterinary practitioner in the lawful practice of their professions, must not sell or supply a Schedule 2 poison unless licensed to do so.

35. A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail sale unless:

- (1) he or she is carrying on the business of selling goods by retail; and
- (2) the premises from which the poison will be sold is more than 25 kilometres by the shortest practical route from the nearest pharmacy; and
- (3) he or she produces such evidence, as may be required, that he or she is a fit and proper person to be so licensed.

Schedule 3 poisons

36. A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.

37. The person who sells or supplies a Schedule 3 poison must:

- (1) provide adequate instructions for use, either written or verbal, at the time of supply or sale; and
- (2) label the container with his or her name or the name of the pharmacy and the address from which it was sold or supplied; and
- (3) if required by regulation, make a record of the transaction in a prescription book or other approved recording system.

Schedule 4 poisons

38. A person, other than a medical, dental or veterinary practitioner in the ordinary course of their professions or a pharmacist dispensing a legal prescription must not sell or supply a Schedule 4 poison.

39. Paragraph 38 does not apply to a pharmacist who sells or supplies a Schedule 4 poison, other than a poison excepted by regulation from this provision, without a prescription if:

- (1) the patient is under medical treatment with the poison and continuation of medication is essential; and
- (2) the quantity sold or supplied does not exceed 3 days medication; and
- (3) the pharmacist is satisfied that an emergency exists.

40. Paragraphs 34, 36, 37 and 38 do not apply to sale by way of wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a person licensed or otherwise authorised to possess, sell or supply such poisons.

Schedule 7 poisons

41. (1) A person must not possess or use a Schedule 7 poison for domestic or domestic garden purposes.

(2) A person must not sell or supply:

- (a) a Schedule 7 poison for domestic or domestic garden purposes; or
- (b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell; or
- (c) a Schedule 7 poison for which an authorisation to possess or use is required by sub-paragraph (3) unless the purchaser produces his or her authorisation.

- (3) A person must not possess or use any of the following Schedule 7 poisons unless he or she is authorised to do so by the appropriate authority:

Arsenic
 Cyanides
 Fluoroacetic acid
 Fluoroacetamide
 Hydrocyanic acid
 Strychnine
 Thallium.

- (4) The appropriate authority may exempt a person or a class of persons from the requirement to hold an authorisation under sub-paragraph (3) and may vary or revoke the exemption by notice in writing.

Prohibitions on sale, prescribing and possession

- 42.** A person must not:

- (1) knowingly have in his or her possession or sell, supply or use a substance listed in Appendix C of this Standard for the purpose or purposes indicated in relation to that poison in Appendix C; or
- (2) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in Appendix D paragraphs 1, 2, 3 or 4 except in accordance with the provisions indicated for that poison in Appendix D; or
- (3) knowingly have in his or her possession a poison listed in Appendix D paragraph 5 without authority.

STORAGE

- 43.** A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way that public access to advice from a pharmacist is available if required.
- 44.** A person who sells or supplies Schedule 3, Schedule 4 or Schedule 7 poisons must keep those poisons in a part of the premises to which the public does not have access.

DISPENSED MEDICINES

- 45.** A person must not supply a dispensed medicine for human use containing:
- (1) a poison for internal use listed in Appendix K unless it is clearly labelled with warning statement 39, 40 or 90 as specified in Appendix F, Part 1; or
 - (2) levocabastine, unless it is clearly labelled with warning statement 62 in Appendix F, Part 1; or

- (3) acitretin, adapalene, bexarotene, etretinate, isotretinoin, thalidomide or tretinoin:
 - (i) for oral use unless it is clearly labelled with warning statements 7, 62 and 76 in Appendix F, Part 1;
 - (ii) for topical use unless it is clearly labelled with warning statements 62 and 77 in Appendix F, Part 1; or
- (4) leflunomide unless it is clearly labelled with warning statements 7, 62 and 87 in Appendix F, Part 1; or
- (5) misoprostol unless it is clearly labelled with warning statement 53 in Appendix F, Part 1.

PART 4
THE SCHEDULES

SCHEDULE 1

This Schedule is intentionally blank.

SCHEDULE 2

(Substances marked † are listed in Appendix C)

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH₃COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

- (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or
- (b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALOXIPRIN.

AMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMOROLFINE for topical use in preparations containing 0.25 per cent or less of amorolfine **except** in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN **except**:

- (a) when included in Schedule 4, 5 or 6;
- (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:
 - (i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and
 - (ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
 - (i) packed in blister or strip packaging or in a container with a child-resistant closure;

SCHEDULE 2-continued

- (ii) in a primary pack of not more than 25 tablets or capsules, each containing 325 mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and
 - (iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
- (i) packed in blister or strip packaging or in a container with a child-resistant closure;
 - (ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and
 - (iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ATROPA BELLADONNA (belladonna):

- (a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
- (b) for oral use:
 - (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 - (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate):

- (a) for oral use:
 - (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

SCHEDULE 2-continued

- (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in preparations containing atropine sulfate when packed and labelled for the treatment of organophosphorus poisoning:
 - (i) in tablets each containing 0.6 mg or less of atropine sulfate in packs of 20 tablets; or
 - (ii) in preparations for injection each containing 0.6 mg per mL or less of atropine sulfate in packs of 5.

AZELAIC ACID in dermal preparations.

AZELASTINE in preparations for nasal use.

BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

- (a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide **except** in preparations containing 5 per cent or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

- (a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or
- (b) in preparations for the treatment of tinea pedis.

SCHEDULE 2-continued

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing brompheniramine in the bed-time dose,

except in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE **except** in preparations containing 0.5 per cent or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use.

CHLOPHEDIANOL.

CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol **except** in preparations containing 0.5 per cent or less of chlorbutol.

CHLOROFORM in preparations for therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 0.5 per cent or less of chloroform.

CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing chlorpheniramine in the bed-time dose,

except in preparations for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use containing 2 per cent or less of ciclopirox **except** in preparations for dermal use for the treatment of tinea pedis.

SCHEDULE 2-continued

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

CODEINE when:

- (a) compounded:
 - (i) with a single non-opiate analgesic substance in tablets or capsules each containing 10 mg or less of codeine when:
 - (A) packed in blister or strip packaging or in a container with a child-resistant closure; and
 - (B) in a primary package containing 25 or less dosage units; or
 - (ii) with a single non-opiate analgesic substance in individually wrapped powders containing 10 mg or less of codeine when in a primary pack containing 25 or less dosage units; or
 - (iii) with one or more other therapeutically active substances:
 - (A) in divided preparations each containing 10 mg or less of codeine; or
 - (B) in undivided preparations containing 0.25 per cent or less of codeine; and
- (b) labelled with a recommended daily dose not exceeding 60 mg of codeine.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

SCHEDULE 2-continued

- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except for smoking or burning.

DATURA TATULA (stramonium) for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except for smoking or burning.

DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2 per cent or less of *Delphinium staphisagria*.

DESLORATADINE in preparations for oral use.

DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing dexchlorpheniramine in the bed-time dose,

except in preparations for the treatment of children under 2 years of age.

SCHEDULE 2-continued

DEXTROMETHORPHAN when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DICLOFENAC in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac.

DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:

- (a) containing 5 mg or less of dihydrocodeine per dosage unit;
- (b) packed in blister or strip packaging or in a container with a child-resistant closure;
- (c) enclosed in primary packs containing 25 or less dosage units; and
- (d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.

DIMENHYDRINATE in primary packs of 10 doses or less, for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

- (a) in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
- (b) when combined with one or more other therapeutically active substances when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing diphenhydramine in the bed-time dose,

except in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

SCHEDULE 2-continued

- (b) in a day-night pack containing doxylamine in the bed-time dose,
except in preparations for the treatment of children under 2 years of age.

DUBOISIA LEICHHARDTII for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.

ETAFEDRINE.

ETHER for therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 10 per cent or less of ether.

ETHYLMORPHINE when:

- (a) compounded with one or more other therapeutically active substances:
- (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or
- (ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine; and
- (b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

SCHEDULE 2-continued

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use.

FLUORIDES for human use (**except** in preparations containing 15 mg/kg or 15 mg/L or less of fluoride ion):

- (a) as sodium fluoride, in preparations for ingestion containing 2.2 mg or less of sodium fluoride per dosage unit; or
- (b) in preparations for topical use containing 2.5 per cent or less of fluoride ion **except**:
 - (i) when included in Schedule 3;
 - (ii) dental hygiene, whitening or bleaching products that are pastes, powders or gels for use on teeth, containing 1000 mg/kg or less of fluoride ion;
 - (iii) other dental hygiene, whitening or bleaching products that are therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
 - (iv) other dental hygiene, whitening or bleaching products that are not therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure and labelled with warnings to the following effect:
 - (A) Do not swallow; and
 - (B) Do not use [this product/name of product] in children six years of age or less.

FLURBIPROFEN in divided preparations for topical oral use containing 10 mg or less of flurbiprofen per dosage unit.

SCHEDULE 2-continued

FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except** in preparations containing 5 per cent or less of formaldehyde.

GELSEMIUM SEMPERVIRENS.

GLUTARALDEHYDE for human therapeutic use.

GLYCERYL TRINITRATE **except** when included in Schedule 3 or 4.

HEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane **except**:

- (a) in preparations containing 0.75 per cent or less of hexachlorophane; or
- (b) in preparations for use on infants, as specified in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for dermal use containing 0.5 per cent or less of hydrocortisone in packs containing 30 g or less of such preparations containing:

- (a) no other therapeutically active substance; or
- (b) an antifungal as the only other therapeutically active substance.

HYDROQUINONE (excluding monobenzene and other alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone **except** hair preparations containing 1 per cent or less of hydroquinone.

SCHEDULE 2-continued

8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1 per cent or less of such substances.

HYOSCINE (excluding hyoscine butylbromide):

- (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
- (b) for oral use:
 - (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 - (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE:

- (a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
- (b) for oral use:
 - (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 - (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.

SCHEDULE 2-continued

HYOSCYAMUS NIGER for oral use:

- (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
- (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

except in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:

- (a) in liquid preparations when sold in the manufacturer's original pack containing 4 grams or less of ibuprofen; or
- (b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:
 - (i) as the only therapeutically active constituent other than an effervescent agent;
 - (ii) packed in blister or strip packaging or in a container with a child-resistant closure;
 - (iii) in a primary pack containing not more than 25 dosage units;
 - (iv) not labelled for the treatment of children 6 years of age or less; and
 - (v) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

INDANAZOLINE.

INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.

IODINE:

- (a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
- (b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors).

SCHEDULE 2-continued

IPRATROPIUM in preparations for nasal use.

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use **except**:

- (a) when included in Schedule 4; or
- (b) when labelled with a recommended daily dose of 24 mg or less of iron:
 - (i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or
 - (ii) in divided preparations:
 - (A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
 - (B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

KETOCONAZOLE in preparations for dermal use **except**:

- (a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
- (b) in preparations for the treatment of tinea pedis.

LEVOCABASTINE in topical eye or nasal preparations.

LIGNOCAINE in preparations for topical use other than eye drops:

- (a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.

SCHEDULE 2-continued

LITHIUM in preparations for dermal use containing 1 per cent or less of lithium
except:

- (a) when present as an excipient at 0.25 per cent or less of lithium; or
- (b) in preparations containing 0.01 per cent or less of lithium.

LOBELIA INFLATA **except** for smoking or burning.

LOBELINE **except** in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in preparations for oral use in packs of 20 dosage units or less.

LORATADINE in preparations for oral use.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclizine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCURY for external use in preparations containing 0.5 per cent or less of mercury.

METHOXAMINE **except:**

- (a) when included in Schedule 4; or
- (b) in preparations for external use containing 1 per cent or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails
except in preparations for the treatment of tinea pedis.

MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.

SCHEDULE 2-continued

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NICOTINE for use as an aid in withdrawal from tobacco smoking in preparations for inhalation.

NIZATIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

PAPAVERINE **except** when included in Schedule 4.

PARACETAMOL for therapeutic use **except**:

- (a) when included in Schedule 4;
- (b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent other than effervescent agents when:
 - (i) enclosed in a primary pack that contains not more than 12 such powders or sachets of granules;
 - (ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; and
 - (iii) not labelled for the treatment of children 6 years of age or less; or

SCHEDULE 2-continued

- (c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent other than effervescent agents when:
- (i) packed in blister or strip packaging or in a container with a child-resistant closure;
 - (ii) in a primary pack containing not more than 25 tablets or capsules;
 - (iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; and
 - (iv) not labelled for the treatment of children 6 years of age or less.

PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except** in preparations containing 5 per cent or less of formaldehyde.

PENCICLOVIR for external use for the treatment of *Herpes labialis*.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

- (a) in eye drops; or
- (b) when combined with one or more other therapeutically active substances in oral preparations when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing pheniramine in the bed-time dose,

except in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

- (a) when included in Schedule 4; or
- (b) in preparations for external use containing 3 per cent or less of such substances.

SCHEDULE 2-continued**PHENYLEPHRINE except:**

- (a) when included in Schedule 4;
- (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or
- (c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.

PHOLCODINE:

- (a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
- (b) when compounded with one or more other therapeutically active substances, in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10 per cent or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

- (a) in a primary pack containing 10 dosage units or less, for the prevention or treatment of motion sickness; or

SCHEDULE 2-continued

- (b) when combined with one or more other therapeutically active substances when:
- (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing promethazine in the bed-time dose,

except in preparations for the treatment of children under 2 years of age.

PYRANTEL for human therapeutic use.

PYRITHIONE ZINC for human therapeutic use, **except**:

- (a) in semi-solid hair preparations; or
- (b) in shampoos containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

RANITIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.

SALICYLAMIDE **except** when included in Schedule 4.

SELENIUM in preparations for human topical therapeutic use **except** in preparations containing 3.5 per cent or less of selenium sulfide.

SILVER for therapeutic use **except**:

- (a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (b) in other preparations containing 1 per cent or less of silver.

SODIUM CROMOGLYATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

SQUILL **except** in preparations containing 1 per cent or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis.

SCHEDULE 2-continued

TETRACHLOROETHYLENE for human therapeutic use.

TETRAHYDROZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use **except** in preparations for the treatment of tinea pedis.

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing trimeprazine in the bed-time dose, **except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing triprolidine in the bed-time dose, **except** in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use **except** in preparations containing 5 per cent or less of zinc chloride.

SCHEDULE 3

ADRENALINE in preparations containing 1 per cent or less of adrenaline **except** in preparations containing 0.02 per cent or less of adrenaline.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.

AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.

AMOROLFINE for topical use **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of tinea pedis.

AZATADINE in oral preparations.

AZELASTINE in topical eye preparations containing 0.05 per cent or less of azelastine.

BROMPHENIRAMINE in oral preparations **except** when included in Schedule 2.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CHLORBUTOL in preparations for human use **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 0.5 per cent or less of chlorbutol.

CHLORPHENIRAMINE in oral preparations **except** when included in Schedule 2.

CICLOPIROX in preparations for dermal use **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of tinea pedis.

CIMETIDINE in a primary pack containing not more than 14 days supply.

CLEMASTINE in preparations for oral use.

SCHEDULE 3-continued

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CODEINE when compounded with:

- (a) a single non-opiate analgesic substance in divided preparations containing 10 mg or less of codeine per dosage unit and with a recommended daily dose not exceeding 60 mg of codeine; or
- (b) paracetamol in divided preparations containing 12 mg or less of codeine per dosage unit and with a recommended daily dose greater than 60 mg but not exceeding 100 mg of codeine when:
 - (i) packed in blister or strip packaging or in a container with a child-resistant closure; and
 - (ii) in a primary pack containing 12 or less dosage units,

except when included in Schedule 2.

CYCLIZINE in preparations for oral use.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENIRAMINE in oral preparations **except** when included in Schedule 2.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
- (b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,

except when included in Schedule 2.

SCHEDULE 3-continued

DI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations **except** when included in Schedule 2.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations **except** when included in Schedule 2.

ECONAZOLE in preparations for vaginal use.

ERYTHRITYL TETRANITRATE for therapeutic use.

FLAVOXATE.

FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES in dental hygiene, whitening or bleaching products that are pastes, powders or gels for use on teeth, containing more than 1000 mg/kg of fluoride ion.

GLUCAGON.

GLYCERYL TRINITRATE in oral preparations.

GLYCOPYRRONIUM **except** when included in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations containing 1 per cent or less of hydrocortisone:

- (a) for dermal use, in packs containing 30 g or less of such preparations; and
 - (i) containing no other therapeutically active substance; or
 - (ii) containing an antifungal but no other therapeutically active substance; or
- (b) for rectal use, when combined with a local anaesthetic but no other therapeutically active substance **except** unscheduled astringents:

SCHEDULE 3-continued

- (i) in undivided preparations, in packs of 35 grams or less; or
- (ii) in packs containing 12 or less suppositories,

except when included in Schedule 2.

IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units when labelled:

- (a) with a recommended daily dose of 1200 mg or less of ibuprofen; and
- (b) not for the treatment of children under 12 years of age,

except when included in or expressly excluded from Schedule 2.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.

LEVONORGESTREL for emergency post-coital contraception.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MALATHION in preparations for human external use **except** in preparations containing 2 per cent or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

SCHEDULE 3-continued

MICONAZOLE for human use in topical preparations:

- (a) for the treatment of oral candidiasis; or
- (b) for vaginal use.

NICOTINIC ACID for human therapeutic use in dosage preparations containing 250 mg or less of nicotinic acid **except**:

- (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
- (b) nicotinamide.

NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotiny alcohol per dosage unit.

NYSTATIN in preparations for topical use **except** when included in Schedule 2.

ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PHENIRAMINE in oral preparations **except** when included in Schedule 2.

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations **except** when included in Schedule 2.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:

- (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or

SCHEDULE 3-continued

- (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

SALBUTAMOL as the only therapeutically active substance:

- (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
- (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use **except** in preparations containing 40 per cent or less of salicylic acid.

SANTONIN.

SELENIUM in preparations for human oral use with a recommended daily dose of 100 micrograms or less of selenium **except** where the sum of the organic selenium expressed in micrograms and half the inorganic selenium expressed in micrograms, contained in the recommended daily dose of the preparation, does not exceed 26 micrograms.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.

TERBUTALINE as the only therapeutically active substance:

- (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or
- (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.

TIOCONAZOLE in preparations for vaginal use.

TRANEXAMIC ACID for the treatment of menorrhagia.

SCHEDULE 3-continued

TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

TRIMEPRAZINE:

- (a) in solid oral preparations **except** when included in Schedule 2; or
- (b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL.

TRIPROLIDINE in oral preparations **except** when included in Schedule 2.

SCHEDULE 4

(Substances marked † are listed in Appendix C)

(Substances marked # are listed in Appendix D)

ABACAVIR.

ABCIXIMAB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYL ISOVALERYLTYSIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR **except** in preparations containing 5 per cent or less of aciclovir for the treatment of *Herpes labialis* in packs containing 10 g or less.

SCHEDULE 4-continued

ACIPIMOX.

ACITRETIN.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. **except:**

- (a) when included in Schedule 2;
- (b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or
- (c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRENALINE **except:**

- (a) when included in Schedule 3; or
- (b) in preparations containing 0.02 per cent or less of adrenaline.

ADRENOCORTICAL HORMONES **except** when separately specified in these Schedules.

AGALSIDASE.

AGLEPRISTONE.

ALATROFLOXACIN MESYLATE.

SCHEDULE 4-continuedALBENDAZOLE **except**:

- (a) when included in Schedule 5 or 6; or
- (b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE **except** when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

ALLERGENS.

ALLOPURINOL.

ALLYLOESTRENOL.

ALOSETRON.

ALPHADOLONE.

ALPHAXALONE.

ALPRAZOLAM.

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

SCHEDULE 4-continued

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

AMCINONIDE.

AMETHOCAINE **except:**

- (a) when included in Schedule 2; or
- (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

AMINOMETRADINE.

† AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE **except** when included in Schedule 3.

AMINOPTERIN.

4-AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

SCHEDULE 4-continued

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMODIAQUINE.

AMOROLFINE **except:**

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXYCILLIN.

AMPHOMYCIN.

AMPHOTERICIN.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE.

AMYLOBARBITONE when packed and labelled for injection.

AMYLOCAINE.

ANABOLIC STEROIDAL AGENTS.

ANAGRELIDE.

SCHEDULE 4-continued

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANECORTAVE.

ANDROGENIC STEROIDAL AGENTS.

ANDROISOXAZOLE.

ANDROSTANOLONE.

ANDROSTENEDIOL.

ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANISTREPLASE.

ANTAZOLINE **except** when included in Schedule 2.

ANTIBIOTIC SUBSTANCES **except**:

- (a) when separately specified in these Schedules; or
- (b) nisin.

ANTIGENS for human therapeutic use **except** when separately specified in this Schedule.

ANTI-HISTAMINES **except**:

- (a) when included in Schedule 2 or 3; or
- (b) when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

APOCYNUM spp.

SCHEDULE 4-continued

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREPITANT.

APRONAL.

APROTININ.

ARECOLINE.

ARIPIRAZOLE.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules.

ARTEMETHER.

ARTICAINE.

ASPIRIN:

- (a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or
- (b) for injection.

ASTEMIZOLE.

ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

ATOVAQUONE.

SCHEDULE 4-continued

ATRACURIUM BESYLATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVILAMYCIN **except**:

- (a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or
- (b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE **except** when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 1 per cent or less of azelaic acid for non-human use.

AZELASTINE **except** when included in Schedule 2 or 3.

SCHEDULE 4-continued

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) **except**:

- (a) when included in Schedule 6; or
- (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

BAMETHAN.

BAMIPINE.

BARBITURATES **except** when separately specified in these Schedules.

BASILIXIMAB.

BECAPLERMIN.

BECLAMIDE.

BECLOMETHASONE **except** when included in Schedule 2.

BEMEGRIDE.

BENACTYZINE.

BENZAEPRIIL.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

SCHEDULE 4-continued

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZHEXOL.

BENZILONIUM.

BENZOCAINE **except**:

- (a) when included in Schedule 2;
- (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZTROPINE (benzatropine).

BENZYDAMINE **except** when included in Schedule 2.

BENZYL PENICILLIN.

BEPRIDIL.

BERACTANT.

BETAHISTINE.

SCHEDULE 4-continued

BETAMETHASONE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

BEXAROTENE.

BEZAFIBRATE.

BICALUTAMIDE.

BIFONAZOLE **except:**

- (a) when included in Schedule 2;
- (b) in preparations for dermal use containing 1 per cent or less of bifoconazole for the treatment of the scalp; or
- (c) in preparations for dermal use for the treatment of tinea pedis.

BIMATOPROST.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, **except:**

- (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per cent or less; or
- (b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

SCHEDULE 4-continued

BOLANDIOL.

BOLASTERONE.

BOLAZINE.

BOLDENONE (dehydrotestosterone).

BOLENOL.

BOLMANTALATE.

BORON for human therapeutic use (excluding when present as an excipient):

- (a) in preparations for internal use containing more than 3 milligrams per recommended daily dose;
- (b) in glycerines and honeys of borax or boric acid;
- (c) in preparations for vaginal use;
- (d) in preparations for paediatric dermal use, being:
 - (i) dusting powders; or
 - (ii) other preparations containing more than 0.35 per cent of boron; or
- (e) in other preparations for dermal use containing more than 0.35 per cent of boron **except** antifungal preparations.

BORTEZOMIB.

BOSENTAN.

BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.

BRETYLIUM TOSYLATE.

BRIMONIDINE.

BRINZOLAMIDE.

BROMAZEPAM.

SCHEDULE 4-continued

BROMIDES, inorganic, for therapeutic use **except** when separately specified in these Schedules.

BROMOCRIPTINE.

BROMOFORM for therapeutic use.

BROMPHENIRAMINE **except** when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE **except** when included in Schedule 3.

BUDESONIDE **except** when included in Schedule 2.

BUFEXAMAC **except**:

- (a) in preparations for dermal use containing 5 per cent or less of bufexamac;
or
- (b) in suppositories.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTOCONAZOLE **except** when included in Schedule 3.

BUTRACONAZOLE.

BUTYL AMINOBENZOATE **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

SCHEDULE 4-continued

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABERGOLINE.

CALCIPOTRIOL.

CALCITONIN.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTI-SERUM.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

SCHEDULE 4-continued

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARINDACILLIN.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASPOFUNGIN.

CATHINE.

CEFACETRILE.

CEFACLOR.

SCHEDULE 4-continued

CEFADROXIL.

CEFALORIDINE.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFSULODIN.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

SCHEDULE 4-continued

CELECOXIB.

CELIPROLOL.

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2 per cent or less of emetine.

CEPHAELIS IPECACUANHA **except** in preparations containing 0.2 per cent or less of emetine.

CEPHALEXIN.

CEPHALONIUM.

CEPHALOTHIN.

CEPHRADINE.

CERIVASTATIN.

CERULETIDE.

CETIRIZINE **except** when included in Schedule 2.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE **except** in preparations for topical use containing 2 per cent or less of chloral hydrate.

CHLORALOSE **except** when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL.

CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

SCHEDULE 4-continued

CHLORDIAZEPOXIDE.

CHLORMERODRIN.

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

4-CHLOROMETHANDIENONE.

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

#CHLOROXYDIENONE.

CHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

CHLORTETRACYCLINE **except** when included in Schedule 5.

CHLORTHALIDONE.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLESTYRAMINE (colestyramine) for human therapeutic use.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

SCHEDULE 4-continued

CICLESONIDE.

CICLOPIROX **except** when included in Schedule 2 or 3.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CIMETIDINE **except** when included in Schedule 3.

CINACALCET.

CINCHOCAINE **except** when included in Schedule 2.

CINOXACIN.

CIPROFLOXACIN.

CISAPRIDE.

CISATRACURIUM BESYLATE.

CISPLATIN.

CITALOPRAM.

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLAVULANIC ACID.

CLEMASTINE **except** when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

SCHEDULE 4-continued

† CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use **except** when separately specified in this Schedule.

CLOBAZAM.

CLOBETASOL.

CLOBETASONE (clobetasone-17-butyrate) **except** when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

CLOMIPHENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

CLOSTEBOL (4-chlorotestosterone).

CLOTRIMAZOLE **except**:

- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

SCHEDULE 4-continued

CLOXACILLIN.

CLOZAPINE.

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.

CODEINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
- (b) in undivided preparations containing 1 per cent or less of codeine,

except when included in Schedule 2 or 3.

CO-DERGOCRINE.

COLASPASE.

COLCHICINE.

COLCHICUM AUTUMNALE.

COLESTIPOL.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

- (a) for tissue augmentation; or
- (b) for cosmetic use.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use **except**:

- (a) when separately specified in these Schedules;
- (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
- (c) in other preparations containing 5 per cent or less of copper compounds.

SCHEDULE 4-continued

CORONILLA spp.

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

CO-TRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CRYSTAL VIOLET for human use **except** when used as a dermal marker.

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE **except** when included in Schedule 3.

CYCLOBENZAPRINE.

CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOSPORIN.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE **except** when included in Schedule 3.

SCHEDULE 4-continued

CYPROTERONE.

CYSTEAMINE for human therapeutic use.

CYTARABINE.

DACARBAZINE.

DACLIZUMAB.

DACTINOMYCIN.

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

DANAZOL.

DANTHRON for human use.

DANTROLENE.

DAPSONE.

DARBEPOETIN.

DARIFENACIN.

DATURA spp. **except:**

- (a) when included in Schedule 2; or
- (b) when separately specified in this Schedule.

DATURA STRAMONIUM (stramonium) **except:**

- (a) when included in Schedule 2; or
- (b) for smoking or burning.

DATURA TATULA (stramonium) **except:**

- (a) when included in Schedule 2; or
- (b) for smoking or burning.

SCHEDULE 4-continued

DAUNORUBICIN.

DEANOL.

DEBRISOQUINE.

DECAMETHONIUM.

DEFERASIROX.

DEFERIPRONE.

DEFLAZACORT.

DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE (includes delavirdine mesylate).

DEMBREXINE **except** when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DEOXYCORTONE.

DEOXYRIBONUCLEASE **except**:

(a) when separately specified in this Schedule; or

(b) for external use.

DERACOXIB.

DEFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE **except** when included in Schedule 2.

SCHEDULE 4-continued

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DETOMIDINE.

DEXAMETHASONE.

DEXCHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

DEXFENFLURAMINE.

DEXMEDETOMIDINE.

DEXTROMETHORPHAN **except** when included in Schedule 2.

DEXTROPROPOXYPHENE:

- (a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
- (b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.

DEXTRORPHAN.

DIAMTHAZOLE.

DIAVERIDINE.

DIAZEPAM.

DIAZOXIDE.

DIBENZEPIN.

DIBOTERMIN.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

SCHEDULE 4-continued

DICHLORPHENAMIDE.

DICLOFENAC **except:**

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for dermal use.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENOESTROL.

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

SCHEDULE 4-continued

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine,

except when included in Schedule 2 or 3.

DIHYDROERGOTOXINE.

DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

† DI-iodohydroxyquinoline (iodoquinol) **except**:

- (a) when included in Schedule 3; or
- (b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE **except** when included in Schedule 2 or 3.

DIMERCAPROL.

#DIMETHANDROSTANOLONE.

DIMETHAZINE.

DIMETHINDENE **except** when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL SULFOXIDE for therapeutic use **except**:

- (a) when included in Schedule 6; or
- (b) in in-vitro test kits.

SCHEDULE 4-continued

DIMETRIDAZOLE.

2,4-DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

#DINOPROST.

DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use.

DIPHENHYDRAMINE **except** when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHThERIA TOXOID.

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

SCHEDULE 4-continued

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORNASE.

DORZOLAMIDE.

DOTHIEPIN.

DOXANTRAZOLE.

DOXAPRAM.

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE **except** when included in Schedule 2 or 3.

DROPERIDOL.

DROSPIRENONE.

SCHEDULE 4-continued

DROSTANOLONE.

DROTECOGIN.

DUBOISIA LEICHHARDTII **except** when included in Schedule 2.

DUBOISIA MYOPOROIDES **except** when included in Schedule 2.

DULOXETINE.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE **except:**

- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

EDETIC ACID for human therapeutic use **except:**

- (a) in preparations containing 0.25 per cent or less of edetic acid;
- (b) as dicobalt edetate in preparations for the treatment of cyanide poisoning;
or
- (c) in contact lens preparations.

EDOXUDINE.

EDROPHONIUM.

EFALIZUMAB.

EFAVIRENZ.

EFLORNITHINE.

ELETRIPTAN.

ELTENAC.

SCHEDULE 4-continued

EMEPRONIUM.

EMETINE **except** in preparations containing 0.2 per cent or less of emetine.

EMTRICITABINE.

ENALAPRIL.

ENESTEBOL.

ENFLURANE for therapeutic use.

ENFUVRTIDE.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

EPHEDRA spp. **except** in preparations containing 0.001 per cent or less of ephedrine.

EPHEDRINE.

EPICILLIN.

EPINASTINE.

EPIRUBICIN.

EPITIOSTANOL.

EPLERENONE.

#EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

SCHEDULE 4-continued

EPTIFIBATIDE.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERLOTINIB.

ERTAPENEM.

ERYSIMUM spp.

ERYTHROMYCIN.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in these Schedules.

ESCITALOPRAM.

ESMOLOL.

ESOMEPRAZOLE.

ESTRAMUSTINE.

ESTROPIPATE (piperazine oestrone sulfate).

ETANERCEPT.

ETHACRYNIC ACID.

ETHAMBUTOL.

ETHAMIVAN.

ETHANOLAMINE in preparations for injection.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

SCHEDULE 4-continued

ETHINYLOESTRADIOL.

ETHIONAMIDE.

ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

ETHYLDIENOLONE.

ETHYLHEXANEDIOL.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

- (a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
- (b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine,

except when included in Schedule 2.

ETHYLOESTRENOL.

ETHYNODIOL.

ETIDOCAINE.

ETIDRONIC ACID (includes disodium etidronate):

- (a) for internal use; or
- (b) in topical preparations **except** in preparations containing 1 per cent or less of etidronic acid.

SCHEDULE 4-continued

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE **except** when included in Schedule 2.

ETONOGESTREL.

ETOPOSIDE.

ETORICOXIB.

ETRETINATE.

EVEROLIMUS.

EXEMESTANE.

EZETIMIBE.

FAMCICLOVIR.

FAMOTIDINE **except** when included in Schedule 2.

FELBINAC **except** when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

SCHEDULE 4-continued

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FEXOFENADINE **except** when included in Schedule 2.

FIBRINOLYSIN **except** for external use.

FILGRASTIM.

FINASTERIDE.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

FLUCONAZOLE **except** when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETHASONE.

FLUMETHIAZIDE.

SCHEDULE 4-continued

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use **except:**

- (a) when included in Schedule 2 or 3;
- (b) dental hygiene, whitening or bleaching products that are pastes, powders or gels for use on teeth, containing 1000 mg/kg or less of fluoride ion;
- (c) other dental hygiene, whitening or bleaching products that are therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- d) other dental hygiene, whitening or bleaching products that are not therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure and labelled with warnings to the following effect:
 - (i) Do not swallow; and
 - (ii) Do not use [this product/name of product] in children six years of age or less; or
- (e) other preparations containing 15 mg/kg or 15 mg/L or less of fluoride ion.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

FLUOXYMESTERONE.

SCHEDULE 4-continued

FLUPENTHIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURANDRENOLONE.

FLURAZEPAM.

FLURBIPROFEN **except** when included in Schedule 2.

FLUROXENE for human therapeutic use.

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE **except** when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLE-STIMULATING HORMONE **except** when separately specified in this
Schedule.

FOLLITROPIN ALPHA.

FOLLITROPIN BETA.

FOMIVIRSEN.

FONDAPARINUX.

FORMEBOLONE.

FORMESTANE.

FORMOTEROL.

FOSAMPRENAVIR.

SCHEDULE 4-continued

FOSCARNET.

FOSFESTROL (diethylstilboestrol diphosphate).

FOSINOPRIL.

FOSPHENYTOIN.

FOTEMUSTINE.

FRAMYCETIN.

FRUSEMIDE.

FULVESTRANT.

FURALTADONE.

FURAZABOL.

FURAZOLIDONE.

FUSIDIC ACID.

GABAPENTIN.

GALANTAMINE.

GALANTHUS spp.

GALLAMINE.

GANCICLOVIR.

GANIRELIX.

GATIFLOXACIN.

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

SCHEDULE 4-continued

GENTAMICIN.

GESTODENE.

GESTONORONE.

GESTRINONE.

GITALIN.

GLATIRAMER ACETATE.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLISOXEPIDE.

GLUTATHIONE for parenteral use.

GLUTETHIMIDE.

GLYCERYL TRINITRATE:

- (a) in preparations for injection; or
- (b) in transdermal preparations for the treatment of angina.

GLYCOPYRRONIUM in preparations for injection.

GLYMIDINE.

GnRH VACCINE.

GONADORELIN.

GONADOTROPHIC HORMONES **except** when separately specified in this Schedule.

GOSERELIN.

SCHEDULE 4-continued

GRAMICIDIN.

GRANISETRON.

GREPAFLOXACIN.

GRISEOFULVIN.

GUAIPHENESIN for human therapeutic use **except**:

- (a) in oral liquid preparations containing 2 per cent or less of guaiphenesin;
or
- (b) in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

GUANIDINE.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (Hemerocallis flava).

HEPARINS for internal use **except** when separately specified in this Schedule.

SCHEDULE 4-continued

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

HEXACHLOROPHANE:

- (a) in preparations for use on infants; or
- (b) in other preparations **except**:
 - (i) when included in Schedule 2 or 6; or
 - (ii) in preparations containing 0.75 per cent or less of hexachlorophane.

HEXAMETHONIUM.

HEXETIDINE for human internal use.

HEXOBENDINE.

HEXOCYCLIUM.

HEXOPRENALINE.

HISTAMINE for therapeutic use **except** in preparations containing 0.5 per cent or less of histamine.

HOMATROPINE.

HUMAN CHORIONIC GONADATROPHIN **except** in pregnancy test kits.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:

- (a) for tissue augmentation;
- (b) for cosmetic use; or
- (c) for the treatment of animals.

HYDRALAZINE.

HYDRARGAPHEN.

SCHEDULE 4-continued

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE **except** when included in Schedule 2 or 3.

HYDROCYANIC ACID for therapeutic use.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule)
in preparations for human therapeutic or cosmetic use **except**:

- (a) when included in Schedule 2; or
- (b) in hair preparations containing 1 per cent or less of hydroquinone.

HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

HYDROXYSTENOZOL.

HYDROXYUREA.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE **except** when included in Schedule 2.

HYOSCYAMINE **except** when included in Schedule 2.

HYOSCYAMUS NIGER **except**:

- (a) when included in Schedule 2; or
- (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in
this Schedule.

HYPROMELLOSE in preparations for injection.

SCHEDULE 4-continued

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBRITUMOMAB.

IBUFENAC.

IBUPROFEN **except**:

- (a) when included in or expressly excluded from Schedule 2 or 3; or
- (b) in preparations for dermal use.

IBUTEROL.

IBUTILIDE.

IDARUBICIN.

IDOXURIDINE **except** in preparations containing 0.5 per cent or less of idoxuridine for dermal use.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENEM.

IMIPRAMINE.

IMIQUIMOD.

IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.

INDAPAMIDE.

INDINAVIR.

INDOMETHACIN **except** when included in Schedule 2.

SCHEDULE 4-continued

INDOPROFEN.

INDORAMIN.

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

(a) for parenteral use; or

(b) for nasal administration.

INSULIN-LIKE GROWTH FACTOR I.

INSULIN-LIKE GROWTH FACTORS **except** when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS **except** when separately specified in these Schedules.

IODOTHIOURACIL.

IPRATROPIUM **except** when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

SCHEDULE 4-continued

ISOCARBOXAZID.

ISOCONAZOLE **except** when included in Schedule 2, 3 or 6.

ISOETARINE.

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE **except** when included in Schedule 2.

ISOSORBIDE DINITRATE **except** when included in Schedule 3.

ISOSORBIDE MONONITRATE.

ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVERMECTIN:

- (a) for human use; or
- (b) for the treatment of mange in dogs.

KANAMYCIN.

KETANSERIN **except** in topical veterinary preparations containing 0.5 per cent or less of ketanserin.

KETAZOLAM.

SCHEDULE 4-continued

KETOCONAZOLE except:

- (a) when included in Schedule 2;
- (b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
- (c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN except:

- (a) in preparations for dermal use; or
- (b) when included in Schedule 3.

KETOROLAC (includes ketoralac trometamol).

KETOTIFEN **except** when included in Schedule 3.

KHELLIN.

KITASAMYCIN except:

- (a) when included in Schedule 5 ; or
- (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LAMIVUDINE.

LAMOTRIGINE.

LANATOSIDES.

LANREOTIDE.

LANSOPRAZOLE.

LANTHANUM.

LARONIDASE.

LATAMOXEF.

SCHEDULE 4-continued

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:

- (a) when present as an excipient; or
- (b) when separately specified in these Schedules.

LEAD for human therapeutic use.

LEFETAMINE.

LEFLUNOMIDE.

LENOGRASTIM.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

- (a) for human therapeutic use; or
- (b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

LEVOBUPIVACAINE.

LEVOCABASTINE **except** when included in Schedule 2.

LEVODOPA.

LEVONORGESTREL **except** when included in Schedule 3.

SCHEDULE 4-continued

LEVOSIMENDAN.

LIDOFLAZINE.

LIGNOCAINE **except:**

- (a) when included in Schedule 2;
- (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
- (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINCOMYCIN.

LINDANE for human therapeutic use **except** when included in Schedule 2.

LINEZOLID.

LIOETHYRONINE.

LISINAPRIL.

LISURIDE.

LITHIUM for therapeutic use **except:**

- (a) when included in Schedule 2;
- (b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or
- (c) in preparations containing 0.01 per cent or less of lithium.

LODOXAMIDE **except** when included in Schedule 2.

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LOPERAMIDE **except** when included in Schedule 2.

SCHEDULE 4-continued

LOPINAVIR.

LOPRAZOLAM.

LORACARBEF.

LORATADINE **except** when included in Schedule 2.

LORAZEPAM.

LORMETAZEPAM.

LOSARTAN.

LOXAPINE.

LUMEFANTRINE.

LUMIRACOXIB.

LUTEINISING HORMONE **except** in ovulation test kits.

LYMECYCLINE.

MAFENIDE **except** when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARBOFLOXACIN.

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

MEBOLAZINE.

MEBUTAMATE.

SCHEDULE 4-continued

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE **except** when included in Schedule 2.

MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methylidigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID **except** when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

MELAGATRAN.

MELATONIN for human use.

MELENGESTROL **except** when included in Schedule 6.

MELOXICAM.

MELPHALAN.

MEMANTINE.

SCHEDULE 4-continued

MENINGOCOCCAL VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPYRAMINE **except** when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCURIC OXIDE for human therapeutic use.

MERCURY for cosmetic or therapeutic use **except:**

- (a) when separately specified in these Schedules; or
- (b) in a sealed device which prevents access to the mercury.

MEROPENEM.

MERSALYL.

#MESABOLONE.

MESALAZINE.

MESNA.

MESTANOLONE (androstalone).

SCHEDULE 4-continued

MESTEROLONE.

MESTRANOL.

METANDIENONE.

METARAMINOL.

METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENOESTRIL.

METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE **except** when included in Schedule 3.

METHENOLONE.

METHICILLIN.

METHIMAZOLE.

METHISAZONE.

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOTRIMEPRAZINE.

SCHEDULE 4-continued

METHOXAMINE in preparations for injection.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

METHYLANDROSTANOLONE.

METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYL MERCURY for therapeutic use.

METHYLPENTYNOL.

METHYLPHENOBARBITONE.

METHYLPREDNISOLONE.

#METHYLTESTOSTERONE.

METHYLTHIOURACIL.

METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE **except** when included in Schedule 3.

METOLAZONE.

METOPROLOL.

METRIBOLONE.

SCHEDULE 4-continued

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

MIBOLERONE.

MICONAZOLE **except**:

- (a) when included in Schedule 2, 3 or 6; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

MIDAZOLAM.

MIDODRINE.

MIGLITOL.

MILBEMYCIN OXIME **except** when included in Schedule 5.

MILRINONE.

MINOCYCLINE.

MINOXIDIL **except** when included in Schedule 2.

MIRTAZAPINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

SCHEDULE 4-continued

MIVACURIUM CHLORIDE.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINDONE.

MOMETASONE **except** when included in Schedule 2.

MONENSIN **except:**

- (a) when included in Schedule 5 or 6; or
- (b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and other alkyl ethers of hydroquinone for human therapeutic use or cosmetic use.

MONOCLONAL ANTIBODIES for therapeutic use **except:**

- (a) in diagnostic test kits; or
- (b) when separately specified in these Schedules.

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin **except** when included in Schedule 5.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

SCHEDULE 4-continued

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALORPHINE.

NALOXONE.

NALTREXONE.

NANDROLONE.

NAPROXEN **except** when included in Schedule 2.

NARASIN **except:**

- (a) when included in Schedule 6; or
- (b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN.

NATAMYCIN.

NATEGLINIDE.

SCHEDULE 4-continued

NEBACUMAB.

NEDOCROMIL.

NEFAZODONE.

NEFOPAM.

NELFINAVIR (includes nelfinavir mesylate).

NEOMYCIN.

NEOSTIGMINE.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

NICOTINE for use as an aid in withdrawal from tobacco smoking (including preparations for nasal administration) **except:**

- (a) when included in Schedule 2;
- (b) in chewing gum;
- (c) in lozenges;
- (d) for sublingual use; or
- (e) in preparations for transdermal use.

SCHEDULE 4-continued

NICOTINIC ACID for human therapeutic use **except**:

- (a) when contained in other Schedules;
- (b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
- (c) nicotinamide.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NIRIDAZOLE.

NISOLDIPINE.

NITRAZEPAM.

NITRENDIPINE.

NITROFURANTOIN.

NITROFURAZONE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIZATIDINE **except** when included in Schedule 2.

NOMIFENSINE.

NORADRENALINE.

SCHEDULE 4-continued

19-NORANDROSTENEDIOL.

19-NORANDROSTENEDIONE.

NORANDROSTENOLONE.

NORBOLETHONE.

NORCLOSTEBOL.

NORELGESTROMIN.

NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NYSTATIN **except** when included in Schedule 2 or 3.

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

OESTRADIOL **except** when included in Schedule 5.

OESTRIOL.

OESTROGENS **except** when separately specified in these Schedules.

OESTRONE.

OFLOXACIN.

SCHEDULE 4-continued

OLANZAPINE.

OLEANDOMYCIN **except**:

- (a) when included in Schedule 5; or
- (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLMESARTAN.

OLOPATADINE.

OLSALAZINE.

OMALIZUMAB.

OMEPRAZOLE.

ONDANSETRON.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use **except**:

- (a) when separately specified in these Schedules; or
- (b) preparations containing 2 per cent or less of maldison for external use.

ORLISTAT **except** when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

SCHEDULE 4-continued

OSELTAMIVIR.

OUABAIN.

#OVANDROTONE.

OXABOLONE.

OXACILLIN.

OXALIPLATIN.

OXANDROLONE.

OXAPROZIN.

OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) **except** when included in Schedule 2.

OXICONAZOLE **except**:

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for the treatment of tinea pedis.

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

XPENTIFYLLINE (pentoxifylline).

XPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

OXYMESTERONE.

SCHEDULE 4-continued

OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE **except** when included in Schedule 5.

OXYTOCIN.

PACLITAXEL.

PALIFERMIN.

PALIVIZUMAB.

PALONOSETRON.

PAMAQUIN.

PAMIDRONIC ACID (includes disodium pamidronate).

PANCREATIC ENZYMES **except**:

- (a) in preparations containing 20 000 BP units or less of lipase activity per dosage unit; or
- (b) when separately specified in these Schedules.

PANCURONIUM.

PANTOPRAZOLE.

PAPAVERINE in preparations for injection.

PARACETAMOL:

- (a) when combined with aspirin, caffeine or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;
- (b) in tablets or capsules containing more than 665 mg of paracetamol; or
- (c) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol.

SCHEDULE 4-continued

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARCOXIB.

PAROMOMYCIN.

PAROXETINE.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGFILGRASTIM.

PEGINTERFERON.

PEGVISOMANT.

PEMETREXED.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR **except** when included in Schedule 2.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isethionate).

PENTHIENATE.

SCHEDULE 4-continued

PENTOBARBITONE when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

PERGOLIDE.

PERHEXILINE.

PERICYAZINE.

PERINDOPRIL.

PERMETHRIN for human therapeutic use **except** in preparations containing 5 per cent or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE **except** when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE **except** when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITONE.

SCHEDULE 4-continued

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

PHENTERMINE.

PHENTHIMENTONIUM.

PHENTOLAMINE.

PHENYLBUTAZONE.

PHENYLEPHRINE:

- (a) in preparations for injection; or
- (b) in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHOLCODINE:

- (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
- (b) in undivided preparations containing 2.5 per cent or less of pholcodine, **except** when included in Schedule 2.

PTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PICROTOXIN.

PILOCARPINE **except** in preparations containing 0.025 per cent or less of pilocarpine.

SCHEDULE 4-continued

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

PIPENZOLATE.

PIPER METHYSTICUM (Kava) in preparations for human use **except**:

- (a) in preparations for oral use containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome when labelled with a recommended daily dose of 250 mg or less of kavalactones and:
 - (i) if in tablet or capsule form containing 125 mg or less of kavalactones per tablet or capsule; or
 - (ii) if in the form of a teabag when the amount of dried whole or peeled rhizome does not exceed 3g;

and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

- (b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or
- (c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

SCHEDULE 4-continued

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

PIRETANIDE.

PIROXICAM **except** in preparations for dermal use.

PIRPROFEN.

PITUITARY HORMONES **except** when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

- (a) internally;
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

- (a) internally;
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations **except** when included in Schedule 2 or 3.

SCHEDULE 4-continued

PODOPHYLLUM PELTATUM (podophyllin) for human use:

- (a) internally;
- (b) in preparations for the treatment of anogenital warts; or
- (c) in other preparations **except** when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

POLYACRYLAMIDE in preparations for injection or implantation:

- (a) for tissue augmentation; or
- (b) for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

- (a) for tissue augmentation; or
- (b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.

POLYTHIAZIDE.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

- (a) when containing less than 600mg of potassium chloride per dosage unit;
- (b) in preparations for oral rehydration therapy;
- (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
- (d) in preparations for enteral feeding.

SCHEDULE 4-continued

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMOCAINE.

PRAMPINE.

PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRAVASTATIN.

PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISON.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE **except** when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

SCHEDULE 4-continued

PROCAINE PENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2.

PROGESTERONE **except** when included in Schedule 5.

PROGESTOGENS **except** when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROLINTANE.

PROMAZINE.

PROMETHAZINE **except** when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

SCHEDULE 4-continued

PROSCILLARIDIN.

PROSTAGLANDINS **except** when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PSEUDOEPHEDRINE **except** when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use
except:

- (a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

QUAZEPAM.

QUETIAPINE.

SCHEDULE 4-continued

QUINAGOLIDE.

QUINAPRIL.

QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE.

RABIES VACCINE.

RACTOPAMINE **except** when included in Schedule 5.

RALOXIFENE.

RALTITREXED.

RAMIPRIL.

RANITIDINE **except** when included in Schedule 2.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

REMOXIPRIDE.

SCHEDULE 4-continued

REPAGLINIDE.

RESERPINE.

RETEPLASE.

RIBAVIRIN.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RILUZOLE.

RIMITEROL.

RISEDRONIC ACID.

RISPERIDONE.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVASTIGMINE.

RIZATRIPTAN.

ROCURONIUM.

ROFECOXIB.

ROLITETRACYCLINE.

ROMIFIDINE.

RONIDAZOLE.

ROPINIROLE.

ROPIVACAINE.

SCHEDULE 4-continued

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROXIBOLONE.

ROXITHROMYCIN.

RUBELLA VACCINE.

SALBUTAMOL **except** when included in Schedule 3.

SALCATONIN.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN **except:**

- (a) when included in Schedule 6; or
- (b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAQUINAVIR.

SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of *Schoenocaulon officinale*.

SCOPOLIA CARNIOLICA for therapeutic use.

SELEGILINE.

SELENIUM for therapeutic use **except:**

- (a) when included in Schedule 2, 3, 6 or 7;
- (b) in preparations for human oral use where the sum of the organic selenium expressed in micrograms and half the inorganic selenium expressed in micrograms, contained in the recommended daily dose of the preparation, does not exceed 26 micrograms;
- (c) in preparations for human topical use containing 3.5 per cent or less of selenium sulfide; or

SCHEDULE 4-continued

- (d) for the treatment of animals:
- (i) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;
 - (ii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;
 - (iii) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
 - (iv) in feeds containing 1 g/tonne or less of selenium.

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.

SIBUTRAMINE.

SILANDRONE.

SILDENAFIL.

SILICONES for intra-ocular use.

SILVER SULFADIAZINE.

SIMVASTATIN.

SIROLIMUS.

SISOMICIN (sisomycin).

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SCHEDULE 4-continued

SODIUM CROMOGLYCATE **except** when included in Schedule 2.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for injection for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SOLASODINE.

SOLIFENACIN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

SOMATROPIN (human growth hormone).

SONTOQUINE.

SOTALOL.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPIRAMYCIN.

SPIRAPRIL.

SPIRONOLACTONE.

STANOLONE.

STANOZOLOL.

STAVUDINE.

SCHEDULE 4-continued

STENBOLONE.

STEROID HORMONES **except** when separately specified in these Schedules.

STILBOESTROL (diethylstilboestrol).

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.

STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SULBACTAM.

SULCONAZOLE **except** when included in Schedule 2.

SULFACETAMIDE **except** when included in Schedule 3 or 5.

SULFADIAZINE **except** when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE **except** when included in Schedule 5.

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE **except** when included in Schedule 5.

SULFAMETHIZOLE.

SCHEDULE 4-continued

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE **except** when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDES **except**:

(a) when separately specified in this Schedule; or

(b) when included in Schedule 3, 5 or 6.

SULFONMETHANE (sulfonal) and alkyl sulfonals.

SULINDAC.

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN.

SUPROFEN.

SCHEDULE 4-continued

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE **except** in preparations containing 0.8 per cent or less of oil
of tansy.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

T-CELL RECEPTOR ANTIBODY.

TEGAFUR.

TEGASEROD.

TELITHROMYCIN.

TEICOPLANIN.

TELMISARTAN.

TEMAZEPAM.

TEMOZOLOMIDE.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

SCHEDULE 4-continued

TENOXICAM.

TEPOXALIN.

TERAZOSIN.

TERBINAFINE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE **except** when included in Schedule 3.

TERFENADINE.

TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

TESTOLACTONE.

TESTOSTERONE **except** when included in Schedule 6.

TETANUS ANTITOXIN **except** when used for short-term protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

TETRABENAZINE.

TETRACOSACTRIN.

TETRACYCLINE **except** when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

THALIDOMIDE.

THENYLDIAMINE.

SCHEDULE 4-continued

THEOPHYLLINE **except** when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heart worm
in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

THIOGUANINE.

THIOMESTERONE (tiomesterone).

THIOPENTONE.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1 per cent or less
of thiourea.

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID **except** when separately specified in this Schedule.

THYROTROPHIN.

SCHEDULE 4-continued

THYROXINE (includes thyroxine sodium).

TIAGABINE.

TIAMULIN.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGLOIDINE.

TILETAMINE.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE **except:**

- (a) when included in Schedule 2 or 3; or
- (b) in preparations for dermal use for the treatment of tinea pedis.

TIOTROPIUM.

TIPEPIDINE.

TIPRANAVIR.

SCHEDULE 4-continued

TIRILAZAD.

TIROFIBAN.

TOBRAMYCIN.

TOCAINIDE.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

TOPIRAMATE.

TOPOTECAN.

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use **except** when separately specified in these Schedules.

TRAMADOL.

TRANDOLAPRIL.

TRANEXAMIC ACID **except** when included in Schedule 3.

TRANYLCYPROMINE.

SCHEDULE 4-continued

TRASTUZUMAB.

TRAVOPROST.

TRAZODONE.

TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

TRESTOLONE.

TRETAMINE.

TRETINOIN.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE **except** when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZQUONE.

TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

SCHEDULE 4-continued

TRIFLUPROMAZINE.

TRIMEPRAZINE **except** when included in Schedule 2 or 3.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

TRIOXYSALEN.

TRIPLENNAMINE.

TRIPLE ANTIGEN VACCINE.

TRIPROLIDINE **except** when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROMETAMOL in preparations for injection **except** in preparations containing
3 per cent or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a
recommended daily dose of 100 mg or less of tryptophan.

TUBOCURARINE.

TULATHROMYCIN.

TULOBUTEROL.

SCHEDULE 4-continued**TYLOSIN except:**

- (a) when included in Schedule 5;
- (b) in animal feeds containing 50 mg/kg or less of antibiotic substances:
 - (i) for growth promotion;
 - (ii) for the prevention of liver abscesses in cattle; or
 - (iii) for the prevention of ileitis in pigs; or
- (c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

TYPHOID VACCINE.

UNOPROSTONE.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

VACCINES for human therapeutic use **except** when separately specified in this Schedule.

VACCINES, veterinary live virus **except:**

- (a) poultry vaccines;
- (b) pigeon pox vaccine; or
- (c) scabby mouth vaccine.

VALACICLOVIR.

VALDECOXIB.

SCHEDULE 4-continued

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VARDENAFIL.

VARICELLA VACCINE.

VASOPRESSIN.

VECURONIUM.

VEDAPROFEN.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. **except** when separately specified in this Schedule.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

SCHEDULE 4-continued

VIRGINIAMYCIN **except** when included in Schedule 5.

VISNADINE.

VITAMIN A for human therapeutic or cosmetic use **except**:

- (a) in preparations for topical use containing 1 per cent or less of vitamin A;
- (b) in preparations for internal use, containing 100 IU or less of vitamin A per dosage unit of a divided preparation, or 100 IU or less of vitamin A per gram of an undivided preparation; or
- (c) in other preparations for internal use in adults when:
 - (i) labelled with a recommended daily amount of 5 000 IU or less of vitamin A; and
 - (ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

VITAMIN D for human internal therapeutic use **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

VORICONAZOLE.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR.

SCHEDULE 4-continued

ZERANOL **except** when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZIMELDINE.

ZINC COMPOUNDS for human internal use **except**:

- (a) in preparations with a recommended daily dose of 25 mg or less of zinc;
or
- (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ZIPRASIDONE.

ZOLAZEPAM.

ZOLEDRONIC ACID.

ZOLMITRIPTAN.

ZOLPIDEM.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

SCHEDULE 5

(Substances marked † are listed in Appendix C)

ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH₃COOH) **except**:

- (a) when included in Schedule 2 or 6; or
- (b) for therapeutic use.

ACETONE **except** in preparations containing 25 per cent or less of designated solvents.

ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

- (a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5;
- (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;
- (c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (d) in liquid or semi-solid preparations the pH of which is more than 11.5,

except when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxyated fatty alkylamine polymer **except** in preparations containing 20 per cent or less of alkoxyated fatty alkylamine polymer.

SCHEDULE 5-continued

ALLETHRIN in preparations containing 10 per cent or less of allethrin **except**:

- (a) in insecticidal mats; or
- (b) in other preparations containing 1 per cent or less of allethrin.

ALLOXYDIM.

ALPHA-CYPERMETHRIN:

- (a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or
- (b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

AMETRYN.

AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.

AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

AMITROLE.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia **except**:

- (a) in preparations for human internal therapeutic use;
- (b) in preparations for inhalation when absorbed in an inert solid material; or
- (c) in preparations containing 0.5 per cent or less of free ammonia.

AMMONIUM THIOCYANATE **except** in preparations containing 10 per cent or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID, for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

ANISE OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 5-continued

- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of anise oil.

ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.

ATRAZINE.

† AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed
Pseudomonas fluorescens.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq.cm.

BASIL OIL **except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 5 per cent or less of methyl chavicol.

BEAVERIA BASSIANA in preparations containing 1×10^8 Colony Forming Units (CFU)/mL or less of *Beauveria bassiana*.

BENALAXYL.

BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.

SCHEDULE 5-continued

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride **except** in preparations containing 5 per cent or less of benzalkonium chloride.

BENZOFENAP.

BENZOYL PEROXIDE **except**:

- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 5 per cent or less of benzoyl peroxide.

BERGAMOT OIL **except**:

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 0.4 per cent or less of bergamot oil;
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN in aqueous preparations containing 2.5 per cent or less of betacyfluthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 0.3 per cent or less of total bifluorides.

BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin **except** in preparations containing 1 per cent or less of bioallethrin.

BIORESMETHRIN **except** in preparations containing 10 per cent or less of bioresmethrin.

BORIC ACID (excluding its salts) and BORAX **except**:

- (a) when included in Schedule 4;

SCHEDULE 5-continued

- (b) in preparations, other than insect baits, containing 1 per cent or less of boron; or
- (c) in hand cleaning preparations.

BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF₃).

BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.

BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.

BUTRALIN.

BUTROXYDIM.

CADMIUM SULPHIDE in preparations containing 2.5 per cent or less of cadmium sulphide for human therapeutic use.

CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor **except**:

- (a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

- (c) in rosemary oil, sage oil (Spanish), or lavandin oils; or
- (d) in preparations containing 2.5 per cent or less of camphor.

CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide **except** in preparations containing 9 per cent or less of carbamide peroxide.

SCHEDULE 5-continued

CARBARYL:

- (a) in preparations containing 10 per cent or less of carbaryl **except** when included in Schedule 4; or
- (b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

CASSIA OIL **except:**

- (a) in food additives; or
- (b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or
- (c) in other preparations containing 2 per cent or less of cassia oil.

CHLORFENAC.

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine **except:**

- (a) in preparations containing 1 per cent or less of chlorhexidine; or
- (b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, **except:**

- (a) when separately specified in these Schedules;
- (b) sodium hypochlorite preparations with a pH of less than 11.5;
- (c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

- (d) liquid preparations containing less than 2 per cent of available chlorine;
or
- (e) other preparations containing 4 per cent or less of available chlorine.

CHLORNIDINE.

SCHEDULE 5-continued

CHLOROCRESOL **except** in preparations containing 3 per cent or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

- (a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;
- (b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or
- (c) in other preparations containing 5 per cent or less of chlorpyrifos,

except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

- (a) for topical application to animals for ocular use only; or
- (b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHAL-DIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

- (a) in food additives; or
- (b) in preparations containing 2 per cent or less of cinnamon bark oil.

CLETHODIM.

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole **except** in preparations containing 2 per cent or less of climbazole.

CLOFENTEZINE.

SCHEDULE 5-continued

CLOPYRALID.

CLOQUINTOCET-MEXYL.

CLORSULON.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil
except in preparations containing 25 per cent or less of clove oil.

COPPER ACETATE in preparations containing 20 per cent or less of copper acetate
except in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of
copper **except** in preparations containing 1 per cent or less of copper.

COPPER HYDROXIDE in preparations containing 50 per cent or less of copper
hydroxide **except** in preparations containing 12.5 per cent or less of copper
hydroxide.

COPPER OXIDES in preparations containing 25 per cent or less of copper oxides
except:

- (a) in preparations for internal use;
- (b) in marine paints; or
- (c) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper
oxychloride **except** in preparations containing 12.5 per cent or less of copper
oxychloride.

COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate
except:

- (a) in preparations for internal use; or
- (b) in other preparations containing 5 per cent or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.

4-CPA.

CYANATRYN.

SCHEDULE 5-continued

CYANOACRYLATE ESTERS in contact adhesives **except**:

- (a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

- (b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

- (i) labelled with the approved name or trade name of the poison, the quantity and the warning:

Can cause eye injury. Instantly bonds skin; and

- (ii) enclosed in a primary pack labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANURIC ACID (excluding its salts and derivatives).

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN **except** in preparations containing 10 per cent or less of cycloprothrin.

CYCLOXYDIM.

CYFLUTHRIN:

- (a) in wettable powders containing 10 per cent or less of cyfluthrin;
- (b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or
- (c) in emulsions containing 5 per cent or less of cyfluthrin.

CYHALOFOP-BUTYL.

CYMIAZOLE.

SCHEDULE 5-continued

CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.

CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.

CYPROCONAZOLE **except** in preparations containing 10 per cent or less of cyproconazole.

CYPRODINIL.

CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine **except** in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE for the treatment of animals:

- (a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or
- (b) in undivided preparations containing 5 per cent or less of cythioate.

2,4-D.

DAMINOZIDE.

2,4-DB.

DELTAMETHRIN:

- (a) in aqueous preparations containing 1 per cent or less of deltamethrin when no organic solvent other than a glycol is present;
- (b) in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 grams or less of the formulation;
- (c) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or
- (d) in other preparations containing 0.5 per cent or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4-DES.

DIAFENTHIURON.

SCHEDULE 5-continued

N,N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.

DIAZINON in dust preparations containing 2 per cent or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.

DICHLONE.

para-DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, **except** in:

- (a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

- (b) liquid preparations containing less than 2 per cent of available chlorine; or
- (c) other preparations containing 4 per cent or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

- (a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;
- (b) in other preparations in pressurised spray packs; or
- (c) in paints and tinters containing 5 per cent or less of dichloromethane.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

- (a) when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;
- (b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or
- (c) in pressurised spray packs containing 10 grams or less of dichlorvos.

SCHEDULE 5-continued

DICLOBUTRAZOL.

DICLORAN.

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine **except** in preparations containing 5 per cent or less of diethanolamine.

DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) **except**:

- (a) in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:

WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

- (c) in preparations other than for human use containing 20 per cent or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHIRIMOL.

DIMETHOMORPH **except** in preparations containing 10 per cent or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.

DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide **except** in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DINICONAZOLE.

SCHEDULE 5-continued

DI-N-PROPYL ISOCINCHOMERONATE **except** in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.

DIPHENAMID.

DITHIOPYR.

N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

EMAMECTIN in preparations containing 2 per cent or less of emamectin.

EMODEPSIDE in preparations containing 2.5 per cent or less of emodepside for external treatment of animals.

ENILCONAZOLE.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.

ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin **except** in pressurised spray packs containing 1 per cent or less of esbiothrin.

1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.

ETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine **except**:

- (a) when included in Schedule 4; or
- (b) in preparations containing 5 per cent or less of ethanolamine.

ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.

ETHOFUMESATE.

SCHEDULE 5-continued

ETHOXYQUIN **except** in preparations containing 10 per cent or less of ethoxyquin.

ETHOXYLSULFURON.

ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

- (a) in paints or paint tinters; or
- (b) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use **except** in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25 per cent or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (*Corymbia citriodora*), **except** in preparations containing 40 per cent or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLE-ETHYL.

FENOPROP.

FENOXAPROP-ETHYL.

FENOXAPROP-P-ETHYL.

FENSON.

FENTHION:

- (a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or
- (b) in preparations containing 10 per cent or less of fenthion.

SCHEDULE 5-continued

FIPRONIL in preparations containing 10 per cent or less of fipronil **except** in preparations containing 0.05 per cent or less of fipronil.

FLAMPROP-METHYL.

FLAMPROP-M-METHYL.

FLORASULAM.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUCHLORALIN.

FLUDIOXONIL **except** in preparations containing 10 per cent or less of fludioxonil.

FLUMETHRIN:

- (a) when impregnated in plastic resin strip material containing 3 per cent or less of flumethrin; or
- (b) in oil based preparations containing 1 per cent or less of flumethrin.

FLUMICLORAC PENTYL.

FLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

- (a) when included in Schedule 2, 3 or 4;
- (b) dental hygiene, whitening or bleaching products that are pastes, powders or gels for use on teeth, containing 1000 mg/kg or less of fluoride ion;
- (c) other dental hygiene, whitening or bleaching products that are therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (d) other dental hygiene, whitening or bleaching products that are not therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure and labelled with warnings to the following effect:
 - (i) Do not swallow; and

SCHEDULE 5-continued

(ii) Do not use [this product/name of product] in children 6 years of age or less; or

(e) other preparations containing 15 mg/kg or 15 mg/L or less of fluoride ion.

FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5 per cent or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.

GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.

GLUFOSINATE-AMMONIUM.

GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURON-METHYL.

HEXACONAZOLE **except** in preparations containing 5 per cent or less of hexaconazole.

HEXAZINONE in preparations containing 25 per cent or less of hexazinone.

HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.

SCHEDULE 5-continued

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

- (a) toluene and xylene when included in Schedule 6;
- (b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;
- (c) food grade and pharmaceutical grade white mineral oils;
- (d) in solid or semi-solid preparations;
- (e) in preparations containing 25 per cent or less of designated solvents;
- (f) in preparations packed in pressurised spray packs;
- (g) in adhesives packed in containers each containing 50 grams or less of adhesive; or
- (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) **except**:

- (a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl);
or
- (b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.

HYDROGEN PEROXIDE (excluding its salts and derivatives):

- (a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide **except** in hair dyes containing 6 per cent or less of hydrogen peroxide; or
- (b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide **except** in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H₂SiF₆).

SCHEDULE 5-continued

IMAZALIL.

IMAZAMOX **except** in preparations containing 25 per cent or less of imazamox.

IMAZAPIC **except** in preparations containing 25 per cent or less of imazapic.

IMAZAPYR **except** in preparations containing 25 per cent or less of imazapyr.

IMAZETHAPYR **except** in preparations containing 25 per cent or less of imazethapyr.

IMIDACLOPRID in preparations containing 20 per cent or less of imidacloprid **except** in preparations containing 5 per cent or less of imidacloprid.

IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin **except** in preparations containing 10 per cent or less of imiprothrin.

INDOXACARB (Includes the R and S enantiomers) in preparations containing 1 per cent or less of indoxacarb when packed in child-resistant packaging.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate **except** in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IODOSULFURON-METHYL-SODIUM.

IRON COMPOUNDS:

- (a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):
 - (i) in preparations for injection containing 20 per cent or less of iron **except** in preparations containing 0.1 per cent or less of iron; or
 - (ii) in other preparations containing 4 per cent or less of iron **except**:
 - (A) in liquid or gel preparations containing 0.1 per cent or less of iron; or
 - (B) in animal feeds or feed premixes; or
- (b) in garden preparations **except** in preparations containing 4 per cent or less of iron.

SCHEDULE 5-continued

ISOEUGENOL in preparations containing 25 per cent or less of isoeugenol **except** in preparations containing 10 per cent or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

- (a) in preparations for the prophylaxis of heartworm in cats and dogs;
- (b) in intraruminal implants containing 160 mg or less of ivermectin;
- (c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or
- (d) in other preparations containing 2 per cent or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

LAMBDA-CYHALOTHRIN:

- (a) in aqueous preparations containing 1 per cent or less of lambda-cyhalothrin; or
- (b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.

LEAD COMPOUNDS in preparations for use as hair cosmetics.

LEMON OIL **except**:

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 0.05 per cent or less of lemon oil;
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

SCHEDULE 5-continued

- (f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals, **except** when included in Schedule 4.

LIME OIL except:

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 0.5 per cent or less of lime oil;
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10 per cent or less of lindane **except** when included in Schedule 2 or 4.

LUFENURON except:

- (a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or
- (b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.

MAGNESIUM CHLORATE **except** in preparations containing 10 per cent or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.

SCHEDULE 5-continued

MALDISON (malathion) in preparations containing 10 per cent or less of maldison
except:

- (a) for human therapeutic use; or
- (b) in dust preparations containing 2 per cent or less of maldison.

MANCOZEB.

MARJORAM OIL **except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of marjoram oil.

MCPA

- (a) in preparations containing 25 per cent or less of MCPA (acid); or
- (b) in preparations containing 50 per cent or less of the salts and esters of MCPA.

MCPB.

MEBENDAZOLE for the treatment of animals:

- (a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or
- (b) in undivided preparations containing 25 per cent or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.

MECOPROP in preparations containing 2 per cent or less of mecoprop.

MEFENPYR-DIETHYL.

MEPIQUAT.

SCHEDULE 5-continued

METALAXYL in preparations containing 35 per cent or less of metalaxyl.

METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.

METHABENZTHIAZURON.

METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol **except** in preparations containing 2 per cent or less of methanol.

METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

- (a) when included in preparations or admixtures; or
- (b) when packed in containers having a capacity of more than 5 litres.

METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

N-METHYL-2-PYRROLIDONE:

- (a) when packed in single use containers having a capacity of 2 mL or less; or
- (b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE in liquid preparations containing 25 per cent or more of methyl salicylate **except** when included in Schedule 6.

SCHEDULE 5-continued

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.

METIRAM.

METOLACHLOR.

METRIBUZIN.

MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.

MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MORANTEL in preparations containing 25 per cent or less of morantel **except** in preparations containing 10 per cent or less of morantel.

MOXIDECTIN:

- (a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;
- (b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or
- (c) for internal use for the treatment of animals:
 - (i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or
 - (ii) in other preparations containing 2 per cent or less of moxidectin.

MYCLOBUTANIL.

NAA **except** in preparations containing 25 per cent or less of NAA.

NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.

NAPTALAM.

NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.

SCHEDULE 5-continued

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO₃) **except** in preparations containing 0.5 per cent or less of nitric acid.

NITROSCANATE for the treatment of animals.

NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 **except**:

- (a) when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

- (b) in preparations containing 12.5 per cent or less of nonoxinol 9; or
(c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
- KEEP OUT OF REACH OF CHILDREN; or
- (c) in preparations containing 50 per cent or less of nutmeg oil.

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10 per cent or less of N-octyl bicycloheptene dicarboximide.

N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

OESTRADIOL in implant preparations for growth promotion in animals.

SCHEDULE 5-continued

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.

ORANGE OIL (BITTER) **except:**

- (a) when steam distilled or rectified;
- (b) in preparations for internal use;
- (c) in preparations containing 1.4 per cent or less of orange oil (bitter);
- (d) in soaps or bath or shower gels that are washed off the skin;
- (e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
or
- (f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

- (a) for topical application to animals for ocular use only; or
- (b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

SCHEDULE 5-continued

PENDIMETHALIN.

PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.

PERMETHRIN (excluding preparations for human therapeutic use):

- (a) in preparations containing 25 per cent or less of permethrin; or
- (b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,

except in preparations containing 2 per cent or less of permethrin.

PETROL **except** preparations containing 25 per cent or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, **except** in preparations containing 3 per cent or less of such substances.

PHENYL METHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

ortho-PHENYLPHENOL **except** in preparations containing 5 per cent or less of o-phenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of phosphonic acid (H_3PO_3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H_3PO_4) **except**:

- (a) in preparations containing 15 per cent or less of phosphoric acid (H_3PO_4);
- (b) in solid or semi-solid preparations; or
- (c) in professional dental kits.

ortho-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.

SCHEDULE 5-continued

PICARIDIN **except** in preparations containing 20 per cent or less of picaridin.

PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.

PINOXADEN in preparations containing 10 per cent or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.

POLIHEXANIDE **except** in preparations containing 5 percent or less of polihexanide.

POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts **except** in preparations containing 1 per cent or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- ω -HYDROXY-, MONO-C₁₃₋₁₅-ALKYL ETHERS.

POTASSIUM CHLORATE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 10 per cent or less of potassium chlorate.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:

- (a) solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (b) liquid or semi-solid preparations the pH of which is more than 11.5.

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite **except**:

- (a) in preparations containing 0.5 per cent or less of potassium nitrite;
- (b) when present as an excipient in preparations for therapeutic use; or
- (c) in aerosols.

SCHEDULE 5-continued

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

- (a) solid preparations the pH of which in a 10 g/L aqueous solution is less than 2.5; or
- (b) liquid or semi-solid preparations the pH of which is less than 2.5.

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin **except** in insecticidal mats containing 1 per cent or less of prallethrin.

PROFOXYDIM **except** in preparations containing 20 per cent or less of profoxydim.

PROGESTERONE:

- (a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or
- (b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, **except**:

- (a) in preparations containing 30 per cent or less of propionic acid; or
- (b) for therapeutic use.

PROPOXUR:

- (a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;

SCHEDULE 5-continued

- (b) in dust preparations containing 3 per cent or less of propoxur;
- (c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;
- (d) in pressurised spray packs containing 10 g or less of propoxur; or
- (e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

PROPYZAMIDE.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFEN-ETHYL.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids **except** in preparations containing 10 per cent or less of such substances.

PYRIDABEN in preparations containing 25 per cent or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds **except**:

- (a) when separately specified in these Schedules;
- (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
- (c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1 per cent or less of quinine.

QUINTOZENE.

QUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of quizalofop-p-ethyl.

SCHEDULE 5-continued

RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.

RESMETHRIN in preparations containing 10 per cent or less of resmethrin.

RIMSULFURON.

ROBENIDINE **except** in preparations containing 20 per cent or less of robenidine.

SALICYLANILIDE.

SELAMECTIN **except** in preparations containing 12 per cent or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion
except:

- (a) barium silicofluoride when separately specified in this Schedule; or
- (b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin
except in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM CHLORATE **except** in preparations containing 10 per cent or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60 per cent or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10 per cent or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium hydrosulfite.

SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:

- (a) solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
- (b) liquid or semi-solid preparations the pH of which is more than 11.5.

SCHEDULE 5-continued

SODIUM LAURETH-6 CARBOXYLATE **except** in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite **except:**

- (a) in preparations containing 0.5 per cent or less of sodium nitrite;
- (b) when present as an excipient in preparations for therapeutic use; or
- (c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate **except** in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10 per cent or less of sodium polystyrene sulphonate.

SODIUM STANNATE **except** in preparations for cosmetic use containing 1 per cent or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPINOSAD **except** in aqueous suspensions containing 25 per cent or less of spinosad.

STAR ANISE OIL **except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of star anise oil.

STYRENE (excluding its derivatives).

SCHEDULE 5-continued

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid ($\text{H}_3\text{NO}_3\text{S}$).

SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFOMETURON-METHYL.

†SYMPHYTUM spp. (Comfrey) for dermal use.

2,3,6-TBA.

TDE (1,1-dichloro-2,2-bis [4-chlorophenyl] ethane) in preparations containing 10 per cent or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.

TEMEPHOS:

- (a) in liquid preparations containing 10 per cent or less of temephos;
- (b) in powders containing 2 per cent or less of temephos; or
- (c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

SCHEDULE 5-continued

TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene **except**:

- (a) when included in Schedule 2;
- (b) in preparations for the treatment of animals; or
- (c) when absorbed into an inert solid.

TETRACHLORVINPHOS **except** in animal feed containing 0.2 per cent or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.

TETRACYCLINE in preparations:

- (a) for topical application to animals for ocular use only; or
- (b) containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.

THIABENDAZOLE:

- (a) for the treatment of animals; or
- (b) when packed and labelled for use as a fungicide **except** in preparations containing 50 per cent or less of thiabendazole.

THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.

THYME OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 5-continued

- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

- (c) in preparations containing 50 per cent or less of thyme oil.

TIOCARBAZIL.

TOLCLOFOS-METHYL.

TOLTRAZURIL.

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.

TRIADIMENOL.

TRI-ALLATE.

TRIBENURON-METHYL.

TRICHLOROACETIC ACID, alkali salts of.

† 1,1,1-TRICHLOROETHANE **except:**

- (a) in preparations packed in pressurised spray packs;
- (b) in preparations containing 25 per cent or less of designated solvents;
- (c) in preparations, other than writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less; or
- (d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:
- (i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and

SCHEDULE 5-continued

(ii) the expression:

WARNING - DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

written in bold face sanserif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRIDIPHANE.

TRIETAZINE.

TRIETHANOLAMINE (excluding its salts and derivatives) **except** in preparations containing 5 per cent or less of triethanolamine.

TRIFLOXYSTROBIN.

TRIFLUMIZOLE.

TRIFLUMURON.

TRISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30 per cent or less of trisopropanolamine lauryl ether sulfate when labelled with the statements:

Avoid contact with eyes and skin; and

Wash hands after handling.

TRINEXAPAC-ETHYL **except**:

- (a) when packed in a sealed water-soluble measure pack; or
- (b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.

3,6,9-TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5 per cent or less of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRITICONAZOLE.

TURPENTINE OIL **except** in preparations containing 25 per cent or less of turpentine oil.

SCHEDULE 5-continued

TYLOSIN in animal feed premixes containing 5 per cent or less of antibiotic substances:

- (a) for growth promotion;
- (b) for the prevention of liver abscesses in cattle; or
- (c) for the prevention of ileitis in pigs.

VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.

ZINEB.

SCHEDULE 6

(Substances marked † are listed in Appendix C)

ABAMECTIN in preparations for pesticidal use containing 2 per cent or less of abamectin **except** when included in Schedule 5.

ACEPHATE.

ACETAMIPRID **except** in preparations containing 1 per cent or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH₃COOH) **except** when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE **except** in preparations containing 20 per cent or less of acinitrazole.

ALBENDAZOLE for the treatment of animals **except:**

- (a) when included in Schedule 5; or
- (b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:

- (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
- (b) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER **except:**

- (a) when included in Schedule 5; or
- (b) in preparations containing 20 per cent or less of alkoxyated fatty alkylamine polymer.

ALLETHRIN **except:**

- (a) when included in Schedule 5;

SCHEDULE 6-continued

- (b) in insecticidal mats containing 20 per cent or less of allethrin; or
- (c) in other preparations containing 1 per cent or less of allethrin.

ALPHA-CYPERMETHRIN:

- (a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or
- (b) in other preparations containing 10 per cent or less of alpha-cypermethrin,

except when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMINOCARB in preparations containing 25 per cent or less of aminocarb.

AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15 per cent or less of aminoethoxyvinylglycine.

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

AMINOPYRALID.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide)
except:

- (a) when included in Schedule 5;
- (b) in preparations for human internal therapeutic use;
- (c) in preparations for inhalation when absorbed in an inert solid material; or
- (d) in preparations containing 0.5 per cent or less of ammonia.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) **except** in preparations containing 1 per cent or less of aniline.

SCHEDULE 6-continuedANTIMONY COMPOUNDS **except**:

- (a) when included in Schedule 4;
- (b) antimony chloride in polishes;
- (c) antimony titanate pigments in paint; or
- (d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.

ARSENIC:

- (a) in ant poisons containing 0.4 per cent or less of arsenic;
- (b) in animal feed premixes containing 4 per cent or less of arsenic; or
- (c) in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,

except when separately specified in this Schedule.

ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5.

AZACONAZOLE **except** in preparations containing 1 per cent or less of azaconazole

AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:

- (a) when included in Schedule 5;
- (b) in preparations for human internal use;
- (c) debitterised neem seed oil;
- (d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

SCHEDULE 6-continued

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

BARIUM SALTS except:

- (a) when included in Schedule 5;
- (b) barium sulfate; or
- (c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except** in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN;

If in eyes wash out immediately with water; and

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

BAY OIL except:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

SCHEDULE 6-continued

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (e) in preparations containing 25 per cent or less of bay oil.

BEAUVERIA BASSIANA **except** when included in Schedule 5.

BENDIOCARB:

- (a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;
- (b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;
- (c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or
- (d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,

except when included in Schedule 5.

BENOMYL **except** in paint containing 0.5 per cent or less of benomyl.

BENQUINOX.

BENSULIDE.

BENZALKONIUM CHLORIDE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of benzalkonium chloride.

6-BENZYLADENINE **except** in preparations containing 2 per cent or less of 6-benzyladenine.

BERYLLIUM.

SCHEDULE 6-continued

BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin **except** when included in Schedule 5.

BETA-CYPERMETHRIN.

BHC (excluding lindane).

BIFENTHRIN in preparations containing 10 per cent or less of bifenthrin **except** in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3 per cent or less of total bifluorides **except** when included in Schedule 5.

BIOALLETHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of bioallethrin.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.

SCHEDULE 6-continued

† BITHIONOL for treatment of animals.

BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF₃) **except** when included in Schedule 5.

BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.

BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.

BROMOFORM **except** when included in Schedule 4.

BROMOPHOS.

BROMOPHOS-ETHYL.

BROMOXYNIL.

BROMUCONAZOLE **except** when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM **except** when included in Schedule 5.

2-BUTOXYETHANOL and its ACETATES **except** in preparations containing 10 per cent or less of such substances.

2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

- (a) in animal feed premixes containing 4 per cent or less of arsenic; or
- (b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.

SCHEDULE 6-continued**CADMIUM COMPOUNDS except:**

- (a) when included in Schedule 5; or
- (b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.

CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.

CAJUPUT OIL except:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (e) in preparations containing 25 per cent or less of cajuput oil; or
- (f) in oils containing 25 per cent or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.

CAMBENDAZOLE.

SCHEDULE 6-continued**CAMPHOR except:**

- (a) when included in Schedule 4 or 5;
- (b) when enclosed in an inhaler device which prevents ingestion of its contents;
- (c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;
- (d) in liquid preparations containing 2.5 per cent or less of camphor;
- (e) in essential oils when the camphor is present as a natural component of the oil:
 - (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

SCHEDULE 6-continued

CARBARYL **except** when included in Schedule 4 or 5.

CARBENDAZIM **except** in paint containing 0.5 per cent or less of carbendazim.

CARBON DISULFIDE.

CARBAMIDE PEROXIDE **except**:

- (a) when included in Schedule 5; or
- (b) in other preparations containing 9 per cent or less of carbamide peroxide.

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 1 per cent or less of chlorhexidine; or
- (c) when in solid preparations.

CHLORINATING COMPOUNDS **except**:

- (a) when included in Schedule 5;
- (b) when separately specified in these Schedules;
- (c) sodium hypochlorite preparations with a pH of less than 11.5;
- (d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

- (e) in liquid preparations containing less than 2 per cent of available chlorine; or
- (f) in other preparations containing 4 per cent or less of available chlorine.

SCHEDULE 6-continued

CHLORMEQUAT.

CHLOROFORM **except**:

- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 10 per cent or less of chloroform.

alpha-CHLOROHYDRIN.

CHLOROPHACINONE.

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) **except** in preparations containing 5 per cent or less of (E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.

CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.

CHLOROTHALONIL **except** in water-based paint containing 0.5 per cent or less of chlorothalonil.

CHLORPYRIFOS **except**:

- (a) when included in Schedule 5; or
- (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORPYRIFOS-METHYL.

CHLORTHIAMID.

CHROMATES (including dichromates) **except** in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CINEOLE **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 6-continued

- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (e) in preparations containing 25 per cent or less of cineole;
- (f) in oils containing 25 per cent or less of cineole; or
- (g) in rosemary oil or camphor oil (white).

CINNAMON LEAF OIL except:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

SCHEDULE 6-continued

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (e) in preparations containing 25 per cent or less of cinnamon leaf oil.

CLIMBAZOLE except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 2 per cent or less of climbazole.

CLODINAFOP-PROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN.

CLOTRIMAZOLE for external treatment of animals.

CLOVE OIL except:

- (a) when included in Schedule 5;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

SCHEDULE 6-continued

- (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (f) in preparations containing 25 per cent or less of clove oil.

N-COCO-1,3-DIAMINOPROPANE.

COPPER ACETATE except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS except:

- (a) when separately specified in these Schedules;
- (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;
- (c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;
- (d) in feed additives containing 1 per cent or less of copper; or
- (e) in other preparations containing 5 per cent or less of copper compounds.

COPPER HYDROXIDE except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES except:

- (a) when included in Schedule 5;
- (b) in preparations for internal use;

SCHEDULE 6-continued

- (c) in marine paints; or
- (d) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 12.5 per cent or less of copper oxychloride.

COPPER SULFATE except:

- (a) when included in Schedule 5;
- (b) in preparations for internal use; or
- (c) in other preparations containing 5 per cent or less of copper sulfate.

COUMAPHOS in preparations containing 5 per cent or less of coumaphos.

COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl
except when included in Schedule 5.

CREOSOTE derived from wood other than beechwood except:

- (a) when included in Schedule 2;
- (b) in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or
- (c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.

SCHEDULE 6-continued

CYFLUTHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN **except** when included in Schedule 5.

CYPHENOTHRIN **except** when included in Schedule 5.

CYSTEAMINE for cosmetic use **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE **except** when included in Schedule 5.

DAZOMET.

DELTAMETHRIN:

- (a) in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;
- (b) in wettable granular preparations containing 25 per cent or less of deltamethrin;
- (c) in water-dispersible tablets each containing 500 mg or less of deltamethrin;
- (d) in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or
- (e) in other preparations containing 3 per cent or less of deltamethrin,

except when included in Schedule 5.

DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5.

DICHLOBENIL.

DICHLOFENTHION.

SCHEDULE 6-continued

DICHLORFLUANID.

ortho-DICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID **except**:

- (a) when included in Schedule 5;
- (b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
- (c) in liquid preparations containing less than 2 per cent of available chlorine; or
- (d) in other preparations containing 4 per cent or less of available chlorine.

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.

DICHLOROPHEN **except**:

- (a) when included in Schedules 4 or 5; or
- (b) in fabrics other than when:
 - (i) for human therapeutic use; or
 - (ii) as part of a registered pesticidal product.

1,2-DICHLOROPROPANE.

2,4-DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50 per cent or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP-METHYL.

DICYCLANIL **except** in preparations containing 5 per cent or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM CHLORIDE **except** in preparations containing 1 per cent or less of didecyldimethylammonium chloride labelled with the statement:

Avoid contact with eyes.

SCHEDULE 6-continued

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of diethanolamine.

DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.

DIMETHENAMID-P.

DIMETHIPIN.

DIMETHOATE.

DIMETHYLACETAMIDE **except** when included in Schedule 5.

DIMETHYLFORMAMIDE **except**:

- (a) when included in Schedule 5; or
- (b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DIMETHYL SULFOXIDE:

- (a) when not for therapeutic use; or
- (b) for the treatment of animals:
 - (i) when combined with no other therapeutic substance(s);
 - (ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl salicylate as the only other therapeutic substances; or
 - (iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide.

SCHEDULE 6-continued

DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

- (a) when included in Schedule 4; or
- (b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

- (a) when included in Schedule 4; or
- (b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE.

DIPHACINONE.

DIQUAT in preparations containing 20 per cent or less of diquat.

DISULFIRAM **except** when included in Schedule 4.

DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

N-(N-DODECYL)-2-PYRROLIDONE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 25 per cent or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.

ECONAZOLE for external treatment of animals.

SCHEDULE 6-continued

EMAMECTIN in preparations containing 5 per cent or less of emamectin **except** when included in Schedule 5.

EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20 per cent or less of endothal.

EPTC.

ESBIOTHRIN **except**:

- (a) when included in Schedule 5; or
- (b) in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE.

ETHANOLAMINE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 4 or 5; or
- (b) in preparations containing 5 per cent or less of ethanolamine.

ETHEPHON (excluding its salts and derivatives).

ETHER **except**:

- (a) when included in Schedule 2, 4 or 5; or
- (b) in preparations containing 10 per cent or less of ether.

ETHIOFENCARB.

ETHOATE-METHYL.

ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.

ETHYL BROMIDE.

ETHYL FORMATE when packed and labelled for use as a fumigant.

ETHYLENE CHLOROXYDRIN.

SCHEDULE 6-continued

ETHYLENE DICHLORIDE.

ETHYLENE GLYCOL (excluding its salts and derivatives) **except:**

- (a) when included in Schedule 5;
- (b) in paints or paint tinters; or
- (c) in preparations containing 2.5 per cent or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, **except:**

- (a) when separately specified in these Schedules; or
- (b) in preparations containing 10 per cent or less of such substances.

ETRIMFOS.

EUCALYPTUS OIL **except:**

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (e) in preparations containing 25 per cent or less of eucalyptus oil.

SCHEDULE 6-continued**EUGENOL except:**

- (a) when included in Schedule 5;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;

- (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (f) in preparations containing 25 per cent or less of eugenol.

FAMPHUR in preparations containing 20 per cent or less of famphur.

FEBANTEL except:

- (a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or
- (b) in undivided preparations containing 10 per cent or less of febantel.

FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.

FENAZAFLOR.

SCHEDULE 6-continued

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPYROXIMATE.

FENTHION in preparations containing 60 per cent or less of fenthion **except** when included in Schedule 5.

FENVALERATE.

FIPRONIL **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 0.05 per cent or less of fipronil.

FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.

FLUAZIFOP-BUTYL.

FLUAZIFOP-P-BUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUMETHRIN **except** when included in Schedule 5.

FLUORIDES **except**:

- (a) when included in Schedule 2, 3, 4 or 5;
- (b) dental hygiene, whitening or bleaching products that are pastes, powders or gels for use on teeth, containing 1000 mg/kg or less of fluoride ion;
- (c) other dental hygiene, whitening or bleaching products that are therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 6-continued

- (d) other dental hygiene, whitening or bleaching products that are not therapeutic goods, containing 220 mg/kg or 220 mg/L or less of fluoride ion, in packs containing not more than 120 mg total fluoride, fitted with a child-resistant closure and labelled with warnings to the following effect:
- (i) Do not swallow; and
 - (ii) Do not use [this product/name of product] in children six years of age or less; or
- (e) other preparations containing 15 mg/kg or 15 mg/L or less of fluoride ion.

FLUPROPANATE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL **except** in fertilisers containing 0.5 per cent or less of flutriafol.

FLUVALINATE **except** when included in Schedule 5.

FORMALDEHYDE (excluding its derivatives) **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 5 per cent or less of formaldehyde.

FORMOTHION.

FOSPIRATE **except** when included in Schedule 5.

FUMAGILLIN.

GLUTARALDEHYDE **except**:

- (a) when included in Schedule 2 or 5; or
- (b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

SCHEDULE 6-continued

GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:

Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:

- (a) in cosmetic preparations for salon use only which are labelled in accordance with the *National Occupational Health and Safety Commission's National Code of Practice for the Labelling of Workplace Substances* [NOHSC:2012 (1994)] or its successors;
- (b) in preparations containing 5 per cent or less of glycolic acid; or
- (c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.

GUAZATINE.

HALOXON.

HALOXYFOP.

HEPTACHLOR.

HEXACHLOROPHANE in preparations for the treatment of animals.

HEXAZINONE **except** when included in Schedule 5.

HYDRAMETHYLNON **except** when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5;
- (b) in preparations for therapeutic use; or
- (c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride **except** when included in Schedule 5.

SCHEDULE 6-continued

HYDROGEN PEROXIDE (excluding its salts and derivatives) **except:**

- (a) when included in Schedule 5;
- (b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or
- (c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROQUINONE **except:**

- (a) when included in Schedule 2 or 4; or
- (b) in preparations containing 10 per cent or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H_2SiF_6) **except** when included in Schedule 5.

IMIDACLOPRID **except:**

- (a) when included in Schedule 5; or
- (b) in preparations containing 5 per cent or less of imidacloprid.

IMIDOCARB.

IMINOCTADINE TRIALBESILATE.

IMIPROTHRIN **except:**

- (a) when included in Schedule 5; or
- (b) in preparations containing 10 per cent or less of imiprothrin.

INDOXACARB (Includes the R and S enantiomers) **except** when included in Schedule 5.

IODINE (excluding its salts, derivatives and iodophors) **except:**

- (a) when included in Schedule 2; or
- (b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.

SCHEDULE 6-continued

IODOPHORS **except** in preparations containing 1.5 per cent or less of available iodine.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) **except:**

- (a) when included in Schedule 5; or
- (b) in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IOXYNIL.

IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals **except:**

- (a) when included in Schedule 5;
- (b) in liquid or gel preparations containing 0.1 per cent or less of iron; or
- (c) in animal feeds or feed premixes.

ISOCONAZOLE for external treatment of animals.

ISOCYANATES, free organic, boiling below 300° C, **except** in:

- (a) viscous polyurethane adhesives; or
- (b) viscous polyurethane sealants;

containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.

ISOEUGENOL **except:**

- (a) when included in Schedule 5; or
- (b) in preparations containing 10 per cent or less of isoeugenol.

LAMBDA-CYHALOTHRIN:

- (a) in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or
- (b) in other preparations containing 1 per cent or less of lambda-cyhalothrin,
except when included in Schedule 5.

SCHEDULE 6-continued

LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURYLISOQUINOLINIUM BROMIDE.

LEAD COMPOUNDS **except**:

- (a) when included in Schedule 4 or 5;
- (b) in zinc based paints or tinters containing 0.2 per cent or less of lead as an impurity in the zinc and calculated on the non-volatile content of the paint or tinter;
- (c) in other paints or tinters containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint or tinter;
- (d) in preparations for cosmetic use containing 100 mg/kg or less of lead;
- (e) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or
- (f) in ceramic glazes when labelled with the warning statement:

CAUTION - Harmful if swallowed. Do not use on surfaces which contact food or drink.

written in letters not less than 1.5 mm in height.

LEVAMISOLE for the treatment of animals **except**:

- (a) when included in Schedule 4 or 5; or
- (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE **except** when included in Schedule 2, 4 or 5.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALDISON (malathion) **except**:

- (a) when included in Schedule 5;
- (b) for human therapeutic use; or
- (c) in dust preparations containing 2 per cent or less of maldison.

SCHEDULE 6-continued

MCPA **except** when included in Schedule 5.

MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.

MECOPROP **except** when included in Schedule 5.

MECOPROP-P.

MEFLUIDIDE.

MELALEUCA OIL (tea tree oil) **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
- (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or
- (e) in preparations containing 25 per cent or less of melaleuca oil.

MELENGESTROL ACETATE when used as an animal feed additive.

MENAZON.

2-MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

SCHEDULE 6-continued

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METALAXYL **except** when included in Schedule 5.

METALDEHYDE **except** when included in Schedule 5.

METHACRIFOS in preparations containing 60 per cent or less of methacrifos.

METHAM.

METHANOL (excluding its derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 2 per cent or less of methanol.

METHIOCARB in preparations containing 20 per cent or less of methiocarb **except** when included in Schedule 5.

METHOMYL in fly-baits containing one per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.

METHYLENE BISTHIOCYANATE **except** in preparations containing 1 per cent or less of methylene bithiocyanate.

METHYLEUGENOL **except** in preparations containing 1 per cent or less of methyleugenol.

METHYL ISOTHIOCYANATE.

METHYL NEODECANAMIDE **except** in liquid preparations containing 2 per cent or less of methyl neodecanamide.

N-METHYL-2-PYRROLIDONE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE excluding admixtures (see also Schedule 5).

SCHEDULE 6-continued

METOSULAM.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN **except** when included in Schedule 5.

MONENSIN in animal feed premixes containing 12.5 per cent or less of antibiotic substances.

MORANTEL **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 10 per cent or less of morantel.

MOXIDECTIN for external use:

- (a) in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or
- (b) in preparations containing 2 per cent or less of moxidectin for the treatment of animals,

except when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.

NALED **except** when included in Schedule 5.

NAPHTHALENE (excluding its derivatives).

NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.

NARASIN in animal feed premixes containing 12 per cent or less of narasin.

NETOBIMIN for the treatment of animals **except** when included in Schedule 5.

NICKEL SULFATE.

NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.

NIMIDANE in preparations containing 25 per cent or less of nimidane.

NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

SCHEDULE 6-continued

NITRIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 0.5 per cent or less of nitric acid (HNO₃).

NITROBENZENE **except**:

- (a) in solid or semi-solid polishes;
- (b) in soaps containing 1 per cent or less of nitrobenzene; or
- (c) in other preparations containing 0.1 per cent or less of nitrobenzene.

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides **except** when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;
- (c) in preparations containing 12.5 per cent or less of nonoxinol 9; or
- (d) in preparations for human use.

1-OCTEN-3-OL **except** in preparations containing 5 per cent or less of 1-octen-3-ol.

OCTHILINONE **except** in paints containing 1 per cent or less of octhilineone calculated on the non-volatile content of the paint.

N-(N-OCTYL)-2-PYRROLIDONE **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 25 per cent or less of designated solvents.

SCHEDULE 6-continued

OLAQUINDOX **except** in preparations containing 10 per cent or less of olaquinox.

N-OLEYL-1,3-DIAMINOPROPANE.

OMETHOATE in preparations containing 30 per cent or less of omethoate **except** when included in Schedule 5.

OXADIAZON.

OXALIC ACID **except** its derivatives and insoluble salts.

OXYCLOZANIDE.

PAECILOMYCES LILACINUS STRAIN 251.

PARAFORMALDEHYDE (excluding its derivatives) **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 5 per cent or less of formaldehyde.

PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

- (c) in preparations containing 4 per cent or less of d-pulegone.

PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.

SCHEDULE 6-continued

PERACETIC ACID **except** when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.

PERMETHRIN **except**:

- (a) when included in Schedule 4 or 5;
- (b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or
- (c) in preparations containing 2 per cent or less of permethrin.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:

- (a) when separately specified in these Schedules;
- (b) when included in Schedule 5; or
- (c) in preparations containing 3 per cent or less of such substances.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10 per cent or less of phenothiazine.

PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in these Schedules:

- (a) in preparations packed and labelled for photographic purposes;
- (b) in preparations packed and labelled for testing water **except** tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, "Do not discard testing solutions into the pool";
- (c) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

SCHEDULE 6-continued

written in letters not less than 1.5 mm in height; or

- (d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 15 per cent or less of phosphoric acid (H_3PO_4);
- (c) in solid or semi-solid preparations; or
- (d) in professional dental kits.

PHOXIM.

ortho-PHTHALALDEHYDE **except** when included in Schedule 5.

PICRIC ACID (excluding its derivatives) **except** in preparations containing 5 per cent or less of picric acid.

PINDONE.

PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5.

PINOXADEN **except** when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB **except** when included in Schedule 5.

SCHEDULE 6-continued

PIRIMIPHOS-ETHYL.

PIRIMIPHOS-METHYL.

POLIXETONIUM SALTS **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE **except** in preparations containing 0.5 per cent or less of potassium bromate.

POTASSIUM CYANATE.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) preparations containing 5 per cent or less of potassium hydroxide being:
 - (i) solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
 - (ii) liquid or semi-solid preparations the pH of which is 11.5 or less.

POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 0.5 per cent or less of potassium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:

- (a) when included in Schedule 5;
- (b) in solid orthodontic device cleaning preparations, the pH of which as an "in-use" aqueous solution is 2.5 or more, but not more than 11.5; or

SCHEDULE 6-continued

- (c) in preparations containing 5 per cent or less of potassium peroxydisulfate triple salt being:
- (i) solid preparations the pH of which in a 10 g/L aqueous solution is 2.5 or more; or
 - (ii) liquid or semi-solid preparations the pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) **except**:

- (a) when included in Schedule 5; or
- (b) in insecticidal mats containing 1 per cent or less of prallethrin.

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE **except** when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5;
- (b) in preparations containing 30 per cent or less of propionic acid; or
- (c) for therapeutic use.

PROPOXUR **except** when included in Schedule 5.

PROSULFOCARB.

PROTHIOFOS.

SCHEDULE 6-continued

d-PULEGONE **except** in preparations containing 4 per cent or less of d-pulegone.

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.

PYRIDALYL.

PYRIDATE.

PYRITHIONE COPPER.

PYRITHIONE ZINC **except**:

- (a) when included in Schedule 2;
- (b) in semi-solid hair preparations;
- (c) in shampoos containing 2 per cent or less of pyrrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
- (d) when immobilised in solid preparations containing 0.5 per cent or less of pyrrithione zinc.

QUATERNARY AMMONIUM COMPOUNDS **except**:

- (a) when separately specified in these Schedules;
- (b) when included in Schedule 5;
- (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
- (d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUIZALOFOP ETHYL.

QUIZALOFOP-P-ETHYL **except** when included in Schedule 5.

QUIZALOFOP-P-TEFURYL.

RESMETHRIN **except** when included in Schedule 5.

SCHEDULE 6-continued

ROTENONE **except** in solid or semi-solid preparations containing 2 per cent or less of rotenone.

† SAFROLE **except**:

- (a) for internal use; or
- (b) in other preparations containing 1 per cent or less of safrole.

SAGE OIL (Dalmatian) **except**:

- (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

- (c) in preparations containing 4 per cent or less of thujone.

SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.

SASSAFRAS OIL **except**:

- (a) for internal use; or
- (b) in other preparations containing 1 per cent or less of safrole.

SELENIUM:

- (a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:
 - (i) for the blueing of gun barrels;
 - (ii) for photographic purposes; or
 - (iii) for the colouring of lead or lead alloys;

SCHEDULE 6-continued

- (b) in coated granules containing 1 per cent or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or
- (c) for the treatment of animals:
 - (i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;
 - (ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;
 - (iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or
 - (iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.

SILICOFLUORIDES except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE except:

- (a) when included in or expressly excluded from Schedule 2; or
- (b) in preparations containing 1 per cent or less of silver.

SINBIOALLETHRIN except:

- (a) when included in Schedule 5; or
- (b) in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM ALUMINATE (excluding its salts and derivatives) except:

- (a) in solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
- (b) in liquid preparations the pH of which is 11.5 or less.

SCHEDULE 6-continued

SODIUM BROMATE **except** in preparations containing 0.5 per cent or less of sodium bromate.

SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:

- (a) when included in Schedule 5; or
- (b) preparations containing 5 per cent or less of sodium hydroxide being:
 - (i) solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
 - (ii) liquid or semi-solid preparations the pH of which is 11.5 or less.

SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite **except**:

- (a) when included in Schedule 2 or 5;
- (b) in preparations containing 0.5 per cent or less of sodium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of sodium nitrite.

SODIUM PERCARBONATE (CAS No. 15630-89-4) **except**:

- (a) when included in Schedule 5; or
- (b) in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM PERSULFATE

- (a) in hair preparations; or
- (b) in products for the treatment of water for swimming pools and spas.

SODIUM SULFIDE in preparations for use as insect lures.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.

SULFLURAMID.

SCHEDULE 6-continued

SULFURIC ACID (excluding its salts and derivatives) **except**:

- (a) in fire extinguishers; or
- (b) in preparations containing 0.5 per cent or less of sulfuric acid (H₂SO₄).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5-T.

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW
ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230 -290°C inclusive.

TCMTB (2-[thiocyanomethylthio]benzothiazole).

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) **except** when included in
Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS **except** when in Schedule 5.

TERBUTHYLAZINE **except** in preparations containing 5 per cent or less of
terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

TETRACHLOROETHYLENE **except**:

- (a) when included in Schedule 2 or 5;
- (b) in preparations containing 6 per cent or less of tetrachloroethylene when
absorbed into an inert solid; or
- (c) in preparations for the treatment of animals.

TETRACONAZOLE **except** when included in Schedule 5.

TETRADIFON.

SCHEDULE 6-continued

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2',6,6'-tetraisopropyl-diphenyl-carbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

THIAMETHOXAM **except** when included in Schedule 5.

THIAZAFLURON.

THIODICARB **except** when included in Schedule 5.

THIOMETON.

THIOUREA and ALKYL THIOUREAS **except**:

- (a) when separately specified in these Schedules; or
- (b) for therapeutic use.

THIRAM **except** in paint containing 0.5 per cent or less of thiram.

THUJONE **except** in preparations containing 4 per cent or less of thujone.

TOLUENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of toluene or toluene and xylene.

TOLUENEDIAMINE not elsewhere specified in these Schedules:

- (a) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

- (b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

SCHEDULE 6-continued

WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

TOLYLFLUANID.

TRANSFLUTHRIN **except**:

- (a) in preparations containing 1 per cent or less of transfluthrin; or
- (b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON **except**:

- (a) when included in Schedule 5; or
- (b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON **except** metrifonate included in Schedule 4.

TRICHLOROACETIC ACID **except**:

- (a) when included in Schedule 4 or 5; or
- (b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE **except** when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE **except** in preparations containing 20 per cent or less of triclabendazole.

TRICLOPYR.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

SCHEDULE 6-continued

TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20 per cent or less of trisodium nitrilotriacetate.

VAMIDOTHION.

WARFARIN **except** when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.

ZINC CHLORIDE **except**:

- (a) when included in Schedule 2; or
- (b) in preparations containing 5 per cent or less of zinc chloride.

ZINC para-PHENOLSULFONATE **except** in preparations containing 5 per cent or less of zinc para-phenolsulfonate.

ZINC SULFATE **except**:

- (a) when included in or expressly excluded from Schedule 4; or
- (b) in other preparations containing 5 per cent or less of zinc sulfate.

ZIRAM in granular preparations.

SCHEDULE 7

ABAMECTIN **except** when included in Schedule 5 or 6.

ACIBENZOLAR-S-METHYL.

ACRIFLAVINE for veterinary use **except** when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL.

ALPHA-CYPERMETHRIN **except** when included in Schedule 5 or 6.

AMINACRINE for veterinary use **except** when included in Schedule 5.

AMINOCARB **except** when included in Schedule 6.

4-AMINOPYRIDINE **except** when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC **except**:

- (a) when separately specified in this Schedule;
- (b) when included in Schedule 4 or 6;
- (c) as selenium arsenide in photocopier drums;
- (d) as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;
- (e) as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:
 - (i) in contact with food stuffs, animal feeds or potable water;
 - (ii) of clothing and footwear in contact with the skin;

SCHEDULE 7-continued

- (iii) used as infant wear; or
- (iv) intended for use as packaging materials;
- (f) in animal feeds containing 75 g/tonne or less of arsenic; or
- (g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.

AZAFENIDIN.

AZINPHOS-ETHYL.

AZINPHOS-METHYL.

AZOCYCLOTIN.

BENDIOCARB **except** when included in Schedule 5 or 6.

BENZENE (excluding its derivatives) **except**:

- (a) preparations containing 15 mL/L or less of benzene; or
- (b) petrol containing 50 mL/L or less of benzene.

BETACYFLUTHRIN **except** when included in Schedule 5 or 6.

BIFENTHRIN **except**:

- (a) when included in Schedule 6; or
- (b) in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.

BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOUM **except** when included in Schedule 6.

BROMADIOLONE **except** when included in Schedule 6.

BROMETHALIN **except** when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

SCHEDULE 7-continued

BRUCINE **except** in alcohol containing 0.02 per cent or less of brucine as a denaturant.

CACODYLIC ACID **except**:

- (a) when included in Schedule 6; or
- (b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS **except** when included in Schedule 6.

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBOFURAN.

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR **except** when included in Schedule 6.

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE **except**:

- (a) when included in Schedule 5 or 6;
- (b) in preparations containing 1 per cent or less of chlorhexidine; or
- (c) when in solid preparations.

CHLOROMETHIURON.

5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

4-CHLORO-o-TOLUIDINE.

SCHEDULE 7-continued

CHLOROPICRIN **except** when included in Schedule 6.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS **except** when included in Schedule 6.

COUMATETRALYL **except** when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic **except**:

- (a) ferricyanides;
- (b) ferrocyanides; or
- (c) when separately specified in these Schedules.

CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN **except** when included in Schedule 5 or 6.

DEMETON.

DEMETON-O-METHYL.

DEMETON-S-METHYL.

DIALIFOS.

4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2-DIBROMO-3-CHLOROPROPANE.

1,3-DICHLOROPROPENE.

DICHLORVOS **except** when included in Schedule 5 or 6.

DICROTOPHOS.

SCHEDULE 7-continued

DIFENACOUM **except** when included in Schedule 6.

DIFETHIALONE **except** when included in Schedule 6.

DIMEFOX.

4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS **except** when included in Schedule 4 or 6.

DINITROPHENOLS **except** when included in Schedule 4 or 6.

DINOCAP.

DINOSEB.

DIQUAT **except** when included in Schedule 6.

DISULFOTON **except** when included in Schedule 6.

DORAMECTIN **except** when included in Schedule 5 or 6.

DSMA **except** when included in Schedule 6.

EMAMECTIN **except** when included in Schedule 5 or 6.

ENDOSULFAN **except** when included in Schedule 6.

ENDOTHAL **except** when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR other than for human therapeutic use.

EPRINOMECTIN **except** when included in Schedule 5.

ETACONAZOLE.

ETHION.

SCHEDULE 7-continued

ETHOPROPHOS **except** when included in Schedule 6.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR **except** when included in Schedule 6.

FENAMIPHOS **except** when included in Schedule 6.

FENOXACRIM **except**:

- (a) when included in Schedule 6; or
- (b) in treated carpets.

FENSULFOTHION.

FENTHION **except** when included in Schedule 5 or 6.

FENTHION-ETHYL.

FLOCOUMAFEN **except** when included in Schedule 6.

FLUCOFURON **except**:

- (a) when included in Schedule 6; or
- (b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN.

FLUROACETAMIDE.

FLUROACETIC ACID.

FOLPET.

FORMETANATE.

FURATHIOCARB **except** when included in Schedule 5.

GAMMA-CYHALOTHRIN **except** when included in Schedule 5.

SCHEDULE 7-continued

HALOFUGINONE **except** when included in Schedule 4.

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C **except**:

- (a) when in solid polymers;
- (b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or
- (c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

HYDROCYANIC ACID **except**:

- (a) when included in Schedule 4; or
- (b) its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

LAMBDA-CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCCTANE SULFONATE **except** in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.

SCHEDULE 7-continued

MADURAMICIN **except**:

- (a) when included in Schedule 5; or
- (b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX

MECARBAM.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

- (a) when separately specified in this Schedule;
- (b) when included in Schedule 2, 4 or 6;
- (c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;
- (d) mercury (metallic) in scientific instruments;
- (e) dental amalgams; or
- (f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6.

METHOMYL **except** when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

SCHEDULE 7-continued

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL **except**:

- (a) when included in Schedule 6;
- (b) when used in laboratory analysis; or
- (c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN **except** when included in Schedule 4, 5 or 6.

MSMA **except** when included in Schedule 6.

NAPHTHALOPHOS **except** when included in Schedule 6.

NICOTINE **except**:

- (a) when included in Schedule 2, 4 or 6;
- (b) in tobacco prepared and packed for smoking; or
- (c) for use as an aid in withdrawal from tobacco smoking in chewing gum, lozenges, or preparations for sublingual or transdermal use.

NIMIDANE **except** when included in Schedule 6.

NITROFEN.

SCHEDULE 7-continued

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

OMETHOATE **except** when included in Schedule 5 or 6.

OXAMYL.

OXYDEMETHON METHYL.

PARAQUAT.

PARATHION.

PARATHION-METHYL **except** when included in Schedule 6.

PENTACHLOROPHENOL **except** when included in Schedule 6.

PHENYLMERCURIC ACETATE **except** in preparations containing 0.01 per cent or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE **except**:

- (a) when included in Schedule 5 or 6;
- (b) in preparations containing 0.5 per cent or less of potassium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

QUININE for veterinary use **except** when included in Schedule 5.

SCHEDULE 7-continued

SCHRADAN.

SELENIUM **except**:

- (a) when included in Schedule 6;
- (b) as selenium arsenide in photocopier drums;
- (c) in preparations for therapeutic use other than:
 - (i) drench concentrates containing 2.5 per cent or less of selenium; or
 - (ii) pour-on preparations containing 0.5 per cent or less of selenium;
- (d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or
- (e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN **except**:

- (a) when included in Schedule 6; or
- (b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE **except**:

- (a) when included in Schedule 2, 5 or 6;
- (b) in preparations containing 0.5 per cent or less of sodium nitrite;
- (c) when present as an excipient in preparations for therapeutic use; or
- (d) in aerosols containing 2 per cent or less of sodium nitrite.

STRYCHNINE **except** when included in Schedule 4.

SULCOFURON **except**:

- (a) when included in Schedule 6; or
- (b) in treated carpets.

SULFOTEP.

TEFLUTHRIN **except** when included in Schedule 5.

SCHEDULE 7-continued

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

- (a) when separately specified in this Schedule;
- (b) in plastics;
- (c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or
- (d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.

ortho-TOLIDINE **except** in solid-state diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (S,S,S-tributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETA-CYPERMETHRIN **except** when included in Schedule 6.

ZIRAM **except** when included in Schedule 6.

SCHEDULE 8

(Substances marked # are subject to additional controls - see Appendix D)

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

AMPHETAMINE.

AMYLOBARBITONE **except** when included in Schedule 4.

ANILERIDINE.

BENZYLMORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITONE.

BUTORPHANOL.

CARFENTANYL.

COCAINE.

CODEINE **except** when included in Schedule 2, 3 or 4.

CODEINE-N-OXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITONE.

SCHEDULE 8-continued

DEXAMPHETAMINE.

DEXTROMORAMIDE.

DEXTROPROPOXYPHENE **except** when included in Schedule 4.

DIFENOXIN **except** when included in Schedule 4.

DIHYDROCODEINE **except** when included in Schedule 2, 3 or 4.

DIHYDROMORPHINE.

DIPHENOXYLATE **except** when included in Schedule 3 or 4.

DIPIPANONE.

DRONABINOL (*delta*-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ETHYLAMPHETAMINE.

ETHYLMORPHINE **except** when included in Schedule 2 or 4.

FENTANYL.

FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMPHETAMINE.

LEVOMETHAMPHETAMINE.

LEVOMORAMIDE.

LEVORPHANOL.

METHADONE.

SCHEDULE 8-continued

METHYLAMPHETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1-METHYL-4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID
(Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINE-N-OXIDE.

NABILONE.

NORCODEINE.

NORMETHADONE.

OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

PENTOBARBITONE **except** when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER
(Pethidine intermediate B).

PHOLCODINE **except** when included in Schedule 2 or 4.

PIRITRAMIDE.

SCHEDULE 8-continued

PROPIRAM.

QUINALBARBITONE.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITONE.

SUFENTANIL.

THEBACON.

THEBAINE.

TILIDINE.

SCHEDULE 9

(Trivial or unofficial names are marked *)

ACETORPHINE.

ACETYL-ALPHA-METHYLFENTANYL.

ALKOXYAMPHETAMINES and substituted alkoxyamphetamines **except** when separately specified in these Schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.

ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines **except** when separately specified in these Schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHA-METHYLFENTANYL.

ALPHA-METHYLTHIOFENTANYL.

ALPHAMETHADOL.

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).

5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans **except** when separately specified in these Schedules.

BENZETHIDINE.

BENZYLPIPERAZINE *(BZP).

BETACETYLMETHADOL.

BETA-HYDROXYFENTANYL.

BETA-HYDROXY-3-METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

BETAPRODINE.

SCHEDULE 9-continued

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).

BUFOTENINE.

CANNABIS **except:**

- (a) when separately specified in these Schedules; or
- (b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.

CATHINONE.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE.

DESOMORPHINE.

DIAMPROMIDE.

DIETHYLTHIAMBUTENE.

N,N-DIETHYLTRYPTAMINE *(DET).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5-DIMETHOXYAMPHETAMINE *(DMA).

2,5-DIMETHOXY-4-BROMOAMPHETAMINE *(DOB).

2,5-DIMETHOXY-4-ETHYL- α -AMPHETAMINE *(DOET).

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).

SCHEDULE 9-continued

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(DMHP).

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA).

N,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

N,N-DIMETHYLTRYPTAMINE *(DMT).

DIOXAPHETYL BUTYRATE.

ECGONINE.

N-ETHYL- α -METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE *(PCE).

ETONITAZENE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

FURETHIDINE.

HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:

- (a) containing 0.1 per cent or less of harmala alkaloids; or
- (b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).

4-HYDROXYBUTANOIC ACID and its salts.

HYDROXPETHIDINE.

SCHEDULE 9-continued

ISOMETHADONE.

KETOBEMIDONE.

LEVOMETHORPHAN.

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

5-METHOXY- α -METHYLTRYPTAMINE *(5-MeO-AMT).

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE *(MMDA).

4-METHOXY- α -METHYLPHENYLETHYLAMINE *(PMA).

METHYL (2*S*, 4*aR*, 6*aR*, 7*R*, 9*S*, 10*aS*, 10*bR*)-9-ACETOXY-6*a*,10*b*-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-*c*]PYRAN-7-CARBOXYLATE *(SALVINORIN A).

4-METHYLAMINOREX.

METHYLDESORPHINE.

3,4-METHYLENEDIOXYAMPHETAMINE *(MDA).

3-METHYLFENTANYL.

N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N-HYDROXY MDA).

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).

SCHEDULE 9-continued

4-METHYLTHIOAMPHETAMINE.

3-METHYLTHIOFENTANYL.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

MUSCIMOL.

MYROPHINE.

NICOCODINE.

NICODICODINE.

NICOMORPHINE.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARA-FLUOROFENTANYL.

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE *(PCP).

PHENOMORPHAN.

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).

PIMINODINE.

PROHEPTAZINE.

SCHEDULE 9-continued

PROPERIDINE.

PSILOCYBINE.

RACEMETHORPHAN.

RACEMORPHAN.

ROLICYCLIDINE *(PHP or PCPY).

SALVIA DIVINORUM.

TENOCYCLIDINE *(TCP).

TETRAHYDROCANNABINOLS and their alkyl homologues **except:**

- (a) when separately specified in this Schedule;
- (b) when included in Schedule 8;
- (c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:
 - Not for internal use; or
 - Not to be taken; or
- (d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.

THIOFENTANYL.

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).

TRIMEPERIDINE.

3,4,5-TRIMETHOXY- α -METHYLPHENYLETHYLAMINE *(TMA).

3,4,5-TRIMETHOXYPHENETHYLAMINE (Mescaline) and other substances structurally derived from methoxy-phenylethylamine **except:**

- (a) methoxyphenamine; or
- (b) where separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBTUTANE.

PART 5 - APPENDICES

APPENDIX A**GENERAL EXEMPTIONS**

This Standard does not apply to a poison in any of the following products:

ALGICIDES, BACTERIOCIDES OR SLICIDES for industrial use that do not fit the definition of an agvet chemical product.

BACTERIAL CULTURE MEDIA containing antibiotics.

CERAMICS.

CHEMISTRY SETS:

- (a) toy, when complying with the requirements of Australian Standard AS 1647-1995 Part 3 Section 6.15; or
- (b) for educational use, containing Schedule 5 or 6 poisons in containers of 3 mL or less of each liquid preparation or 5 g or less of each solid preparation in a discrete unit.

COPPER COMPOUNDS in paints.

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.

ELECTRONIC COMPONENTS.

ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.

EXPLOSIVES.

FOOD **except**:

- (a) food additives before incorporation into food; or
- (b) when used as a means of administering a poison for therapeutic use.

FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.

GLASS (including CRYSTAL WARE).

GLAZED POTTERY.

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.

APPENDIX A-continued

INTRAOCULAR VISCOELASTIC PRODUCTS.

LUBRICANTS **except** soluble oils and solvent-deposited lubricating agents.

MATCHES.

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.

MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, as in force from time to time, **except:**

- (a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;
- (b) medical devices which include anticoagulants;
- (c) artificial tears;
- (d) urinary catheters; or
- (e) intra-articular fluids.

MOTOR, HEATING or FURNACE FUELS **except:**

- (a) when the contrary intention appears in any Schedule;
- (b) when containing methanol;
- (c) toy or hobby fuels; or
- (d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.

PAPER **except:**

- (a) when prepared for pesticidal use; or
- (b) when containing a poison included in Schedule 8 or 9.

PHOTOGRAPHIC PAPER or FILM.

PIGMENTS when immobilised in a polymer.

APPENDIX A-continued

PORCELAIN.

PRINTING INKS or INK ADDITIVES **except** when containing a pesticide.

RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.

RADIOISOTOPES for therapeutic use.

SEEDS treated with seed protectants.

SINGLE-USE TUBES for the estimation of alcohol content of breath.

TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.

TIMBER or WALLBOARD.

VITREOUS ENAMELS.

WHOLE BLOOD AND BLOOD COMPONENTS **except** when separately specified in these Schedules.

WRITING CORRECTION pens which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.

APPENDIX B

SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING

[This appendix should be read in conjunction with Appendix A]

INTRODUCTION

At various times, the NDPSC has considered substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary or not the most appropriate means of controlling the risk to public health.

Listing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

- The toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;
- The use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or
- The public access was limited such that scheduling was inappropriate or unnecessary.

The list has been developed from current scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns "Reason for Entry" and "Area of Use".

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

The NDPSC considers applications for scheduling. Applications for entry into Appendix B will not be accepted.

APPENDIX B-continued**PART 1****REASONS FOR ENTRY**

- a Low Toxicity.
- b Use pattern restricts hazard.
- c Presentation/packaging restricts hazard.
- d Industrial use only

PART 2**AREAS OF USE**

- 1. Agricultural
 - 1.1 Herbicide
 - 1.2 Insecticide
 - 1.2.1 Insecticide for codling moth
 - 1.2.2 Termiticide
 - 1.3 Fungicide
 - 1.3.1 On seed fungicide
 - 1.4 Bird Repellent
 - 1.5 Fertiliser
 - 1.6 Plant Growth Regulator
 - 1.7 Insect Pheromone
 - 1.8 Mushroom Bactericide
 - 1.9 Acaricide
 - 1.10 Biological control agent
- 2. Veterinary
 - 2.1 For animal use
 - 2.2 Treatment of mastitis in cows
 - 2.3 Coccidiostat
 - 2.4 Feed additive
 - 2.5 Antiseptic
 - 2.6 Scabicide
 - 2.7 Anthelmintic
 - 2.8 Vitamin/Mineral
 - 2.9 Growth Promotant
 - 2.10 Ectoparasiticide

APPENDIX B, Part 2-continued

3. Domestic
 - 3.1 Aromatherapy
 - 3.2 Food additive
 - 3.3 Cosmetic
 - 3.4 Human use
 - 3.5 Miticide
4. Industrial
 - 4.1 Water Treatment
 - 4.2 Biological control agent
5. Environmental
 - 5.1 Mosquito control
6. Human therapeutic use
 - 6.1 Diagnostic agent
 - 6.2 Medical device
 - 6.3 Antiseptic
 - 6.4 Sunscreen
 - 6.5 External Use
 - 6.6 Laxative
 - 6.7 Antiseborrheic
 - 6.8 Cytoprotective
 - 6.9 Vitamin/Mineral
 - 6.10 Eye Drops
7. General
 - 7.1 Any use.
 - 7.2 Excipient
 - 7.3 Synergist
 - 7.4 Flux
 - 7.5 Pesticide
 - 7.6 Insect Repellent
 - 7.7 Solvent
 - 7.8 Disinfectant
 - 7.9 Preservative
 - 7.10 Antioxidant
 - 7.11 Resin Activator/Accelerant
 - 7.12 Sweetener Artificial
 - 7.13 Food additive

APPENDIX B-continued

PART 3

SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL
BY SCHEDULING

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE	Feb 2005	b	1.7
AGROBACTERIUM RADIOBACTER	Nov 1989	a	1
ALCOHOL, DEHYDRATED	Aug 2000	b	6
ALUM	May 1997	a	7.1
ALUMINIUM AMMONIUM SULFATE	May 1997	a	7.1
ALUMINIUM POTASSIUM SULFATE	May 1997	a	7.1
ALUMINIUM SILICATE	Nov 1974	a	7.1
ALUMINIUM tris (ETHYLPHOSPHONATE)	Aug 1986	a	1
AMINACRINE	Aug 1999	b	6.3
AMMONIUM PHOSPHATE	Nov 1974	a	7.1
AMMONIUM THIOSULPHATE	Nov 1974	a	7.1
AMPROLIUM	Jun 1969	a	2.3
AMYL ACETATE	Nov 1974	a	7.1
α -AMYLASE derived from <i>Aspergillus niger</i>	Feb 2005	a	2.4
ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN			
ADJUNCT	Jun 2004	a	2.1
ASPARTIC ACID	-	a	6
ASULAM	May 1986	a	1
AZIMSULFURON	Jun 2003	a	1.1
BACILLUS SPHAERICUS STRAIN 2362	Feb 2003	a	5.1
BACILLUS THURINGIENSIS	May 1992	a	5.1
(excluding endotoxin)	Jun 2003	a	2.10
BACILLUS TOYOI	Aug 1980	a	2.9
BACULOVIRUS CYDIA POMONELLA	Jun 2006	a	1.2
BENFLURALIN	-	a	1.1
BENSULFURON-METHYL	Aug 1987	a	1
BENTONITE	Jun 2002	a	7.1

APPENDIX B, Part 3-continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
BENZYL BENZOATE	Aug 1989	a	1.3.4
BETAINE HYDROCHLORIDE	Nov 1974	a	7.1
BIFENAZATE	Oct 2002	a	1.9
BISMUTH SUBNITRATE	Nov 1999	b, c	2.1
BIURET	Nov 1974	a	2.4
BOSCALID	June 2003	a	1.3
BOVINE SOMATOTROPHIN	May 1992	a	2
BROMACIL	Aug 1987	a	1
BROMOPROPYLATE	Nov 1994	a	1
BUPIRIMATE	Nov 1990	a	1
BUTAFENACIL	May 2000	a	1
BUTOXPOLYPROPYLENE GLYCOL	Nov 1974	a	7.7
n-BUTYL BUTYRATE	-	a	7.1
n-BUTYL LACTATE	-	a	7.1
CARBETAMIDE	Aug 1991	a	1
CARBOXIN	Aug 1987	a	1
CARFENTRAZONE-ETHYL	Aug 1998	a	1
CELLULASE derived from Aspergillus niger	Feb 2005	a	2.4
CETYL ALCOHOL	Nov 1974	a	7.1
CHAMOMILE OIL	Feb 2000	a	3.1
CHINA CLAY	Nov 1974	a	7.1
CHLORFLUAZURON	Oct 2005	a	1.2.2
CHLORFLURENOL	Feb 1974	a	1.6
CHLORIDAZON	May 1988	a	1
CHLOROXYLENOLS	Feb 1975	a	7.8
CITRONELLA OIL	Feb 2000	a	7.1
CLARY SAGE OIL	Feb 2000	a	7.1
CLOPIDOL	Nov 1974	d	2.3
COBALT NAPHTHENATE	-	d	7.1
COLOPHONY	Feb 1997	b	7.4
CROSPVIDONE	Aug 1996	a	2
CULICINOMYCES CLAVOSPORUS	Nov 1982	a	5.1
CYCLAMIC ACID	Nov 1971	a	7.1
CYCLOHEXANE	Nov 1974	a	7.7

APPENDIX B, Part 3-continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
CYCLOHEXANOL ACETATE	-	a	7.7
CYROMAZINE	Nov 1980	a	2
DIBROMPROPAMIDINE	Feb 2006	a	6.10
DICLAZURIL	Nov 2001	a	2.3
DIETHYL CARBONATE	-	a	7.1
DIFLUFENICAN	Feb 1987	a	1
DIKEGULAC-SODIUM	Mar 1980	a	1.6
DIMETHICONE		a	7.1
DIMETHYL ETHER	Nov 1988	d	4
DIPHENYLAMINE	Feb 1988	a	1
DIPROPYLENE GLYCOL			
MONOMETHYL ETHER	Nov 1987	a	4
DIURON	Nov 1987	a	1
DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)	Feb 1970	a	7.1
2,2-DPA	Nov 1989	a	1
DROMETRIZOLE TRISILOXANE	Oct 2003	a	6.4
EPSIPRANTEL	Nov 1991	a	2
ETHAMETSULFURON-METHYL	Nov 2000	a	1.1
ETHOPABATE	Jun 1969	d	2.3
ETHYL ACETATE	Nov 1974	a	7.1
ETHYL ALCOHOL	Nov 1974	a	7.1
ETHYLBUTYLACETYL- AMINOPROPIONATE	Aug 2000	a	3.4
ETHYL BUTYRATE	-	a	7.1
ETHYL LACTATE	-	a	7.1
ETOXAZOLE	Oct 2003	a	1.2
FENFURAM	May 1977	a	1.3.1
FENHEXAMID	Feb 1999	a	1
FENOXYCARB	Feb 1988	a	1
FLUFENOXURON	Feb 1997	a	1
FLUMETSULAM	Feb 1992	a	1
FLUOMETURON	Aug 1989	a	1
FLUTOLANIL	Nov 2001	a	1.3
FLUROXYPYR	May 1986	a, c	1

APPENDIX B, Part 3-continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
FORCHLORFENURON	Feb 2005	a	1.6
FULLERS EARTH	Nov 1974	a	7.1
FUNGAL PROTEASE derived from Aspergillus niger	Feb 2005	a	2.4
GERANIUM OIL	Feb 2000	a	7.1
GIBBERELIC ACID	Nov 1974	a	1.6
β-GLUCANASE derived from Aspergillus niger	Feb 2005	a	2.4
HEXAFLURON	Nov 1988	a	1
HEXYL ACETATE	-	a	7.7
HEXYTHIAZOX	Feb 1988	a	1
HUMAN OSTEOGENIC PROTEIN-1 (OP-1)	Aug 2001	b	6.2
HYDROPRENE	Feb 1988	a	1
HYDROXYPROPYL CELLULOSE	Nov 1982	a	7.1
ICODextrin	Nov 2000	b	6
INDOLE-3-ACETIC ACID	Feb 1985	b	1.6
ISOPRENE ALCOHOL	-	a	7.1
IPRODIONE	Feb 1997	a	1
ISOSTEARYL ALCOHOL ETHOXYLATE	Nov 1999	a	5.1
KAOLIN	Nov 1974	a	7.1
KRESOXIM-METHYL	Aug 1999	a	1
KUNZEA OIL	Feb 2000	a	7.1
LAURIC ACID	Oct 2005	a	7.1
LAURYL ALCOHOL (1-DODECANOL)	Nov 1974	a	7.1
LAVANDIN OIL	Feb 2000	a	7.1
LAVENDER OIL	Feb 2000	a	7.1
LEAD, METALLIC	-	a	7.1
LEMONGRASS OIL	Feb 2000	a	7.1
LEPIDOPTEROUS SEX PHEROMONES	Nov 1990	a	1
LIMONENE (DIPENTENE)	Jun 2002	a	7.1
LINOLEIC ACID	Oct 2005	a	7.1
LINSEED FATTY ACIDS	Aug 1990	a	2.1
LINURON	Feb 1990	a	1
LIQUORICE, DEGLYCYRRHISINISED	May 1999	a	7.1
MALEIC HYDRAZIDE	Nov 1992	a	1
MANGANESE DIOXIDE	May 1999	b	1

APPENDIX B, Part 3-continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
MESOLSULFURON-METHYL	Feb 2002	a	1.1
METARHIZIUM ANISOPLIAE	Feb 2000	b	4.2
METARHIZIUM ANISOPLIAE	Jun 2003	a	1.10
METHOPRENE	Aug 1987	a	1
METHOXYFENOZIDE	Nov 2000	a	1
METHYL ACETATE	-	a	7.7
METHYL BENZOQUATE	Nov 1974	d	2.3
1-METHYLCYCLOPROPENE	Jun 2003	a	1.6
METHYL p-HYDROXYBENZOATE	Nov 1974	a	7.9
METSULFURONMETHYL	Nov 1985	a	1.1
MYRISTIC ACID	Oct 2005	a	7.1
NAPROPAMIDE	Aug 1987	a	1
NAPHTHYL ACETAMIDE	Nov 1974	a	1.6
NEROLI OIL	Feb 2000	a	7.1
NICABAZIN	Jun 1969	d	2.3
NISIN	Jun 2003	a	3.2
NORFLURAZON	Nov 1983	a	1.1
NOVALURON	Nov 2000	a	1
NUCLEAR POLYHEDROSIS VIRUS OF <i>HELICOVERPA</i> ARMIGERA			
OCCLUSION BODIES	Feb 2004	a	1.2
OCTYL ALCOHOLS	Nov 1974	a	7.1
OLEIC ACID	Oct 2005	a	7.1
ORANGE OIL, SWEET	Aug 2000	a	7.1
OXABETRINIL	Feb 1987	a	1
OXYFLUORFEN	May 2001	a	1
PALMAROSA OIL	Feb 2000	a	7.1
PALMITIC ACID	Oct 2005	a	7.1
PATCHOULI OIL	Feb 2000	a	7.1
PECTINASE derived from <i>Aspergillus niger</i>	Feb 2005	a	2.4
PENCYCURON	Aug 1994	a	1
PENTADECANOIC ACID	Oct 2005	a	7.1
PEPPERMINT OIL	Feb 2000	a	7.1
PHENMEDIPHAM	May 1989	a	1.1
d-PHENOTHRIN	Feb 1982	a	7.5, 1.2

APPENDIX B, Part 3-continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
PHYTASE	Feb 1996	a	2.4
PICLORAM	Aug 1987	a	1
PICOLINAFEN	May 2000	a	1
PIMELIC ACID	Oct 2005	a	7.1
PIPERONYL BUTOXIDE	Aug 1991	a	7.5
POLOXALENE	Nov 1974	a	7.1
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC)	Nov 1997	a	4.1
POLYHEDROSIS VIRUS OF HELICO ZEA OCCLUSION BODIES	Nov 1996	a	1
POLY (GNRF) OVALBUMIN	Feb 1990	a	2
POLYSORBATE 20	May 2001	a	1
PORCINE SOMATOTROPHIN	Nov 1991	c	2
POTASSIUM SORBATE	Oct 2004	a	1.3
POTASSIUM BICARBONATE	Jun 2004	a	1
PRAZIQUNTEL	Oct 2005	a	2.1
PROPAMIDINE	Nov 1992	a	6.10
PROPYL ACETATES	-	a	7.1
PROPYLENE GLYCOL	Nov 1974	a	7.1
2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER	Nov 1987	a	4
PROTHIOCONAZOLE	June 2005	a	1.3.1
PSEUDOMONAS FLUORESCENS	May 1985	a	1.8
PYRIMETHANIL	Feb 1996	a	1
PYRIPROXYFEN	Aug 1994	a	1
QUASSIA	Nov 1974	d	6, 2.1
QUINOXYFEN	Nov 2001	a	1.3
ROSEMARY OIL	Feb 2000	a	7.1
SAGE OIL (Spanish)	Feb 2000	a	7.1
SANDALWOOD OIL	Feb 2000	a	7.1
SEAWEED & UNFRACTIONED SEAWEED EXTRACTS	Feb 1985	d	1.5
SIMAZINE	Nov 1987	a	1.1
SODIUM BICARBONATE	Jun 2004	a	1
SODIUM PROPIONATE	Oct 2004	a	1.3

APPENDIX B, Part 3-continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
SOMATOTROPIN, EQUINE	Feb 1997	b	2
STERIC ACID	Oct 2005	a	7.1
SUCRALFATE	Aug 1982	a	6.8
SULESOMAB	Jun 2002	b	6.1
SULFOSULFURON	Feb 1998	a	1
SULPHATED POLYSACCHARIDES	-	a	7.1
TANNIC ACID	Dec 1965	a	7.1
TANNIC ACID/BENZYL ALCOHOL PRODUCT	Nov 1993	a	7.1
TERBACIL	Aug 1987	a	1
THAUMATIN	Nov 1990	a	3.2
THIDIAZURON	Nov 1989	a	1
TRIASULFURON	Feb 1988	a	1
TRICHODERMA HARZIANUM	May 1996	a	1
(Z)-9-TRICOSENE	Aug 1991	a	1
TRIETHYLENE GLYCOL	Nov 1974	a	7.1
TRIFLOXYSULFURON	Feb 2002	a	1.1
TRIFLURALIN	Aug 1990	a	1
TRIFORINE	Aug 1987	a	1
ULOCLADIUM OUDEMANSII	Oct 2003	a	1.10
UREA	Nov 1974	a	7.1
¹³ C-UREA	May 2001	a	6.1
VETIVER OIL	Feb 2000	a	7.1
VINYL ETHER	Nov 1987	b	6
VITAMIN K	Jul 1963	a	6.9, 2.8
XANTHOPHYLL (lutein)	Nov 1974	a	7.1
XYLANASE derived from Aspergillus niger	Feb 2005	a	2.4
YLANG YLANG OIL	Feb 2000	a	7.1
ZINC NAPHTHENATE	-	a	1.3

APPENDIX C

SUBSTANCES, OTHER THAN THOSE INCLUDED IN SCHEDULE 9, OF SUCH DANGER TO HEALTH AS TO WARRANT PROHIBITION OF SALE, SUPPLY AND USE

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

- (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
- (b) in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.

ALLYLISOPROPYLACETYLUREA for therapeutic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.

AMYGDALIN for therapeutic use.

ANCHUSA OFFICINALIS for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use **except** 'debitterised neem seed oil'.

BITHIONOL for human therapeutic use.

BORAGO OFFICINALIS (Borage) for therapeutic use **except** the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

APPENDIX C-continued

CACALIA spp. for therapeutic use.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use **except** when being used solely for experimental purposes in humans and such use:

- (a) is in accordance with an approval granted under paragraph 19(1)(b), and the requirements of subsection 19(4A), of the *Therapeutic Goods Act 1989* (as amended from time to time) - otherwise known as the Clinical Trial Exemption (CTX) scheme; or
- (b) is in accordance with the requirements of subsection 18(1) of the *Therapeutic Goods Act 1989* and Regulation 12(1A) of the *Therapeutic Goods Regulations 1990* (as amended from time to time) - otherwise known as the Clinical Trial Notification (CTN) scheme.

COAL TAR for cosmetic use other than in therapeutic goods.

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLPHTHALATE in sunscreens or personal insect repellents for human use **except** in preparations containing 0.5 per cent or less of diethylphthalate.

DI-iodoHYDROXYQUINOLINE (iodoquinol) for human internal use.

DIMETHYLPHTHALATE in sunscreens or personal insect repellents for human use **except** in preparations containing 0.5 per cent or less of dimethylphthalate.

DULCIN for therapeutic use.

ETHYLHEXANEDIOL for human use.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

APPENDIX C-continued

HELIOTROPIUM spp. for therapeutic use.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

LIGULARIA DENTATA for therapeutic use.

MELIA AZEDARACH including its extracts and derivatives.

METHYL METHACRYLATE for cosmetic use **except** in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

OXYPHENISATIN for therapeutic use.

PETASITES spp. for therapeutic use.

PHENYLENEDIAMINES in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

PTERIDIUM spp. for therapeutic use.

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use **except** in preparations containing 0.1 per cent or less of safrole.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation **except** when included in Schedule 4.

SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use **except** when included in Schedule 5.

TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

APPENDIX D

ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8

(Note - The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)

1. Poisons available only from or on the prescription or order of an authorised medical practitioner.

CLOMIPHENE for human use.

CLOZAPINE for human use.

CYCLOFENIL for human use.

DINOPROST for human use.

DINOPROSTONE for human use.

FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.

FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.

LUTEINISING HORMONE for human use.

TERIPARATIDE for human use.

UROFOLLITROPIN (human follicle-stimulating hormone) for human use.

2. Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age,:

(1) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(2) if the drug is -

(a) acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or

(b) bexarotene, isotretinoin orthalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

ACITRETIN for human use.

BEXAROTENE for human use.

ETRETINATE for human use.

ISOTRETINOIN for human oral use.

THALIDOMIDE for human use.

APPENDIX D-continued

- 3. Poisons available only from or on the prescription or order of a medical practitioner authorised by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the *Therapeutic Goods Act 1989*.**

DRONABINOL (delta-9-tetrahydrocannabinol).

- 4. Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:**

- (a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
- (b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

TRETINOIN for human oral use.

- 5. Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).**

ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

DARBEPOETIN.

DEXTROPROPOXYPHENE.

EPHEDRINE.

EPOETINS.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in this Appendix.

GLUTETHIMIDE.

INSULIN-LIKE GROWTH FACTORS.

PHENTERMINE.

SOMATROPIN (human growth hormone).

- 6. Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:**

- (a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and
- (b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

BOSENTAN for human use.

APPENDIX D-continued

- 7. Poisons available only from or on the prescription or order of a dermatologist.**

ALEFACEPT for human use.

APPENDIX E

FIRST AID INSTRUCTIONS FOR POISONS

[other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority]

INTRODUCTION

Directions for First Aid Attention

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this appendix may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as "If in eyes rinse well with water" may be appropriate.

Modified First Aid Instruction on Primary Pack

Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

- (a) each immediate container must be labelled with first aid instructions appropriate for its contents; and
- (b) the primary pack must be labelled with the statement:

FIRST AID: See inner packs.

Exempt Preparations

This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.

APPENDIX E-continued**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 131 126; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. The poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. Calls must be logged and submitted for incorporation into the official collection of poisoning data.

APPENDIX E-continued**PART 1****STANDARD STATEMENTS**

To be grouped together and prefaced with the words "FIRST AID"
(see Sub-paragraph 7(p) of this Standard).

Basic

- A For advice, contact a Poisons Information Centre (Phone *eg Australia* 13 1126; *New Zealand* 0800 764 766) or a doctor (at once).
- Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (Phone 13 1126) or a doctor.

General

- G1 Urgent hospital treatment is likely to be needed.
(Note - the words 'at once' to be added to instruction A).
- G2 If swallowed, give activated charcoal if instructed.
(Note - the words 'at once' to be added to instruction A).
- G3 If swallowed, do NOT induce vomiting.
- G4 Immediately give a glass of water.
- G5 Avoid giving milk or oils.
- G6 If sprayed in mouth, rinse mouth with water.

Eyes

- E1 If in eyes wash out immediately with water.
- E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes.

Respiratory system

- R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
- R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.

APPENDIX E, Part 1-continued*Skin*

- S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.
- S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by the Poisons Information Centre or a doctor.
- S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact the Poisons Information Centre or a doctor.
- S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by the Poisons Information Centre or a doctor.
- S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact the Poisons Information Centre.

Special Purpose

- SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (Phone *eg Australia 131 126; New Zealand 0800 764 766*) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.

APPENDIX E-continued**PART 2****FIRST AID INSTRUCTIONS**

Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the INTRODUCTION to this Appendix).

POISON	STANDARD STATEMENTS
Acetic acid	A,G3,E2,S1
Acetic anhydride	A,G3,E2,S1
Acetone	A,G3
Acrolein	A,G1,G2,G3,E2,S2,R2
Alkaline Salts	A,G3,E2,S1
Amines for use as curing agents for epoxy resins	A,G3,E1,S1
4-Aminopyridine	A,G1,G2,E1,S1
Ammonia	
• 5 per cent or less	A
• above 5 per cent	A,G3,E1,S1,R1
Ammonium persulfate	A,G3,E2
Ammonium thiocyanate	A
Anhydrides, organic acid, for use as curing agents for epoxy resins	A,G3,E1,S1
Aniline	A,S1,E2,R1
Anise oil	A,G3
Antimony chloride	A,S2,E2

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Antimony compounds, except antimony chloride	A
Azadirachta indica (neem) including its extracts and derivatives when included in Schedule 6.	A,E1
Barium salts, except barium sulfate	A
Basil oil	A,G3
Bay oil	A,G3
Benzalkonium chloride	
• when included in Schedule 5	A,G3,E2
• when included in Schedule 6	A,G3,E2,S1
Benzene	A,G3,E1,S1,R1
Benzoyl peroxide	
• above 20 per cent	A,S1,E2
• above 10 per cent up to 20 per cent	A,E1
• 10 per cent or less	A
Bergamot oil	A,G3
Bifluorides (including ammonium, potassium and sodium salts)	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,G3,E2,S5
Borax	A
Boric Acid	A
Boron trifluoride	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,E2,S5,G3

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Bromoform	A,G3,E2,R1,S2
Brucine	A,G1,G2,G3,R2
2-Butoxyethanol and its acetates	A,E2,S1
Cadmium compounds	A
Cajuput oil	A,G3
Camphor	A,G1,G3,G5
Carbamide peroxide	
• more than 9 per cent up to 60 per cent	A,G3,E2,S1
• more than 60 per cent	A,G1,G3,G4,E2,S1
Carbon disulfide	A,G3,E2,R1,S2
Carbon tetrachloride	A,G3,E1,R1,S1
Cassia oil	A,G3
Chlorinating compounds, except when separately specified, containing	
• above 4 per cent and below 10 per cent of available chlorine	A,G3,E1,S1
• 10 per cent or more of available chlorine	A,G3,E2,S1
Chlorine (gas)	A,R1,E1
Chlorocresol	A,G3,E2,S2
Chloroform	A,G3,E1,R1,S1
Chromates	A,G3,E2,S1
Chromium trioxide	A,G3,E2,S1
Cineole	A,G1,G3

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Cinnamon bark oil	A,G3
Cinnamon leaf oil	A,G3
Climbazole	A
Clove oil	A,G1,G3,E2
Copper sulfate	A,G3,E2,S1
Creosote	A,G3,E2,S1
Cresols	A,G3,E2,S3
Cresols in pressurised spray packs	A,E1,S1,G6
Cyanides	A,G1,E1,R2
Cyanoacrylic acid esters	A
Cyanuric acid	A
Cyclohexanone peroxide	A,E2,G3,S1
Cysteamine	E1
ortho-Dichlorobenzene	A,G3,E1,S1
para-Dichlorobenzene (PDB)	A
Dichloroethyl ether	A,G3,E1,S1,R1
Dichloroisocyanurates	A,G3,E1,S1
Dichloromethane (methylene chloride)	A,G3,G5,E1,S1,R1
• in pressurised spray packs	A,S1,G6
Dichromates	A,G1,G3,E2,S1
Didecyldimethylammonium chloride	A,G3,E2,S1
Diesel (distillate)	A,G3

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Diethanolamine	
• when included in Schedule 5	A,G3
• when included in Schedule 6	A,G3,E2,S1
Dimethylformamide	
• less than 75 per cent	A
• 75 per cent or more	A,E1,R1,S1
Dimethyl sulfoxide	A,G3,E1,S1
Dinitrocresols	A,G1,E1,S1
Dinitrophenols	A,G1,E1,S1
Dioxane	A,G3,E1,S1,R1
Distillate	A,G3
N-(N-Dodecyl)-2-pyrrolidone	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2,S1
Epoxy resins liquid	A,G3,E2,S1
Essential oils containing camphor as natural component unless otherwise specified.	A,G3
Ethanolamine	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2,S1
Ether	A,G3,E1,R1
Ethyl bromide	A,E2,S1,R1
Ethylene glycol	A

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Ethylene glycol monoalkyl ethers and their acetates, except when separately specified	A,G3,E2,S1
Ethylene oxide	A,E2,R1
Eucalyptus oil	A,G1,G3
Eugenol	A,G1,G3,E2
Fluorides except when separately specified	
• when included in Schedule 5	A
• when included in Schedule 6	A,G1,G3,E2,S1
Formaldehyde (see also paraformaldehyde)	A,G3,E2,S1,R1
Formic acid	A,G3,E2,S1
Glutaraldehyde	
• below 5 per cent	A,G3,E1
• 5 per cent or more	A,G3,E2,S1
Glycolic acid	A,G3,E2
Hexachlorophane when included in Schedule 6	A
Hydrazine	A,G1,G3,E2,R1,S1
Hydrocarbons, liquid	A,G3
Hydrochloric acid	A,G3,E2,S1
• when included in Schedule 5	A,G3
Hydrofluoric acid and admixtures that generate hydrofluoric acid	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,G3,E2,S5

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Hydrogen peroxide	
• more than 3 per cent up to 20 per cent	A,G3,E2,S1
• more than 20 per cent	A,G1,G3,G4,E2,S1
Hydroquinone	A,G2,G3,S1,E2,R2
Hydrosilicofluoric acid	
• when included in Schedule 5	A
• when included in Schedule 6 or 7	A,G3,E2,S5
Iodine (excluding salts, derivatives and iodophors)	
• 2.5 per cent or more for human external use	A,E2
• 2.5 per cent or more for other uses	A,S1,E2
• below 2.5 per cent	A
Iodophors	A
Isocyanates, free organic	A,E2,S1
Isophorone	A,G3,E2,S1
Kerosene	A,G3
Lauryl isoquinolinium bromide	A,E1
Lead compounds	
• in hair cosmetics	A
• in other preparations	A,S1
Lemon oil	A,G3
Lime oil	A,G3
Magnesium chlorate	A

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Maldison at 20 per cent or less	A
Marjoram oil	A,G3
Melaleuca oil	A,G1,G3
Mercuric chloride	
• for external therapeutic use	A
• for other uses	A,G1,G3,E2,R2,S1
Mercuric iodide	A,G1,G3,E2,R2,S1
Mercuric nitrate	A,G1,G3,E2,R2,S1
Mercuric oxide	A,G1,G3
Mercuric potassium iodide	A,G1,G3,E2,R2,S1
Mercuric thiocyanate	A,G1,G3,E2,R2,S1
Mercurochrome	A
Mercurous chloride	A
Mercury metallic	A
Mercury, organic compounds	A,S1
• in preparations for human external use	A
Metaldehyde	A,E1,S1
Methanol	
• above 10%	A,G3
• 10% or less	A
Methylated spirit	A,G3
Methyl ethyl ketone	A,G3
Methyl ethyl ketone peroxide	A,G3,E2,S1

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Methyleugenol	A
Methyl isoamyl ketone	A,G3
Methyl isobutyl ketone	A,G3
N-Methyl-2-pyrrolidone	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2
Methyl salicylate liquid when included in Schedule 5 or 6	A,G3,E1
Naphthalene	A,G1,G3
Nitric acid	A,G3,E2,S1
Nitrobenzene	A,G3,E1,S1
Nitrophenol	A,G3,E2,S1
Nitroprussides	
• In aerosols	A,G6,R1
• In other preparations	A,G3
Nonoxinol 9	A,E2
Nutmeg oil	A,G3
2-Octyl-4-isothiazolin-3-one (Octhilinone)	A,G3,E2,S1
N-(N-Octyl)-2-pyrrolidone	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2
Orange oil (bitter)	A,G3
Oxalic acid	A,G3,E2,S1

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Paraformaldehyde	A,G3,E2,R1,S1
Pennyroyal oil	A,G3
Peracetic acid	
• when included in Schedule 5	A,G3,E1,S1
• when included in Schedule 6	A,G3,E2,S1
Permanganates	A,G3,E2,S1
Petrol	A,G3,R1
Phenols	
• 25 per cent and less	A,G3,E2,S3
• above 25 per cent	A,G3,E2,S4
Phenols in pressurised spray packs	A,E1
Phenylenediamines and alkylated phenylenediamines	
• in hair dyes	A,E1
• in other preparations	A,G1,G3,E1,S1
Phenyl methyl ketone	
• As such, or in preparations of similar viscosity	A,G3,E1
N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine	A,E2,S1
N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,6-dimethanamine	A,E2,S1
ortho-Phenylphenol	A,G3,E2,S1
• in pressurised spray packs	A,G6,E2,S1

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Phosphonic acid	A,G3,E2,S1
• neutralised to pH 6 (approx)	A
• in spray packs	A,E2,S1
Phosphoric acid	A,G3,E2,S1
Phosphorus, yellow	A,G1,G3,E2,R2,S2
ortho-Phthalaldehyde	
• when included in Schedule 5	A,E1
• when included in Schedule 6	A,G3,E2,S1
Picric acid	A,G1,G3,E2,R1,S1
Polyethanoxy (15) tallow amine	A,E2,S1
Poly(oxy-1,2-ethanediyl), α - [2-[(2-hydroxyethyl)amino]-2- oxoethyl]- ω -hydroxy-,mono-C ₁₃₋₁₅ -alkyl ethers	A,E1
Potassium bromate	A
Potassium chlorate	A
Potassium cyanate	A,E1,S1
Potassium hydroxide	A,G3,E2,S1
Potassium metabisulphite	A
Potassium nitrite	
• when included in Schedule 7	A,G1,G3
• when included in Schedule 5 or 6	A,G3
Potassium peroxomonosulfate triple salt	
• when included in Schedule 5	A,G3,E1
• when included in Schedule 6	A,G3,E2,S1

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Potassium persulfate	A,G3,E2
Potassium sulfide	A,G3,E2,S1
Propionic acid	A,G3,E1,S1
d-Pulegone	A,G3
Pyrithione zinc	A,E1
Quaternary ammonium compounds except when separately specified	
• above 20 per cent	A,G3,E2
• 20 per cent and below	A, E2
• in pressurised spray packs	A, E2, G6
Safrole	A,G1,G3
Sage oil (Dalmatian)	A,G3
Sassafras oil	A,G1,G3
Selenium compounds	A,G1,E1,S1
Silicofluorides	
• when included in Schedule 5	A
• when included in Schedule 6	A,G1,G3,E2,S1
Silver salts	A,E2
Sodium aluminate	A,G3,E2,S1
Sodium bromate	A,G1
Sodium chlorate	A
Sodium diacetate	A,G3,E2,S1
Sodium dichloroisocyanurate	A,G3,E1,S1

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Sodium dodecylbenzene sulfonate	A,G3,E2,S1
Sodium hydrogen sulfate	A,G3,E1,S1
Sodium hydrosulfite	A,G3,E2,S1
Sodium hydroxide	A,G3,E2,S1
Sodium laureth-6 carboxylate	A
Sodium metabisulphite	A, G3
Sodium nitrite	
• when included in Schedule 7	A,G1,G3
• when included in Schedule 5 or 6	A,G3
Sodium percarbonate	
• when included in Schedule 5	A,G3,S1
• when included in Schedule 6	A,G3,E2,S1
Sodium persulfate	A,G3,E2
Sodium stannate	A,E1
Sodium sulfide	A,G3,E2,S1
Sodium trichloroacetate	A
Strychnine	A,G1,G2,G3,R2
Styrene	A,G3,S1,E1
Sulcofuron	A
Sulfamic acid	A,G3,E2,S1
Sulfuric acid	A,G3,E2,S1
Terpenes, chlorinated	A,G3

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Tetrachloroethane	A,G3,E1,R1,S1
Tetrachloroethylene	A,G3,E2,S1,R1
Thiourea	A
Thujone	A,G3
Thyme oil	A,G3
ortho-Tolidine	A
Toluene	
• above 75 per cent	A,G3,E1,S1,R1
• 75 per cent and below	A,G3
• in pressurised spray packs	A
Toluenediamine	
• in hair dyes	A,E1
• in other preparations	A,G1,G3,E1,S1
Trichloroacetic acid	A,G3,E2,S1
Trichloroacetic acid alkali salts	A
1,1,1-Trichloroethane	A,G3,E1,S1,R1
Trichloroethylene	A,G3,E1,S1,R1
Trichloroisocyanuric acid	A,G3,E1,S1
Triethanolamine	A,G3,E1,S1
Triethyl phosphate	A,E1
Trifluoromethane-sulphonic acid	A,G3,E2
Triisopropanolamine lauryl ether sulfate	A,E1,S1
Turpentine (mineral)	A,G3

APPENDIX E, Part 2-continued

POISON	STANDARD STATEMENTS
Turpentine oil (vegetable)	A,G3,E2
White spirit	A,G3
Xylene	
• above 75 per cent	A,G3,E1,S1,R1
• 75 per cent and below	A,G3
• in pressurised spray packs	A,G6,E1,S1
Xylenols	A,G3,E2,S3
• in pressurised spray packs	A,E1
Zinc chloride	A,G3,E2,S1
Zinc sulfate	A,G3,E2,S1

APPENDIX F

WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS

[other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority and medicines for human use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*]

INTRODUCTION

Warning Statements and Safety Directions

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in this appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

Poisons Information Centre Telephone Numbers

Companies should use the Poisons Information Centre telephone number(s) (Australia 131 126; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:

1. The poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and
2. Calls must be logged and submitted for incorporation into the official collection of poisoning data.

APPENDIX F-continued**PART 1****WARNING STATEMENTS**

1. Highly corrosive.
2. Corrosive.
3. Corrosive liquid.
4. Strongly alkaline.
5. Irritant.
6. May cause cancer.
7. WARNING - Causes Birth Defects.
8. WARNING - May be fatal to children.
9. Can be fatal to children if sucked or swallowed.
10. May produce severe burns.
11. WARNING - Vapour may be harmful.
12. Vapour is harmful to health on prolonged exposure.
13. May be fatal if inhaled, swallowed or absorbed through skin.
14. Dust will irritate and burn eyes, nose and skin.
15. Liquid will cause burns.
16. Forms dangerous gas near radiators or naked flames.
17. Contact with eyes even for short periods can cause blindness.
18. Product will irritate the eyes, nose, throat and skin.
19. WARNING - Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.
20. May give off dangerous gas if mixed with other products.

APPENDIX F, Part 1-continued

21. **WARNING** - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
22. Highly reactive oxidising chlorine compound.
23. May cause fire or explosion.
24. For external washing only. Rinse skin thoroughly after use.
25. Do not use on broken skin. Wash hands thoroughly after use.
26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.
27. Not for therapeutic use.
28. (Over) (Repeated) exposure may cause sensitisation.
29. If congestion persists, consult your doctor or pharmacist.
30. **WARNING** - Do not use on face or on anal or genital areas.
31. **WARNING** - Do not use on face or on anal or genital areas except on doctor's advice.
32. This preparation should be part of an overall treatment plan regularly assessed with your doctor.
33. Do not take for periods longer than four weeks except on medical advice.
34. **WARNING** - This medication may be dangerous when used in large amounts or for a long time (period).
35. **CAUTION** - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

or

CAUTION - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.
36. For use under medical supervision only.

APPENDIX F, Part 1- continued

37. Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.
38. CAUTION - Do not use for children under 2 years old unless a doctor has told you to.
39. This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.
40. This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.
41. Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor's advice.
42. WARNING - Overuse may stain the skin or mouth.
43. Use of this product is not necessary in areas supplied with fluoridated water.
44. WARNING - May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.
45. WARNING - If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor's advice.
46. WARNING - Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).
47. WARNING - This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
48. WARNING - This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.
49. WARNING - Do not mix with other medication except on veterinarian's advice.
50. Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.

APPENDIX F, Part 1- continued

51. Irritant to skin, eyes, mucous membranes and upper respiratory tract.
52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.
53. CAUTION - (Name of substance) should not be used by pregnant women.
54. Seek medical advice before first course of treatment.
55. Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.
56. WARNING - Can cause elevated blood pressure and interact adversely with other medication.
57. Not to be applied to infants under 12 months of age unless on doctor's advice.
58. Highly reactive oxidising bromine and chlorine compound.
59. May cause allergy.
60. Do not mix with detergents or other chemicals.
61. WARNING - Can react with other medicines. Ask your doctor or pharmacist before taking.
62. Do not use if pregnant.
63. See a doctor if you are pregnant or diabetic.
64. See a doctor (or) (*dentist*) if no better after (Insert number of days as per approved Product Information) days.
65. If getting better, keep using for (Insert number of days as per approved Product Information) days.
66. See a doctor if problem returns.
67. Do not use if pregnant or likely to become pregnant.
68. If symptoms persist beyond 5 days consult a doctor (or) (*dentist*).
69. If symptoms recur within two weeks of completing the course, consult a doctor.
70. Use only under medical supervision if you are taking other medicines.
71. Do not use during the last three months of pregnancy.

APPENDIX F, Part 1-continued

72. Do not use in the eyes.
73. Do not use for acne.
74. Do not use under waterproof bandages unless a doctor has told you to.
75. Do not use for more than 7 days unless a doctor has told you to.
76. Do not become pregnant during use or within (*Insert number of months as per approved product information*) month(s) of stopping treatment.
77. WARNING - May Cause Birth Defects.
78. Attacks skin and eyes.
79. Will irritate eyes.
80. (Intentionally blank)
81. (Intentionally blank)
82. (Intentionally blank)
83. This paint is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use on, in or around the home.
84. Breathing the vapour is dangerous.
Provide adequate ventilation during application.
Do not use in the presence of a naked flame.
Do not smoke.
85. This paint contains lead and is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use for painting any building or fixed structure.
Do not use where contact with food or drinking water is possible.
86. This tinter contains lead.
Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.
87. (*Insert brand name*) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.

APPENDIX F, Part 1-continued

88. This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.
89. Application to skin may increase sensitivity to sunlight.
90. This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.
91. CAUTION - Total iodine intake may exceed recommended level when taking this preparation.
92. WARNING - Contains iodine - do not take when pregnant **except** on physician's advice.
93. Causes severe burns, which are not likely to be immediately painful or visible.
94. WARNING - Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.
95. CAUTION - Do not use for children under 12 years old unless a doctor has told you to.
96. CAUTION - This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.
97. *Adults:* Keep to the recommended dose. Don't take this medicine for longer than a few days at a time unless advised to by a doctor.
98. *Children and adolescents:* Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.
99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 131 126; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.
100. Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.
101. Don't use [this product / name of the product]:
 If you have a stomach ulcer
 In the last 3 months of pregnancy [*This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea*]
 If you are allergic to (name of substance) or anti-inflammatory medicines.

APPENDIX F, Part 1- continued

102. Unless a doctor has told you to, don't use [this product / name of the product]:
For more than a few days at a time
With other medicines containing aspirin or other anti-inflammatory medicines
If you have asthma
In children under 12 years of age
If you are pregnant.

(Please note that the statement "In children 12-16 years of age with or recovering from chicken pox, influenza or fever" will be incorporated into WS 102 effective from 1 January 2006.)

103. See a doctor before taking [this product / name of the product] for thinning the blood or for your heart. [*This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.*]
104. Unless a doctor has told you to, don't use [this product / name of the product]:
For more than a few days at a time
With other medicines containing (name of substance) or other anti-inflammatory medicines
If you have asthma
If you are pregnant [*This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.*]
105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.

APPENDIX F -continued**PART 2****SAFETY DIRECTIONS - GENERAL**

To be grouped together and prefaced with the words "SAFETY DIRECTIONS"
- see Sub-paragraph 7(n) to this Standard.

1. Avoid contact with eyes.
2. Attacks eyes - protect eyes when using.
3. Wear eye protection when mixing or using.
4. Avoid contact with skin.
5. Wear protective gloves when mixing or using.
6. Wash hands after use.
7. Wash hands thoroughly after use.
8. Avoid breathing dust (or) vapour (or) spray mist.
9. Use only in well ventilated area.
10. Ensure adequate ventilation when using.
11. No smoking.
12. Do not allow product to come into contact with other chemicals, especially acids.
13. Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.
14. Do not allow to get damp.
15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.
16. Store and transport in an upright container.
17. Do not mix with other chemicals.
18. Do not mix with different types of chlorinating chemicals.
19. Use clean containers for dispensing.

APPENDIX F, Part 2-continued

20. Mix with water only.
21. Do not add water to product - add product to water, but in case of fire drench with water.
22. In case of spillage flush with large quantities of water.
23. Keep away from heat, sparks and naked flames.
24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.
25. Avoid contact with food.
26. Avoid contact with clothing.
27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.
28. Do not mix with hot water.
29. Obtain a supply of calcium gluconate gel.
30. (Intentionally blank.)
31. Do not use on broken skin.
32. Do not use under occlusive dressing.
33. Mix strictly according to instructions.
34. May cause fire if it comes into contact with other chemicals, paper or other flammable materials.
35. Wash gloves thoroughly, immediately after use.

APPENDIX F -continued**PART 3**

**POISONS (other than agricultural and veterinary chemicals)
TO BE LABELLED WITH WARNING STATEMENTS
OR SAFETY DIRECTIONS**

(Where more than one statement or direction is required they may be combined to form simple sentences where appropriate.)

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Acetic acid in concentrations of 80 per cent or more except when in Schedule 2.	2	1,4,8
Acetic anhydride	2	1,4,8
Acetone in concentrations greater than 75 per cent.		1,4,8
Acitretin	7,62,76	
Adapalene for topical use.	77,62	
Alclometasone when included in Schedule 3.	38,72,73, 74,75	
Alkaline salts	4	1,4
Amines used as curing agents for epoxy resins.		1,4,8,3,5
Ammonia/ammonium hydroxide in concentrations greater than 20 per cent ammonia except in smelling salts.	4	1,4,8
Ammonium persulfate	5,21,25	1,5,23,33,34
Anhydrides, organic acid, for use as curing agents for epoxy resins.		1,4,8,3,5
Aniline	13	1,4,8

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Antihistamines not separately specified in this Appendix except :	39 or 40	
(a) dermal, ocular, parenteral and paediatric preparations;		
(b) oral preparations of astemizole, desloratadine, fexofenadine, loratadine or terfenadine;		
(c) nasal preparations of azelastine; or		
(d) preparations for the treatment of animals.		
Aromatic extract oils		1,4,3,5,6
Aspirin		
(a) for inhibition of platelet aggregation.	36	
(b) in sustained release preparations containing 650mg or more of aspirin.	36	
(c) in other preparations	101,102,103	
Astemizole	61	
Azadirachta indica (neem) including its extracts and derivatives when included in Schedule 6.	67	
Azocyclotin	48	
Benzene	12	1,4,9
Benzoyl peroxide when included in Schedule 2.	55	
Benzoyl peroxide when included in Schedule 5.		1,4,8

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Bergamot oil	89	
Beryllium		1,4,8
Bifluorides (including ammonium, potassium and sodium salts)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35
Bithionol for the treatment of animals.		1,4,8
Bexarotene		
(a) for human use.	7,62,76	
(b) for topical use.	77,62	
Boron trifluoride (including mixtures that generate boron trifluoride)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35
Bosentan	7,62,76	
Bromoform		1,4,8
2-Butoxy-2'-thiocyanodiethyl ether		1,4,8
2-Butoxyethanol and its acetates		1,4,8
Camphor		
(a) in block, ball, disc or pellet form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents;	9	
(b) in other forms.	9	1

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Carbamide peroxide		
(a) more than 9 per cent up to 30 per cent	5	1
(b) more than 30 per cent up to 60 per cent	5	2
(c) more than 60 per cent	2	2,4
Carbon disulphide	12	1,4,8,9,23
Carbon tetrachloride	12	1,4,8,9
Cassia oil		4
Chlorinating compounds		
(a) in household cleaning or bleaching preparations.	20	
(b) in preparations containing less than 10 per cent of available chlorine.	11	1,4,10
(c) in liquid preparations containing 10 per cent or more of available chlorine.	3,18	1,4,6,8,10, 15,16,17,18, 19,20,22,26
(d) in dry preparations containing 10 per cent or more of available chlorine.	22,23,10,18 22,26	1,4,8,12,13, 14,15,16,17, 18,19,20,21,
(e) in dry preparations containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances).	22,10,18	1,4,8,12,13, 14,15,16,17, 18,19,20,21, 22,26
(f) in compressed block or tablets containing 10 per cent or more of available chlorine except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid.	22,23,10	12,13,14,15, 17,18,19,21

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
(g) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances) except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid.	22,10	12,13,14,15, 17,18,19,21
Chloroform when included in Schedule 6.		1,4,8
alpha-Chlorohydrin	51,13	1,4,8,9
Chromates (including dichromates) of alkali metals or ammonia		1,4,8
Chromium trioxide	2,14,15,23	1,4,8,13
Cimetidine when included in Schedule 3.	70,96	
Cinnamon bark oil		4
Clobetasone when included in Schedule 3.	72,73,74,75,95	
Clotrimazole in vaginal preparations when included in Schedule 3.	54,63,64,66	
Clove oil		1
Cyanides when included in Schedule 7.	13	4,8
Cyanuric acid		1,4,8
Cyclohexanone peroxide		1,4,8
Cysteamine		1
4,4-Diaminodiphenylmethane (methylene dianiline)		1,4,8
ortho-Dichlorobenzene		1,4,8

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
para-Dichlorobenzene		1,4
Dichloroethylene		1,4,8
Dichloroethyl ether		1,4,8
Dichloroisocyanurates		
(a) in household cleaning or bleaching preparations.	20	
(b) in preparations containing less than 10 per cent of available chlorine.	11	1,4,10
(c) in liquid preparations containing 10 per cent or more of available chlorine.	3,18	1,4,6,8,10, 15,16,17,18, 19,20,22,26
(d) in dry preparations containing 10 per cent or more of available chlorine.	10,18,22,23	1,4,8,12,13,14, 15,16,17,18,19, 20,21,22,26
(e) in dry preparations containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances).	10,18,22	1,4,8,12,13,14, 15,16,17,18,19, 20,21,22,26
(f) in anti-bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate.	60	
(g) in other compressed blocks or tablets containing 10 per cent or more of available chlorine except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only.	10,22,23	12,13,14,15, 17,18,19,21

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
(h) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances) except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only.	10,22	12,13,14,15,17, 18,19,21
(i) in other compressed blocks or tablets containing 10 per cent or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only.		
(i) during storage	22,23,10 18,21	12,13,14,15,17,
(ii) during use	5	1,4,7,12
(j) in other compressed blocks or tablets containing 10 per cent or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5.1 (oxidising substances) in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only.		
(i) during storage	22,10 18,21	12,13,14,15,17,
(ii) during use	5	1,4,7,12
Dichloromethane (methylene chloride)		
(a) in paint or lacquer removers.	12,16	1,4,8,11
(b) other than in paint or lacquer removers.		1,4,8,25

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Diclofenac	101,104	
Diethanolamine when included in Schedule 5.	5	1,4
Diethanolamine when included in Schedule 6.	2,11,18	1,4,8
Diethyltoluamide for human use.	44	
Dimethylformamide		1,4,8
Dimethyl sulfate	2	1,4,8
Dimethyl sulfoxide		
(a) when not packed and labelled for therapeutic use.	27	1,4,5,8
(b) when packed and labelled for treatment of animals.	49	1,4,5,8
Dinitrocresols (and their homologues) except when for therapeutic use.		1,4,8
Dinitrophenols (and their homologues) except when for therapeutic use.		1,4,8
Dinocap	47	
Dioxane		1,4,8
Diphenoxylate when included in Schedule 3.	39 or 40, 41	
Econazole in vaginal preparations when included in Schedule 3.	54,63,64,66	
Ephedrine in nasal preparations for topical use.	29	
Epichlorohydrin	2	1,4,8
Epoxy resins, liquid.		1,3,4,5,8
Ethanolamine when included in Schedule 5.	5	1,4

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Ethanolamine when included in Schedule 6.	2,11,18	1,4,8
Ether when included in Schedule 5 or 6.		1,4,8
Ethoxyethylmercuric chloride		1,4
Ethyl bromide		1,4,8
Ethylene chlorohydrin		1,4,8
Ethylene glycol monoalkyl ethers and their acetates except when separately specified.		1,4,8
Ethylene oxide		1,4,8
Ethylmercuric chloride		1,4
Ethyl methacrylate	28	4,9,23
Etretnate		7,62,76
Eugenol		1
Famotidine when included in Schedule 2.	96	
Fenoterol in metered aerosols.	32	
Fluconazole in oral preparations when included in Schedule 3.	64	
Fluorides (including silicofluorides) when included in Schedule 5 or 6 except when separately specified.		1,4
Formaldehyde		1,4,8
Formic acid	1,4,8	

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Glazing preparations containing lead compounds.	50	
Glutaraldehyde except when in Schedule 2		
(a) 25 per cent or less.	5,59	1,4,5
(b) more than 25 per cent.	3,59	1,4,5,8
Glycolic acid	79	1,5,6,31
Hexachlorophane in preparations for skin cleansing purposes containing 3 per cent or less of hexachlorophane.	24	
Hydrazine		1,4,8
Hydrochloric acid		
(a) 30 per cent or less of HCl.		1,4
(b) more than 30 per cent of HCl.		1,4,8
Hydrocortisone		
(a) for dermal use when included in Schedule 2 or 3	38,72,73,74,75	
(b) for topical rectal use when included in Schedule 3	38,75	
Hydrocyanic acid when included in Schedule 7.	13	4,8
Hydrofluoric acid (including mixtures that generate hydrofluoric acid)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Hydrogen peroxide		
(a) more than 3 per cent up to 10 per cent.	5	1
(b) more than 10 per cent up to 20 per cent.	5	2
(c) more than 20 per cent.	2	2,4
Hydroquinone		
(a) when in Schedule 2.	45	
(b) except when in Schedule 2 or 4.		1,4
Hydrosilicofluoric acid (including mixtures that generate hydrosilicofluoric acid)		
(a) when included in Schedule 5.	2	1,4
(b) when included in Schedule 6 or 7.	1,17,93	1,3,4,5,8,29,35
8-Hydroxyquinoline (including salts and derivatives) when prepared for internal use.	33	
Ibuprofen	101,104	
Iodine		
(a) more than 20 per cent.		1,4,8
(b) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose.	91,92	
Ipratropium bromide in metered aerosols.	32	
Isocyanates (free organic)		
(a) when in paint.	28,52	1,5,8,10,27
(b) other than in paint.	28,52	1,4,8

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Isoprenaline in metered aerosols	32	
Isotretinoin		
(a) for human oral use.	7,62,76	
(b) for topical use.	62,77	
Lead compounds		
(a) in hair cosmetics.	25	
(b) when in Schedule 6.		1,4,8
Leflunomide	7,62,87	
Lemon oil	89	
Levocabastine		
(a) in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine.	62	
(b) in other preparations. either 39 or 40	62 and	
Lime oil	89	
Loperamide when in Schedule 2.	41	
Magnesium chlorate		1,4
Mefanamic acid	101,104	
Mercuric thiocyanate		1,4
Metacresolsulphonic acid and formaldehyde condensation product for the treatment of animals.		1,4
Methanol except in methylated spirit.		1,4,8
Methoxamine in nasal preparations for topical use.	29	

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Methyl chloride		1,4,8
Methylene bithiocyanate		1,4
Methyl ethyl ketone	5	1,4,8
Methyl ethyl ketone peroxide	2	2,3,4,6
Methyleugenol		1,6
Methyl iso-amyl ketone		1,4,8
Methyl iso-butyl ketone		1,4,8
Methyl iso-thiocyanate	5,12	1,4,8
1-(beta-Methyl sulphonamidoethyl)- 2-amino-3-N,N-diethylaminobenzene		1,4,8
Miconazole in vaginal preparations when included in Schedule 3.	54,63,64,66	
Misoprostol	53	
Naphazoline in nasal preparations for topical use.	29	
Naphthalene		
(a) in block, ball, disc or pellet form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents;	9,105	
(b) in other forms.	9,105	1
Naproxen	101,104	
Nicotine except when in tobacco or when included in Schedule 2.		1,4

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Nitric acid		
(a) 75 per cent or less HNO ₃ .	2	1,4
(b) more than 75 per cent HNO ₃ .	2	1,4,8
Nitrobenzene		1,4,8
Nitrophenols		1,4
Nitroprussides in aerosols.	84	8
Nizatidine when included in Schedule 2.	96	
Noradrenaline in metered aerosols.	32	
Nystatin in vaginal preparations when included in Schedule 3.	54,63,64,65,66	
Orange oil (bitter)	89	
Orciprenaline in metered aerosols.	32	
Oxalates, metallic		4,8
Oxalic acid	2	4,8
Oxymetazoline in nasal preparations for topical use.	29	
Paint		(a) First
Schedule paints.	83	
(b) Second Schedule paints.	84	
(c) Third Schedule paints.	85	
(d) Tinters containing greater than 0.1% lead.	86	
Paracetamol	97 and/or 98,99,100	
Pentachlorophenol		1,4,8

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Peracetic acid	2	1,4,8
Permanganates	2	24
Phenol and any other homologue of phenol		1,4
Phenols		5
Phenylenediamines and alkylated phenylenediamines		
(a) in hair dyes.	21	
(b) in preparations other than hair dyes.		1,4,8
Phenylephrine in nasal preparations for topical use.	29	
N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine	5,28	1,4,5,10
N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,6-dimethanamine	5,28	1,4,5,10
ortho-Phenylphenol except when in antiseptics.		1,4
Phenylpropanolamine	56	
Phenytoin in pastes for the treatment of horses.	9	
Phosphonic acid		1,4
Phosphoric acid		1,4
Phosphorus (yellow)	2	1,4
ortho-Phthalaldehyde		
• when included in Schedule 6.	51,59,52	2,4,5,8,10
• when included in Schedule 5.	51,59,52	1,4,5,8,10
Picric acid (more than 20 per cent).		1,4

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Podophyllin		
(a) in preparations specifically for use on anal or genital area.	36	
(b) in other liquid preparations when included in Schedule 2 or Schedule 3.	31	
(c) in other solid or semi-solid preparations when included in Schedule 2.	30	
Podophyllotoxin		
(a) in preparations specifically for use on anal or genital area.	36	
(b) in other liquid preparations when included in Schedule 2 or Schedule 3.	31	
(c) in other solid or semi-solid preparations when included in Schedule 2.	30	
Polihexanide		1,4,8
Polyethanoxy (15) tallow amine		1,4
Poly(oxy-1,2-ethanediyl), α -[2-[(2-hydroxyethyl)amino]-2-oxoethyl]- ω -hydroxy-, mono-C ₁₃₋₁₅ -alkyl ethers	5,88	1,5
Potassium hydroxide		
(a) in preparations containing 0.5 per cent or less of potassium hydroxide.	5	1,4,6
(b) in solid preparations containing more than 0.5 per cent of potassium hydroxide.	2,10,78	3,5,28

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
(c) in liquid preparations containing more than 0.5 per cent of potassium hydroxide.	2,10,78	3,5
Potassium metabisulphite	5,26	1,4
Potassium nitrite in pickling or curing salts	94	
Potassium persulfate	5,21,25	1,5,23,33,34
Potassium sulfide	2	1,4
Propionic acid when in Schedule 6.	2	1,4
Ranitidine when included in Schedule 2.	96	
Safrole		
(a) in preparations for therapeutic use.		1
(b) other than for therapeutic use.		1,4
Salbutamol in metered aerosols or in dry powder formulations.	32	
Salicylamide	34 or 35	
Sassafras oil		
(a) in preparations for therapeutic use.		1
(b) other than for therapeutic use.		1,4
Selenium compounds except when for therapeutic use (human or animal).		1,4,8
Silver in smoking deterrents.	42	
Sodium aluminate	2	1,4
Sodium chlorate		1,4
Sodium dodecylbenzene sulfonate	79	1

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Sodium fluoride in preparations for human ingestion when in Schedule 2.	43	
Sodium hydrogen sulfate		1,4,8
Sodium hydrosulfite (more than 50 per cent)	5,26	1,4,8
Sodium hydroxide		
(a) in preparations containing 0.5 per cent or less of sodium hydroxide.	5	1,4,6
(b) in solid preparations containing more than 0.5 per cent of sodium hydroxide.	2,10,78	3,5,28
(c) in liquid preparations containing more than 0.5 per cent of sodium hydroxide.	2,10,78	3,5
Sodium laureth-6 carboxylate	79	1
Sodium metabisulphite (more than 50 per cent)	5,26	1,4
Sodium nitrite		
• in pickling or curing salts	94	
Sodium persulfate	5,21,25	1,5,23,33,34
Sodium sulfide	2	1,4
Styrene		1,4,8
Sulfamic acid	2	1,4
Sulfuric acid	2	1,4
Symphytum spp. (Comfrey) when included in Schedule 5.		31,32

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
Tazarotene for topical use.	77,62	
Terbutaline in metered aerosols or in dry powder formulations.	32	
Terfenadine		61
Terpenes, chlorinated		1,4,8
Tetrachloroethane	12	8
Tetrachloroethylene when in Schedule 5 or 6.	12,16	1,4,8,11
Tetrahydrozoline in nasal preparations for topical use.	29	
Thalidomide	7,62,76	
Thiourea		1,4
Toluene		1,4,8
Toluenediamine		
(a) in hair dyes.	21	
(b) in preparations other than hair dyes.		1,4,8
Tramazoline in nasal preparations for topical use.	29	
Tranexamic acid when included in Schedule 3	54	
Tretinoin		
(a) for human oral use.	7,62,76	
(b) for topical use.	77,62	
Triamcinolone when in topical preparations for the treatment of mouth ulcers.	64 or 68	
Trichloroacetic acid except when for therapeutic use.	2	1,4

APPENDIX F, Part 3 -continued

POISON	WARNING STATEMENTS	SAFETY DIRECTIONS
1,1,1-trichloroethane		8,9
Trichloroethylene except when for therapeutic use.	12	1,4,5,8,9
Trichlorophenol		1,4,8
Triethanolamine	5	1,4
Triethyl phosphate		1,4,8
Trifluoromethanesulfonic acid		
(a) more than 10 per cent.	1,17	1,4,8
(b) 10 per cent or less.		1,4,8
Triisopropanolamine lauryl ether sulfate		1,4,6
3,6,9-Trioxaundecanedioic acid	5	1
Tymazoline in nasal preparations for topical use.	29	
Vinclozolin	46	
Xylene		1,4,8
Xylometazoline in nasal preparations for topical use.	29	
Zinc chloride		1,4
Zinc sulfate when in Schedule 6.		1,4

APPENDIX G

DILUTE PREPARATIONS

The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.

Column 1 Poison	Column 2 Concentration (quantity per litre or kilogram)
ACETYLCHOLINE	1 mg
ALDOSTERONE	10 micrograms
ANTIMONY COMPOUNDS	1 mg
APOMORPHINE	1 mg
ARSENIC	1 mg
ATROPA BELLADONNA (belladonna)	300 micrograms
ATROPINE	300 micrograms
CANTHARIDIN	10 micrograms
CHLORINE	5 mg
CROTON TIGLIUM (croton oil)	1 mg
DIOXANE	100 mg
ERYSIMUM spp.	1 mg
FOLLICLE-STIMULATING HORMONE	100 micrograms
GELSEMIUM SEMPERVIRENS	1 mg
GLUCAGON	100 micrograms
GLYCERYL TRINITRATE	100 micrograms
GROWTH HORMONE	10 micrograms
HALOPERIDOL	1 mg
HYDROCYANIC ACID	1 microgram
HYOSCINE	300 micrograms
HYOSCYAMINE	300 micrograms
HYOSCYAMUS NIGER	300 micrograms
HYPOTHALAMIC RELEASING FACTORS	10 micrograms
INDOMETHACIN	1 mg
MERCURY	1 mg
METHYLMERCURY	300 micrograms
NAPHTHALENE	1 mg
NERIUM OLEANDER	1 mg
OESTRADIOL	10 micrograms
OESTRONE	100 micrograms
OXYTOCIN	1 microgram
PHOSPHORUS	1 mg
PODOPHYLLUM RESIN (podophyllin)	1 mg
PROGESTERONE	1 mg
PROPRANOLOL	1 mg

APPENDIX G-continued

Column 1 Poison	Column 2 Concentration (quantity per litre or kilogram)
SELENIUM	100 micrograms
STROPHANTHUS spp.	1 mg
STRYCHNINE	1 mg
TESTOSTERONE	1 mg
THYROXINE	10 micrograms

APPENDIX H**SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED**

Amorolfine.
Azelastine.
Butoconazole.
Clobetasone.
Clotrimazole.
Diclofenac.
Dimenhydrinate for the prevention and relief of motion sickness.
Diphenoxylate.
Econazole.
Fluconazole.
Hydrocortisone.
Ketotifen.
Miconazole.
Nicotine.
Nystatin.
Orlistat.
Pseudoephedrine.
Tranexamic Acid.

APPENDIX I

UNIFORM PAINT STANDARD

This Appendix provides regulations for adoption by the States and Territories.

1. A person must not manufacture, sell, supply or use a paint containing basic lead carbonate (white lead) **except** for application as a mirror backing:
 - (1) containing not more than 15 per cent of lead in the non-volatile content of the paint; and
 - (2) applied not more than 40 microns thick; and
 - (3) covered by a paint which does not contain lead.
2. A person must not manufacture, sell, supply or use a First Schedule Paint for application to:
 - (1) a roof or for any surface to be used for the collection or storage of potable water; or
 - (2) furniture; or
 - (3) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or
 - (4) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.
3. A person must not manufacture, sell, supply or use a Third Schedule Paint for application to:
 - (1) a roof or for any surface to be used for the collection or storage of potable water; or
 - (2) furniture; or
 - (3) any fence, wall, post, gate, building (interior or exterior), bridge, pylon, pipeline, storage tank or any similar structure; or
 - (4) any premises, equipment or utensils used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.
4. A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Part 3 of Australian Standard 1647 for Childrens Toys (Safety Requirements).

APPENDIX I -continued

5. A person must not manufacture, sell, supply, or use a paint containing a pesticide **except** a fungicide, algicide, bactericide or antifouling agent.

The First Schedule

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

Substance	Proportion
ANTIMONY or antimony compounds other than antimony titanate pigments	more than 5 per cent
BARIUM salts except barium sulfate or barium metaborate	more than 5 per cent
CADMIUM or cadmium compounds	more than 0.1 per cent
CHROMIUM as chromates of ammonia, barium, potassium, sodium, strontium or zinc	more than 5 per cent
SELENIUM or selenium compounds	more than 0.1 per cent

The Second Schedule

Substance	Proportion
DICHLOROMETHANE (methylene chloride)	more than 5 per cent by wt
ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates	more than 10 per cent by vol
TOLUENE	more than 50 per cent by vol
XYLENE	more than 50 per cent by vol

The Third Schedule

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

Substance	Proportion
LEAD or lead compounds	more than 0.1 per cent
LEAD or lead compounds occurring as an impurity in zinc based paint	more than 0.2 per cent

APPENDIX J**CONDITIONS FOR AVAILABILITY AND USE OF
SCHEDULE 7 POISONS****PART 1****CONDITIONS FOR AVAILABILITY AND USE**

(NOTE - the following controls are recommended for poisons only when included in Schedule 7. These conditions for availability and use may be implemented through poisons controls or other State or Territory legislation.)

1. Not to be available except to authorised or licensed persons.
2. Not to be used in printing inks.
3. Not to be used except by or in accordance with the directions of accredited government vermin control officers.
4. Not to be used in industries which handle, process or store foods, animal feeds or packaging materials.

APPENDIX J-continued**PART 2**

A poison listed in this Appendix is to be available only in accordance with the conditions specified beside it in the "Conditions" column. The conditions apply only when the poison is included in Schedule 7.

POISON	CONDITIONS
Abamectin	1
Acibenzolar-s-methyl	1
Acrolein	1
Acrylonitrile	1
Alachlor	1
Allyl alcohol	1
4-Aminopyridine	1
Arprinocid	1
Arsenic	1
Azocyclotin	1
Benzene	1
Bifluorides (including ammonium, potassium and sodium salts)	1
Boron trifluoride	1
Brodifacoum	1
Bromadiolone	1
Bromine	1
Brucine	1
Calciferol	1
Captafol	1
Carbadox	1

APPENDIX J, Part 2-continued

POISON	CONDITIONS
Carbon tetrachloride	1
Chlordecone	1
Chlordimeform	1
Chlorine	1
Chloromethiuron	1
Chloropicrin	1
4-Chloro-o-toluidine	1
Cholecalciferol	1
Coumatetralyl	1
Cyhexatin	1
4,4-Diaminodiphenylmethane (methylene dianiline)	1
1,2-Dibromo-3-chloropropane	1
1,3-Dichloropropene	1
Difenacoum	1
4-Dimethylaminoazobenzene	1
Dinitrocresols	1
Dinitrophenols	1
Dinoseb	1
Epichlorohydrin	1
Epidermal growth factor	1
Etaconazole	1
Ethylene dibromide	1

APPENDIX J, Part 2-continued

POISON	CONDITIONS
Ethylene oxide	1
Fluoracetamide	3
Fluoroacetic acid	3
Folpet	1
Halofuginone	1
Halogenated dibenzodioxins and dibenzofurans	1
HCB	1
Hydrocyanic acid and cyanides	1
Hydrofluoric acid	1
Hydrosilicofluoric acid	1
Iodomethane	1
Maduramicin	1
Mercury	1
Methacrifos	1
Methoxyethylmercuric acetate	1
Methoxyethylmercuric chloride	1
Methyl bromide	1
4,4'-Methylenebis[2-chloroaniline]	1
Mirex	1
Molinate	1
Nicotine	1
Nitrofen	1

APPENDIX J, Part 2-continued

POISON	CONDITIONS
Phenylmercuric acetate	1
Phosphides, metallic	1
Phosphine	1
Propylene oxide	1
Pyriminuron	1
Strychnine	1
Sulcofuron	1
Tetrachloroethane	1
2,2',6,6'-Tetraisopropyl-diphenyl-carbodiimide	1
Thallium	3
ortho-Tolidine	1
Trichloroisocyanuric acid	1
Vinyl chloride	1

APPENDIX K**DRUGS REQUIRED TO BE LABELLED
WITH A SEDATION WARNING**

(See Part 3 Paragraph 45)

Alprazolam
Amisulpride
Amitriptyline
Amylobarbitone
Aripiprazole
Azatadine
Baclofen
Benztropine
Bromazepam
Brompheniramine
Buclizine
Buprenorphine
Butobarbitone
Cetirizine
Chloral Hydrate
Chlordiazepoxide
Chlormethiazole
Chlorpheniramine
Chlorpromazine
Clemastine
Clomipramine
Clonazepam
Clonidine
Clorazepate
Clozapine.
Codeine **except** when included in Schedule 2 or 3.
Cyclizine
Cyclobarbitone
Cycloserine
Cyproheptadine
Cysteamine
Dantrolene
Desipramine
Dexchlorpheniramine
Dextromoramide
Dextropropoxyphene
Diazepam
Difenoxin
Dihydrocodeine
Dimenhydrinate
Dimethindene

APPENDIX K-continued

Diphenhydramine
Diphenoxylate
Diphenylpyraline
Dothiepin
Doxepin
Doxylamine
Dronabinol (*delta*-9-tetrahydrocannabinol)
Droperidol
Duloxetine
Ethylmorphine
Fenfluramine
Flunitrazepam
Flupenthixol
Fluphenazine
Flurazepam
Gabapentin
Gemcitabine
Glutethimide
Haloperidol
Hydrocodone
Hydromorphone
Hydroxyzine
Imipramine
Lamotrigine
Levetiracetam
Levocabastine
Lorazepam
Mazindol
Mebhydrolin
Meclozine
Medazepam
Meprobamate
Mepyramine
Methadone
Methdilazine
Methocarbamol
Methylphenobarbitone
Mianserin
Mirtazapine
Morphine
Nalbuphine
Nitrazepam
Normethadone
Nortriptyline
Olanzapine
Opium in any form **except** the alkaloids Noscapine and Papaverine.
Oxazepam

APPENDIX K-continued

Oxycodone
Papaveretum
Pentazocine
Pentobarbitone
Pericyazine
Perphenazine
Pethidine
Phenelzine
Pheniramine
Phenobarbitone
Phenoperidine
Phenyltoloxamine
Pholcodine
Pimozide
Pizotifen
Prazepam
Pregabalin
Prochlorperazine
Promazine
Promethazine
Protriptyline
Quetiapine
Quinalbarbitone
Risperidone
Secbutobarbitone
Temazepam
Thenyldiamine
Thiethylperazine
Thiopropazate
Thioridazine
Thiothixene
Tramadol
Tranlycypromine
Trifluoperazine
Trimeprazine
Trimipramine
Triprolidine
Ziprasidone
Zolpidem
Zopiclone

INDEX

A

ABACAVIR	63
ABAMECTIN.....	152,188,233,330
ABCIXIMAB	63
ABRUS PRECATORIUS	269
ACAMPROSATE CALCIUM	63
ACARBOSE	63
ACEBUTOLOL.....	63
ACEPHATE	188
ACEPROMAZINE	63
ACETAMIPRID	188
ACETANILIDE.....	63
ACETARSOL.....	63
ACETAZOLAMIDE	63
ACETIC ACID	37,152,188,279,304
ACETIC ANHYDRIDE	188,279,304
ACETOHEXAMIDE.....	63
ACETONE.....	4,152,279,304
ACETORPHINE.....	249
ACETYL-ALPHA-METHYLFENTANYL	249
ACETYLCARBROMAL	63
ACETYLCHOLINE	63,324
ACETYLCYSTEINE	37,63
ACETYLDIGITOXIN	63
ACETYLDIHYDROCODEINE	245
ACETYL ISOVALERYLTYSOSIN	63
ACETYLMETHADOL	245
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE	63
ACETYLMORPHINES.....	245
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE	262
ACETYLSTROPHANTHIDIN	63
ACIBENZOLAR-S-METHYL	233,330
ACICLOVIR.....	63
ACIFLUORFEN	188
ACINITRAZOLE	188
ACIPIMOX.....	64
ACITRETIN	34,64,272,304
ACOKANTHERA OUABAIO	64
ACOKANTHERA SCHIMPERI	64
ACONITUM.....	37,64
ACORUS CALAMUS	269
ACRIFLAVINE.....	152,233
ACRIVASTINE.....	64
ACROLEIN	233,279,330
ACRYLONITRILE	233,330
ADALIMUMAB	64

ADAPALENE	34,64,304
ADEFOVIR	64
ADENOSINE	64
ADIPHENINE	64
ADONIS VERNALIS.....	64
ADRENALINE.....	56,64
ADRENOCORTICAL HORMONES.....	64
AGALSIDASE	64
AGLEPRISTONE.....	64
AGROBACTERIUM RADIOBACTER.....	262
AKLOMIDE	152
ALACHLOR.....	233,330
ALATROFLOXACIN MESYLATE	64
ALBENDAZOLE	65,152,188
ALCLOFENAC	65
ALCLOMETASONE	56,65,304
ALCOHOL,DEHYDRATED	262
ALCURONIUM	65
ALDESLEUKIN.....	65
ALDICARB	233
ALDOSTERONE	65,324
ALDOXYCARB.....	233
ALDRIN	188
ALEFACEPT.....	65,274
ALEMTUZUMAB	65
ALENDRONIC ACID.....	65
ALFACALCIDOL.....	65
ALFENTANIL	245
ALFUZOSIN.....	65
ALGICIDES	256
ALGLUCERASE.....	65
ALKALINE SALT(S)	13,16,26,152,188,269,279,304
ALKOXYAMPHETAMINES	249
ALKOXYLATED FATTY ALKYLAMINE POLYMER.....	152,188
ALKOXYPHENYLETHYLAMINES	249
ALKYL PHENYLENEDIAMINES	318
ALKYL SULFONALS	140
ALKYL TETRAHYDROCANNABINOLS	
<i>See</i> TETRAHYDROCANNABINOLS	
ALKYLTHIOAMPHETAMINES	249
ALKYL THIOUREAS	230
ALLERGENS	65
ALLETHRIN.....	153,188
ALLOPURINOL	65
ALLOXYDIM	153
ALLYL ALCOHOL	233,330
ALLYLISOPROPYLACETYLUREA	269
ALLYLOESTRENOL	65
ALLYLPRODINE.....	249

ALOSETRON.....	65
ALOXIPRIN.....	37
ALPHA-CHLOROHYDRIN.....	198,308
ALPHA-CHLORALOSE	
<i>See</i> CHLORALOSE	
ALPHA-CYPERMETHRIN.....	153,189,233
ALPHA-METHYLFENTANYL.....	249
ALPHA-METHYLTHIOFENTANYL.....	249
ALPHACETYLMETHADOL.....	245
ALPHADOLONE.....	65
ALPHAMEPRODINE.....	249
ALPHAMETHADOL.....	249
ALPHAPRODINE.....	245
ALPHAXALONE.....	65
ALPRAZOLAM.....	65,334
ALPRENOLOL.....	65
ALPROSTADIL.....	65
ALSEROXYLON.....	65
ALTEPLASE.....	66
ALTRENOGEST.....	66
ALTRETAMINE.....	66
ALUM.....	262
ALUMINIUM AMMONIUM SULFATE.....	262
ALUMINIUM PHOSPHIDE	
<i>See also</i> PHOSPHIDES, METALLIC	
ALUMINIUM POTASSIUM SULFATE.....	262
ALUMINIUM SILICATE.....	262
ALUMINIUM TRIS (ETHYLPHOSPHONATE).....	262
AMANTADINE.....	66
AMBENONIUM.....	66
AMBUCETAMIDE.....	66
AMBUTONIUM.....	66
AMCINONIDE.....	66
AMETHOCAINE.....	37,66
AMETRYN.....	153
AMFEBUTAMONE	
<i>See</i> BUPROPION	
AMICARBAZONE.....	189
AMIDITHION.....	189
AMIDOPYRINE.....	66,269
AMIFOSTINE.....	66
AMIKACIN.....	66
AMILORIDE.....	66
AMINACRINE.....	153,233,262
AMINES.....	16,153,279,304
AMINOCAPROIC ACID.....	66
AMINOCARB.....	189,233
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE.....	249
AMINOETHOXYVINYLGLYCINE.....	189

AMINOGLUTETHIMIDE	66
1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.....	189
AMINOMETRADINE	66
AMINOPHENAZONE	66,269
AMINOPHYLLINE	56,66
5-(2-AMINOPROPYL)INDAN.....	249
AMINOPTERIN.....	66
AMINOPYRALID.....	189
4-AMINOPYRIDINE.....	66,233,330,279
AMINOREX.....	66
para-AMINOSALICYLIC ACID	
<i>See</i> AMINOSALICYCLIC ACID	
AMINOSALICYLIC ACID	66
AMIODARONE	66
AMIPHENAZOLE.....	67
AMISOMETRADINE.....	67
AMISULPRIDE.....	67,334
AMITON	233
AMITRAZ.....	189,230
AMITRIPTYLINE.....	67,334
AMITROLE.....	153
AMLODIPINE	67
AMMI VISNAGA	67
AMMONIA	153,189,279,304,308
AMMONIUM BIFLUORIDE	
<i>See also</i> FLUORIDES	
AMMONIUM BROMIDE.....	67
AMMONIUM CHROMATE.....	308
AMMONIUM DICHROMATE	308
AMMONIUM HYDROXIDE	153,189,304
<i>See also</i> AMMONIA	
AMMONIUM PERSULFATE	189,279,304
AMMONIUM PHOSPHATE	262
AMMONIUM THIOCYANATE.....	153,279
AMMONIUM THIOSULPHATE	262
AMODIAQUINE.....	67
AMOROLFINE	37,56,67,326
AMOXAPINE	67
AMOXYCILLIN	67
AMPHETAMINE.....	245
AMPHOMYCIN.....	67
AMPHOTERICIN	67
AMPICILLIN	67
AMPRENAVIR.....	67
AMPROLIUM	262
AMRINONE.....	67
AMSACRINE.....	67
AMYGDALIN.....	269
AMYL ACETATE	262
AMYLASE.....	262

AMYL NITRITE.....	67
AMYLOBARBITONE.....	67,245,334
AMYLOCAINE.....	67
ANABOLIC STEROIDAL AGENTS	67,273
ANAGRELIDE.....	67
ANAKINRA	68
ANALYTICAL PREPARATIONS	256
ANASTROZOLE	68
ANCESTIM.....	68
ANCHUSA OFFICINALIS.....	269
ANCROD	68
ANDROGENIC STEROIDAL AGENTS	68,273
ANDROISOXAZOLE.....	68
ANDROSTALONE.....	113
ANDROSTANOLONE	68
ANDROSTENEDIOL	68
ANDROSTENEDIONE	68
ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT.....	262
ANDROSTERONE	x
<i>See also</i> ANABOLIC STEROIDAL AGENTS	
ANECORTAVE	68
ANGIOTENSIN AMIDE	68
ANHYDRIDES	279,304
ANHYDRIDES,ORGANIC ACID.....	153
ANILERIDINE.....	245
ANILINE	189,304,279
ANIMAL FEED PREMIX.....	1
ANISE OIL.....	27,153,279
ANISTREPLASE	68
ANTAZOLINE.....	37,68
ANTIBIOTIC SUBSTANCES	68
ANTIGENS	68
ANTI HISTAMINES.....	68,305
ANTIMONY.....	68,328
<i>See also</i> ANTIMONY COMPOUNDS	
ANTIMONY CHLORIDE.....	279
ANTIMONY COMPOUNDS	190,280,324,328
ANTISERA.....	68
APOCYNUM	68
APOMORPHINE.....	69,324
APPROPRIATE AUTHORITY	1
APPROVED NAME.....	1
APRACLONIDINE.....	69
APRAMYCIN	69
APREPITANT	69
APRONAL	69
APROTININ.....	69
ARECOLINE.....	69
ARIPIRAZOLE.....	69,334

ARISTOLOCHIA SPP	269
ARISTOLOCHIC ACID(S).....	269
AROMATIC EXTRACT OIL	239,305
<i>See also</i> HYDROCARBONS, LIQUID AROMATIC	
ARPRINOCID	233,330
ARSENIC	x,33,69,190,194,233,235,324,330
ARSENIC TRIOXIDE.....	x
ARTEMETHER.....	69
ARTICAINE.....	69
ASARUM SPP.....	269
ASPARTIC ACID	262
ASPIDOSPERMA QUEBRACHO	
<i>See</i> YOHIMBINE	
ASPIRIN.....	37,43,69,136,154,190,305
ASTEMIZOLE	69,305
ASULAM	262
ATAMESTANE	69
ATAZANAVIR	69
ATENOLOL	69
ATIPAMEZOLE	69
ATOMOXETINE	69
ATORVASTATIN.....	69
ATOSIBAN	69
ATOVAQUONE	69
ATRACURIUM BESYLATE	70
ATRAZINE	154
ATROPA BELLADONNA	38,70,324
ATROPINE.....	38,70,324
ATROPINE METHONITRATE.....	70
ATROPINE SULFATE	58,88,90
AURANOFIN.....	70
AUROTHIOMALATE SODIUM	70
AVILAMYCIN.....	70
AVIPTADIL	70
AVOPARCIN	70
AZACITIDINE	70
AZACONAZOLE.....	190
AZACYCLONOL	70
AZADIRACHTA INDICA.....	190,269,280,305,154
AZAFENIDIN	234
AZAMETHIPHOS	190
AZAPERONE.....	70
AZAPROPAZONE.....	70
AZARIBINE	70
AZATADINE	56,70,334
AZATHIOPRINE	70
AZELAIC ACID.....	39,70
AZELASTINE	39,56,70,326
AZIMSULFURON	262
AZINPHOS-ETHYL	234

AZINPHOS-METHYL.....	234
AZITHROMYCIN.....	71
AZLOCILLIN.....	71
AZOBENZENE.....	190
AZOCYCLOTIN.....	234,305,330
AZOXYSTROBIN.....	154
AZTREONAM.....	71

B

BACAMPICILLIN.....	71
BACILLUS SPHAERICUS STRAIN 2362.....	262
BACILLUS THURINGIENSIS.....	154,262
BACILLUS TOYOI.....	262
BACITRACIN.....	71
BACLOFEN.....	71,334
BACTERIAL CULTURE MEDIA.....	256
BACTERIOCIDES.....	256
BACULOVIRUS CYDIA POMONELLA.....	262
BALSALAZIDE.....	71
BAMBERMYCIN.....	71,191
BAMBUTEROL.....	71
BAMETHAN.....	71
BAMIPINE.....	71
BARBITURATES.....	71
BARIUM.....	328,191,280
BARIUM SILICOFLUORIDE.....	154
BASIC LEAD CARBONATE.....	327
BASIC ORANGE 31.....	191
BASILIXIMAB.....	71
BASIL OIL.....	27,154,280
BATTERIES.....	256
BAY OIL.....	27,191,280
BDMPEA	
<i>See</i> 4-BROMO-2,5-DIMETHOXY-PHENYLETHYLAMINE	
BEAUVERIA BASSIANA.....	154,192
BECAPLERMIN.....	71
BECLAMIDE.....	71
BECLOMETHASONE.....	39,71
BELLADONNA.....	38
BEMEGRIDE.....	71
BENACTYZINE.....	71
BENALAXYL.....	154
BENAZEPRIL.....	71
BENDIOCARB.....	154,192,234
BENDROFLUAZIDE.....	71
BENETHAMINE PENICILLIN.....	71
BENFLURALIN.....	262
BENOMYL.....	192
BENORYLATE.....	72

BENOXAPROFEN	72
BENPERIDOL	72
BENQUINOX.....	192
BENSERAZIDE	72
BENSULFURON-METHYL.....	262
BENSULIDE	192
BENTAZONE	155
BENTONITE.....	262
BENZALKONIUM CHLORIDE	155,192,280
<i>See also</i> QUATERNARY AMMONIUM COMPOUNDS	
BENZATHINE PENICILLIN	72
BENZATROPINE	72
BENZENE	234,280,305,330
BENZETHIDINE	249
BENZHEXOL	72
BENZILONIUM.....	72
BENZOCAINE.....	39,72
BENZODIAZEPINE DERIVATIVES	72
BENZOFENAP	155
BENZOYL METRONIDAZOLE	
<i>See</i> METRONIDAZOLE BENZOATE	
BENZOYL PEROXIDE	39,72,155,280,305
BENZPHETAMINE.....	72
BENZTHIAZIDE	72
BENZTROPINE	72,334
BENZYDAMINE	39,72
6-BENZYLADENINE.....	192
BENZYL BENZOATE.....	263
BENZYLMORPHINE.....	245
BENZYPENICILLIN.....	72
BENZYLPIPERAZINE	249
BEPHENIUM SALTS	39
BEPRIDIL	72
BERACTANT	72
BERGAMOT OIL	155,280,306
BERYLLIUM.....	192,306
BETA-CYPERMETHRIN	193
BETA-HYDROXYFENTANYL.....	249
BETA-HYDROXY-3-METHYLFENTANYL.....	249
BETACETYLMETHADOL.....	249
BETACYFLUTHRIN.....	155,193,234
BETAHISTINE	72
BETAINE HYDROCHLORIDE	263
BETAMEPRODINE.....	249
BETAMETHADOL.....	249
BETAMETHASONE	73
BETAPRODINE.....	249
BETAXOLOL	73
BETHANECHOL CHLORIDE	73
BETHANIDINE	73

BEVACIZUMAB	73
BEVANTOLOL.....	73
BEXAROTENE.....	34,73,272,306
BEZAFIBRATE	73
BEZITRAMIDE	245
BHC	193
BICALUTAMIDE	73
BIFENAZATE.....	263
BIFENTHRIN.....	193,234
BIFLUORIDES	155,193,234,280,306,330
BIFONAZOLE	39,73
BIMATOPROST	73
BIOALLETHRIN	155,193
BIORESMETHRIN	155
BIPERIDEN	73
BISMUTH CITRATE.....	73
BISMUTH COMPOUNDS.....	73
BISMUTH OXYCHLORIDE.....	73
BISMUTH SUBNITRATE.....	263
BISOPROLOL.....	73
BIS(TRIBUTYLTINOXIDE)	
<i>See</i> TRIBUTYL TIN OXIDE	
BITHIONOL.....	194,269,306
BIURET.....	263
BIVALIRUDIN	73
BLEACHES	
<i>See</i> CHLORINATING COMPOUNDS	
BLEOMYCIN.....	73
BLOOD	2
BLOOD COMPONENTS.....	2
BOILING TEMPERATURE	9
BOLANDIOL.....	74
BOLASTERONE.....	74
BOLAZINE	74
BOLDENONE.....	74
BOLENOL.....	74
BOLMANTALATE.....	74
BORAGE.....	269
BORAGO OFFICINALIS	269
BORATES	
<i>See</i> BORON	
BORAX	155,280
<i>See also</i> BORON	
BORIC ACID	155,280
<i>See also</i> BORON	
BORON	74,156
BORON COMPOUNDS	
<i>See</i> BORON	
BORON TRIFLUORIDE	156,194,234,280,306,330
<i>See also</i> BORON	

BORTEZOMIB	74
BOSCALID	263
BOSENTAN	74,273,306
BOTULINUM TOXINS	74
BOVINE SOMATOTROPHIN	263
BRAGANTIA SPP	269
BRETYLIUM	74
BRIMONIDINE	74
BRINZOLAMIDE	74
BRODIFACOUM	194,234,330
BROMACIL	263
BROMADIOLONE	194,234,330
BROMAZEPAM	74,334
BROMETHALIN	194,234
BROMHEXINE	40
BROMIDES	75
BROMINE	234,298,330
BROMOCHLORODIMETHYLHYDANTOIN	306
<i>See also</i> CHLORINATING COMPOUNDS	
BROMOCRIPTINE	75
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE	250
BROMOFORM	75,194,281,306
BROMOPHOS	194
BROMOPHOS-ETHYL	194
BROMOPROPYLATE	263
BROMOXYNIL	194
BROMPHENIRAMINE	40,56,75,334
BROMUCONAZOLE	156,194
BROMVALETONE	75
BROTIANIDE	194
BRUCINE	235,281,330
BRUGMANSIA	75
BUCLIZINE	56,75,334
BUCLOSAMIDE	269
BUDESONIDE	40,75
BUFEXAMAC	75
BUFOTENINE	250
BUMETANIDE	75
BUNAMIDINE	194
BUNIODYL SODIUM	269
BUPHENINE	75
BUPIRIMATE	263
BUPIVACAINE	75
BUPRENORPHINE	245,334
BUPROFEZIN	156
BUPROPION	75
BUSERELIN	75
BUSPIRONE	75
BUSULPHAN	75

BUTACAINE	75
BUTACARB.....	194
BUTAFENACIL.....	263
BUTHIDAZOLE	156
BUTOBARBITONE.....	245,334
BUTOCONAZOLE.....	56,75,326
BUTORPHANOL.....	245
BUTOXYCARBOXIM	156,194
2-(2-BUTOXY)ETHANOL	
<i>See</i> DIETHYLENE GLYCOL MONOBUTYL ETHER	
2-BUTOXYETHANOL.....	194,281,306
BUTOXPOLYPROPYLENE GYLCOL	263
2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER	194,306
BUTRACONAZOLE.....	75
BUTRALIN	156
BUTROXYDIM	156
BUTYL AMINOBENZOATE.....	75
N-BUTYL BUTYRATE.....	263
BUTYLCHLORAL HYDRATE	76
N-BUTYL LACTATE.....	263
BUTYL NITRITE.....	76
BUTYRIC ACID	194
BUTYROPHENONES	
<i>See</i> HALOPERIDOL	
BZP.....	249
C	
CABERGOLINE	76
CACALIA	270
CACODYLIC ACID	194,235
CADMIUM.....	328
<i>See also</i> CADMIUM COMPOUNDS	
CADMIUM ACETATE	
<i>See</i> CADMIUM COMPOUNDS	
CADMIUM CHLORIDE	
<i>See</i> CADMIUM COMPOUNDS	
CADMIUM COMPOUNDS.....	195,281
CADMIUM NITRATE	
<i>See</i> CADMIUM COMPOUNDS	
CADMIUM SULPHIDE	156
CADUSAFOS.....	195,235
CAFFEINE	69,136
CAJUPUT OIL	27,195,281
CALAMUS	
<i>See</i> ACORUS CALAMUS	
CALCIFEROL.....	195,235,330
CALCIPOTRIOL.....	76
CALCITONIN.....	76
CALCITRIOL.....	76

CALCIUM CARBIMIDE.....	76
CALCIUM FOLINATE	
<i>See</i> FOLINIC ACID	
CALCIUM HYPOCHLORITE	
<i>See</i> CHLORINATING COMPOUNDS	
CALCIUM POLYSTYRENE SULPHONATE.....	76
CALOMEL	
<i>See</i> MERCURIC CHLORIDE	
CALOTROPIS GIGANTEA	76
CALOTROPIS PROCERA	76
CALUSTERONE.....	76
CAMBENDAZOLE	195
CAMPHOR.....	23,30,156,196,281,306
CAMPHOR BLOCKS	
<i>See</i> CAMPHOR	
CAMPHOR OIL (WHITE)	
<i>See</i> CINEOLE	
CAMPHORATED OIL	76
CAMPHOTAMIDE.....	76
CANDESARTAN CILEXETIL.....	76
CANDICIDIN.....	76
CANINE TICK ANTI-SERUM.....	76
CANNABIS	250
CANNABIS SATIVA	5
CANTHARIDIN.....	76,324
CAPECITABINE.....	76
CAPREOMYCIN	76
CAPTAFOL.....	235,330
CAPTAN	196
CAPTODIAME	76
CAPTOPRIL.....	76
CAPURIDE	76
CARAMIPHEN	76
CARBACHOL.....	76
CARBADOX.....	235,330
CARBAMATE	16
CARBAMAZEPINE	77
CARBAMIDE PEROXIDE.....	156,197,281,307
CARBARYL.....	77,157,197
CARBAZOCHROME	77
CARBENDAZIM	197
CARBENICILLIN.....	77
CARBENOXOLONE.....	77
CARBETAMIDE.....	263
CARBETAPENTANE.....	40
CARBETOCIN.....	77
CARBIDOPA	77
CARBIMAZOLE.....	77
CARBOCISTEINE.....	40
CARBOCROMEN.....	77

CARBOFURAN	235
CARBON DISULFIDE	197,281,307
CARBON TETRACHLORIDE	235,281,307,331
CARBOPHENOTHION	235
CARBOPLATIN	77
CARBOPROST	77
CARBOSULFAN	235
CARBOXIN	263
CARBROMAL	77
CARBUTAMIDE	77
CARDIAC GLYCOSIDES	
<i>See</i> UNDER INDIVIDUAL ENTRIES	
CARBUTEROL	77
CARFENTANYL	245
CARFENTRAZONE-ETHYL	263
CARINDACILLIN	77
CARISOPRODOL	77
CARMUSTINE	77
CARNIDAZOLE	77
CARPROFEN	77
CARVEDILOL	77
CASPOFUNGIN	77
CASSIA OIL	27,157,281,307
CATALIN	
<i>See</i> PIRENOXINE	
CATHINE	77
CATHINONE	250
CEFACETRILE	77
CEFACLOR	77
CEFADROXIL	78
CEFALORIDINE	78
CEFAMANDOLE	78
CEFAPIRIN	78
CEFAZOLIN	78
CEFEPIME	78
CEFETAMET	78
CEFIXIME	78
CEFODIZIME	78
CEFONICID	78
CEFOPERAZONE	78
CEFOTAXIME	78
CEFOTETAN	78
CEFOTIAM	78
CEFOVECIN	78
CEFOXITIN	78
CEFPIROME	78
CEFPODOXIME	78
CEFSULODIN	78
CEFTAZIDIME	78
CEFTIBUTEN	78

CEFTIOFUR.....	78
CEFTRIAZONE.....	78
CEFUROXIME	78
CELECOXIB.....	79
CELIPROLOL.....	79
CELLULASE	263
CEPHACETRILE	
<i>See</i> CEFACETRILE	
CEPHAELIS ACUMINATA.....	79
CEPHAELIS IPECACUANHA	79
CEPHALEXIN	79
CEPHALONIUM	79
CEPHALORIDINE	
<i>See</i> CEFALORIDINE	
CEPHALORIDINE	79
CEPHALOTHIN	79
CEPHAMANDOLE	
<i>See</i> CEFAMANDOLE	
CEPHAPIRIN	
<i>See</i> CEFAPIRIN	
CEPHAZOLIN	
<i>See</i> CEFAZOLIN	
CEPHRADINE	79
CERAMICS	256
CERIVASTATIN	79
CERULETIDE.....	79
CETIRIZINE	40,79,334
CETRORELIX	79
CETUXIMAB.....	79
CETYL ALCOHOL	263
CHAMOMILE OIL	263
CHEMISTRY SETS	256
CHENODEOXYCHOLIC ACID	79
CHILD-RESISTANT CLOSURE	3
CHILD-RESISTANT PACKAGING	3
CHINA CLAY	263
CHLOPHEDIANOL.....	40
CHLORAL FORMAMIDE	79
CHLORAL HYDRATE.....	79,334
CHLORALOSE	79,197
CHLORAMBUCIL	79
CHLORAMPHENICOL.....	79
CHLORANDROSTENOLONE	79
CHLORAZANIL.....	79
CHLORBUTOL.....	40,56
CHLORCYCLIZINE	79
CHLORDANE.....	197
CHLORDECONE.....	235,331
CHLORDIAZEPOXIDE	80,334
CHLORDIMEFORM	235,331

CHLORFENAC.....	157
CHLORFENAPYR.....	197,235
CHLORFENETHOL	197
CHLORFENSON	157
CHLORFENVINPHOS	235
CHLORFLUAZURON.....	263
CHLORFLURENOL	263
CHLORHEXIDINE.....	157,197,235
CHLORIDAZON.....	263
CHLORINATING COMPOUNDS	157,197,281,307
CHLORINE	235,307,324,331
CHLORINE (GAS).....	281
CHLORMEQUAT.....	198
CHLORMERODRIN.....	80
CHLORMETHIAZOLE	80,334
CHLORMEZANONE.....	80
CHLORNIDINE	157
CHLOROCRESOL.....	158,281
CHLOROFORM.....	40,80,198,281,308
CHLOROMESTERONE	
<i>See</i> DEHYDROCHLOROMETHYLTESTOSTERONE	
4-CHLOROMETHANDIENONE	80
CHLOROMETHIURON	235,331
5-CHLORO-3-METHYL-4-NITROPYRAZOLE	235
CHLOROPHACINONE	198
(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)	
PENT-1-EN-3-OL	198
2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOL	80
CHLOROPICRIN	198,236,331
CHLOROQUINE.....	80
4-CHLOROTESTOSTERONE	82
<i>See also</i> CLOSTEBOL	
CHLOROTHALONIL.....	198
CHLOROTHIAZIDE	80
4-CHLORO-O-TOLUIDINE.....	235
CHLOROTRIANISENE.....	80
CHLOROXYDIENONE.....	80
CHLOROXYLENOLS	263
CHLORPHENIRAMINE	40,56,80,334
CHLORPHENTERMINE.....	80
CHLORPROMAZINE.....	80,334
CHLORPROPAMIDE.....	80
CHLORPROPHAM.....	158
CHLORPROTHIXENE	80
CHLORPYRIFOS	158,198
CHLORPYRIFOS-METHYL.....	198
CHLORQUINALDOL	80
<i>See also</i> CLIOQUINOL	
CHLORSULFURON	158
CHLORTETRACYCLINE.....	80,158

CHLORTHAL-DIMETHYL	158
CHLORTHALIDONE	80
CHLORTHIAMID	198
CHLORTHIOPHOS	236
CHLORZOXAZONE	80
CHOLECALCIFEROL	236,331
CHOLERA VACCINE	80
CHOLESTYRAMINE	80
CHROMATES	x,198,281,308
CHROMIC ACID	
<i>See</i> CHROMIUM TRIOXIDE	
CHROMIUM	328
<i>See also</i> CHROMATES	
CHROMIUM TRIOXIDE	198,281,308
CHRYSANTHEMIC ACID ESTERS	180
CHYMOPAPAIN	80
CICLACILLIN	80
CICLESONIDE	81
CICLOPIROX	40,56,81
CIDOFOVIR	81
CILASTATIN	81
CILAZAPRIL	81
CIMETIDINE	56,81,308
CINACALCET	81
CINCHOCAINE	41,81
CINCHOPHEN	270
CINEOLE	27,198,281
CINEROLONE	180
CINMETHYLIN	158
CINNAMEDRINE	41
CINNAMON BARK OIL	27,158,282,308
CINNAMON LEAF OIL	27,199,282
CINOXACIN	81
CIPROFLOXACIN	81
CISAPRIDE	81
CISATRACURIUM BESYLATE	81
CISPLATIN	81
CITALOPRAM	81
CITRONELLA OIL	263
CLADRIBINE	81
CLANOBUTIN	81
CLARITHROMYCIN	81
CLARY SAGE OIL	263
CLAVULANIC ACID	81
CLEMASTINE	56,57,81,334
CLEMIZOLE	81
CLENBUTEROL	81
CLETHODIM	158
CLIDINIUM	81

CLIMBAZOLE.....	158,200,282
CLINDAMYCIN.....	81
CLIOQUINOL.....	82,270
CLOBAZAM.....	82
CLOBETASOL.....	82
CLOBETASONE.....	57,82,308,326
CLOCORTOLONE.....	82
CLODINAFOP-PROPARGYL.....	200
CLODRONIC ACID.....	82
CLOFAZIMINE.....	82
CLOFENAMIDE.....	82
CLOFENTEZINE.....	158
CLOFIBRATE.....	82
CLOMAZONE.....	200
CLOMIPHENE.....	82,272
CLOMIPRAMINE.....	82,334
CLOMOCYCLINE.....	82
CLONAZEPAM.....	82,334
CLONIDINE.....	82,334
CLONITAZENE.....	250
CLOPAMIDE.....	82
CLOPIDOGREL.....	82
CLOPIDOL.....	263
CLOPROSTENOL.....	82
CLOPYRALID.....	159
CLOQUINTOCET-MEXYL.....	159
CLORAZEPATE.....	82,334
CLOREXOLONE.....	82
CLORPRENALINE.....	82
CLORSULON.....	159
CLOSANTEL.....	200
CLOSTEBOL.....	82
CLOTHIANIDIN.....	200
CLOTRIMAZOLE.....	41,57,82,200,308,326
CLOVE OIL.....	27,159,200,282,308
CLOXACILLIN.....	83
CLOZAPINE.....	83,272,334
CO-DERGOCRINE.....	83
CO-TRIMOXAZOLE.....	84
COAL TAR.....	270
COBALT.....	83
COBALT NAPHTHENATE.....	263
COCAINE.....	245
COCA LEAF.....	250
N-COCO-1,3-DIAMINOPROPANE.....	201
CODEINE.....	9,41,57,83,245,334
CODEINE-N-OXIDE.....	245
CODOXIME.....	250
COLASPAS.....	83

COLCHICINE	83
COLCHICUM	83
COLECALCIFEROL	
<i>See</i> VITAMIN D	
COLESTIPOL	83
COLFOSCERIL PALMITATE	83
COLISTIN	83
COLLAGEN	83
COLOPHONY	263
COLTSFOOT	
<i>See</i> TUSSILAGO	
COMFREY	183,271,321
<i>See also</i> SYMPHYTUM	
CONCENTRATE OF POPPY STRAW	245
CONIINE	270
CONIUM MACULATUM	270
CONTAINERS	24
CONVALLARIA KEISKI	83
CONVALLARIA MAJALIS	83
COPPER ACETATE	159,201
COPPER CHLORIDE	201
COPPER-CHROME-ARSENIC	
<i>See</i> CHROMATES, AND ARSENIC COMPOUNDS	
COPPER COMPOUNDS	83,159,201,256
COPPER HYDROXIDE	159,201
COPPER NITRATE	201
COPPER OXIDES	159,201
COPPER OXYCHLORIDE	159,202
COPPER SULFATE	159,202,282
CORONILLA	84
CORROSIVE SUBLIMATE	
<i>See</i> MERCUROUS CHLORIDE	
CORTICOSTERONE	84
CORTICOTROPHIN	84
CORTISONE	84
COTARNINE	270
COUMAPHOS	202,236
COUMARIN	84
COUMATETRALYL	159,202,236,331
4-CPA	159
CREOSOTE	41,202,236,282
CRESOLS	177,221,282
<i>See also</i> PHENOL	
CROSPROVIDONE	263
CROTALARIA	270
CROTON TIGLIUM	270,324
CROTOXYPHOS	202
CRUFOMATE	202
CRYSTAL VIOLET	84
CRYSTAL WARE	256

CUBÉ	
<i>See</i> ROTENONE	
CULICINOMYCES CLAVOSPORUS	263
CUPRIMYXIN	84
CURARE	84
CURING AGENTS	
<i>See</i> EPOXY RESINS	
CYANAMIDE	202
CYANATRYN	159
CYANAZINE	202
CYANIDES	33,236,282,308,332
CYANOACRYLATE ESTERS	160
CYANOACRYLIC ACID ESTERS	282
4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYLBUTANE	250
4-CYANO-1METHYL-4PHENYLPYPERIDINE	245
CYANURIC ACID	160, 282,308
CYCLAMIC ACID	263
CYCLANDELATE	84
CYCLANILIDE	202
CYCLIZINE	57,84,334
CYCLOBARBITONE	245,334
CYCLOBENZAPRINE	84
CYCLOFENIL	84,272
CYCLOHEXANE	263
CYCLOHEXANOL ACETATE	264
CYCLOHEXANONE PEROXIDE	160,282,308
CYCLOHEXIMIDE	84
N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM	202
CYCLOPENTHIAZIDE	84
CYCLOPENTOLATE	84
CYCLOPHOSPHAMIDE	84
CYCLOPROPANE	84
CYCLOPROTHRIN	160
CYCLOSERINE	84,334
CYCLOSPORIN	84
CYCLOTHIAZIDE	84
CYCLOXYDIM	160
CYCRIMINE	84
CYFLUTHRIN	160,203
CYHALOFOP-BUTYL	160
CYHALOTHRIN	236
CYHEXATIN	236,297,331
CYMARIN	84
CYMIAZOLE	160
CYNOGLOSSUM	270
CYOMETRINIL	203
CYPERMETHRIN	161,203
CYPHENOTHRIN	161,203
CYPROCONAZOLE	161
CYPRODINIL	161

CYPROHEPTADINE.....	57,84,334
CYPROTERONE	85
CYROMAZINE.....	264
CYSTEAMINE.....	85,161,203,282,308,334
CYTARABINE.....	85
CYTHIOATE	161,203

D

2,4-D.....	161
DACARBAZINE.....	85
DACLIZUMAB.....	85
DACTINOMYCIN	85
DALFOPRISTIN.....	85
DALMATIAN	28,290
DALTEPARIN	85
DAMINOZIDE.....	161
DANAPAROID	85
DANAZOL.....	85
DANTHRON.....	85
DANTROLENE.....	85,334
DAPSONE.....	85
DARBEPOETIN.....	85,273
DARIFENACIN	85
DATURA.....	41,85
DATURA STRAMONIUM.....	42,85
DATURA TATULA.....	42,85
DAUNORUBICIN.....	86
DAZOMET.....	17,203
2,4-DB	161
DDAVP	
<i>See</i> DESMOPRESSIN	
DDT	
<i>See</i> DICOPHANE	
DEANOL.....	86
DEBITTERISED NEEM SEED OIL.....	4
DEBRISOQUINE.....	86
DECAMETHONIUM SALTS.....	86
DEET	
<i>See</i> DIETHYLTOLUAMIDE	
DEFERASIROX.....	86
DEFERIPRONE	86
DEFLAZACORT.....	86
DEHYDROCHLOROMETHYLTESTOSTERONE.....	86
DEHYDROCORTICOSTERONE.....	86
DEHYDROEPIANDROSTERONE.....	131
DEHYDROISOANDROSTERONE.....	131
DEHYDROTESTOSTERONE.....	74
DELAVIRDINE	86
DELAVIRDINE MESYLATE	86

DELPHINIUM STAPHISAGRIA	42
DELTAMETHRIN	161,203,236
DELTA-9-TETRAHYDROCANNABINOL.....	246,273,335
DEMBREXINE	86,161
DEMECARIUM BROMIDE	86
DEMECLOCYCLINE.....	86
DEMETON.....	236
DEMETON-O-METHYL.....	236
DEMETON-S-METHYL	236
DENATONIUM BENZOATE	173,217
DEOXYCORTONE.....	86
DEOXYRIBONUCLEASE	86
DERRIS	
<i>See</i> ROTENONE	
DERACOXIB	86
DERMAL USE	4
2,4-DES	161
DEFERRIOXAMINE.....	86
DESFLURANE	86
DESIGNATED SOLVENT	4
DESIPRAMINE.....	86,334
DESIRUDIN	86
DESLANOSIDE.....	86
DESLORATADINE	42,86
DESTORELIN.....	87
DESMOPRESSIN	87
DESOGESTREL	87
DESOMORPHINE	250
DESONIDE	87
DESOXYMETHASONE.....	87
DET	
<i>See</i> N,N-DIETHYLTRYPTAMINE	
DETOMIDINE	87
DEXAMETHASONE.....	87
DEXAMPHETAMINE.....	246
DEXCHLORPHENIRAMINE	42,57,87,334
DEXFENFLURAMINE	87
DEXMEDETOMIDINE	87
DEXTROMETHORPHAN.....	43,87
DEXTROMORAMIDE	246,334
DEXTROPROPOXYPHENE	87,246,273,334
DEXTROPHAN.....	87
DI-ALKYL TIN COMPOUNDS	244
DIAFENTHIURON.....	161
DIALIFOS	236
N,N-DIALLYLDICHLOROACETAMIDE	162
4,4-DIAMINODIPHENYLMETHANE	236,308,331
DIAMPROMIDE.....	250
DIAMTHAZOLE	87
DIAVERIDINE	87

DIAZEPAM.....	87,334
DIAZINON.....	162,203
DIAZOXIDE	87
DIBENZEPIN.....	87
DIBENZODIOXINS	
<i>See</i> HALOGENATED DIBENZODIOXINS	
DIBENZOFURANS	
<i>See</i> HALOGENATED DIBENZODIOXINS	
DIBOTERMIN	87
1,2-DIBROMO-3-CHLOROPROPANE	236,331
DIBROMPROPAMIDINE	264
DIBUTYL TIN COMPOUNDS/SALTS	244
DICAMBA	162,203
DICHLOBENIL.....	203
DICHLOFENTHION	203
DICHLOFLUANID.....	204
DICHLONE.....	162
DICHLORALPHENAZONE.....	87
1,2-DICHLOROBENZENE	
<i>See</i> ortho-DICHLOROBENZENE	
ortho-DICHLOROBENZENE.....	204,282,308
para-DICHLOROBENZENE.....	162,282,309
1,1-DICHLORO-2,2-BIS(4-CHLOROPHENYL)ETHANE	
<i>See</i> TDE	
1,2-DICHLOROETHANE	
<i>See</i> ETHYLENE DICHLORIDE	
DICHLOROETHYLENE	309
DICHLOROETHYL ETHER	204,282,309
DICHLOROISOCYANURATES.....	282,309
<i>See also</i> CHLORINATING COMPOUNDS	
DICHLOROISOCYANURIC ACID	162,204
DICHLOROMETHANE	162,282,310,328
N-(2,6-DICHLORO-3-METHYLPHENYL)-5,7-DIMETHOXY- [1,2,4]-TRIAZOLO-[1,5A]PYRIMIDINE-2-SULFONAMIDE	
<i>See</i> METOSULAM	
4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.....	204
DICHLOROPHEN	87,162,204
4-(2,4-DICHLOROPHENOXY)BUTYRIC ACID	
<i>See</i> 2,4-DB	
1,2-DICHLOROPROPANE	204
1,3-DICHLOROPROPENE.....	236,331
DICHLORPHENAMIDE	88
2,4-DICHLORPROP	204
DICHLORVOS.....	162,204,236
DICHROMATES.....	282,308
<i>See also</i> CHROMATES	
DICLAZURIL	264
DICLOBUTRAZOL.....	163
DICLOFENAC	43,57,88,311,326
DICLOFOP-METHYL	204

DICLORAN.....	163
DICLOXACILLIN.....	88
DICOFOL.....	163
DICOPHANE.....	270
<i>See also</i> DDT	
DICROTOPHOS.....	236
DICYCLANIL.....	204
DICYCLOMINE.....	88
DIDANOSINE.....	88
DIDECYLDIMETHYL-AMMONIUM CHLORIDE.....	204,282
DIELDRIN.....	205
DIENOESTROL.....	88
DIENOGEST.....	88
DIESEL.....	282
DIETHANOLAMINE.....	163,205,283,311
DIETHAZINE.....	88
DIETHYLCARBAMAZINE.....	88
DIETHYL CARBONATE.....	264
DIETHYLENE GLYCOL MONOBUTYL ETHER.....	163
N,N-DIETHYL-M-TOLUAMIDE	
<i>See</i> DIETHYLTOLUAMIDE	
DIETHYLPHTHALATE.....	270
DIETHYLPROPION.....	88
DIETHYLSTILBOESTROL.....	139
DIETHYLTHIAMBUTENE.....	250
DIETHYLTOLUAMIDE.....	163,311
N,N-DIETHYLTRYPTAMINE.....	250
DIFENACOUM.....	205,237,331
DIFENOCONAZOLE.....	163
DIFENOXIN.....	88,246,334
DIFENZOQUAT.....	205
DIFETHIALONE.....	205,237
DIFLORASONE.....	88
DIFLOXACIN.....	88
DIFLUBENZURON.....	163
DIFLUCORTOLONE.....	88
DIFLUFENICAN.....	264
DIFLUNISAL.....	88
DIGITALIS.....	88
DIGITOXIN.....	88
DIGOXIN.....	88
DIGOXIN-SPECIFIC ANTIBODY.....	88
DIHYDRALAZINE.....	88
DIHYDROCODEINE.....	43,57,89,246,334
DIHYDROERGOTOXINE.....	89
DIHYDROLONE.....	89
DIHYDROMORPHINE.....	246
DIHYDROSTREPTOMYCIN.....	89
DI-iodohydroxyquinoline.....	58,89,270
<i>See also</i> CLIOQUINOL	

DIISOPROPYLAMINE DICHLOROACETATE	89
DIKEGULAC-SODIUM	264
DILTIAZEM.....	89
DIMEFOX	237
DIMENHYDRINATE	43,58,89,326,334
DIMENOXADOL	250
DIMEPHEPTANOL.....	250
DIMERCAPROL.....	89
DIMETHANDROSTANOLONE.....	89
DIMETHAZINE.....	89
DIMETHENAMID-P	205
DIMETHICONE.....	264
DIMETHINDENE	58,89,334
DIMETHIPIN	205
DIMETHIRIMOL.....	163
DIMETHISOQUIN	134
DIMETHOATE	205
DIMETHOMORPH.....	163
DIMETHOTHIAZINE	89
DIMETHOXANATE.....	89
2,5-DIMETHOXYAMPHETAMINE.....	250
2,5-DIMETHOXY-4-BROMOAMPHETAMINE.....	250
2,5-DIMETHOXY-4-ETHYL-A-AMPHETAMINE.....	250
2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE.....	250
2,5-DIMETHOXY-4-IODOPHENETHYLAMINE	250
2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE.....	250
DIMETHYLACETAMIDE	163,205
4-DIMETHYLAMINOAZOBENZENE.....	237,331
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE.....	250
N,N-DIMETHYLAMPHETAMINE	251
DIMETHYL ETHER.....	264
DIMETHYLFORMAMIDE	4,163,205,283,311
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO -6,6,9-TRIMETHYL-6H-DIBENZO(B,D)PYRAN	251
N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE	251
N,N-DIMETHYL-4-(PHENYLAZO)-BENZENAMINE.....	237
<i>See also</i> DIMETHYLAMINOAZOBENZENE	
DIMETHYLPHTHALATE	270
DIMETHYL SULFATE	237,311
DIMETHYL SULFOXIDE.....	89,205,283,311
DIMETHYLTHIAMBUTENE.....	251
DIMETHYL TIN COMPOUNDS	244
DIMETHYL-TIN DICHLORIDE	
<i>See</i> TIN ORGANIC COMPOUNDS	
N,N-DIMETHYLTRYPTAMINE	251
DIMETILAN	237
DIMETRIDAZOLE.....	90
DINICONAZOLE	163
2,4-DINITROCHLOROBENZENE	90
DINITROCRESOLS	90,206,237,283,311,331

DINITRONAPHTHOLS	90
DINITROPHENOLS	90,206,237,283,311,331
DINITROTHYMOLS	90
DINOCAP	237,311
DINOPROST	90,272
DINOPROSTONE	90,272
DINOSEB	237,331
DIOCTYL SODIUM SULFOSUCCINATE	
<i>See</i> DOCUSATE SODIUM	
DIOXACARB	206
DIOXANE	206,283,311,324
DIOXAPHETYL BUTYRATE	251
DIOXINS	332
<i>See also</i> HALOGENATED DIBENZODIOXINS	
DIPERODON	90
DIPHACINONE	206
DIPHEMANIL	90
DIPHENAMID	164
DIPHENHYDRAMINE	43,58,90,335
DIPHENIDOL	90
DIPHENOXYLATE	58,90,246,326,335
DIPHENYLAMINE	264
DIPHENYLPYRALINE	58,90,335
DIPHThERIA TOXOID	90
DIPIANONE	246
DIPIVEFRIN	90
DIPROPYLENE GLYCOL MONOMETHYL ETHER	264
DI-N-PROPYL ISOCINCHOMERONATE	164
DIPROPYL TIN COMPOUNDS	244
DIPYRIDAMOLE	90
DIQUAT	206,237
DIRITHROMYCIN	90
DISODIUM ETIDRONATE	95
DISODIUM TILUDRONATE	144
DISOPHENOL	90
DISOPYRAMIDE	90
DISTIGMINE	90
DISTILLATE	283
<i>See also</i> HYDROCARBONS, LIQUID	
DISTILLATION TEMPERATURE	9
DISTRIBUTOR	4
DISULFIRAM	91,206
DISULFOTON	206,237
DISULPHAMIDE	91
DITHIANON	206
DITHIAZANINE	91,206
DITHIOCARBAMATES	
<i>See</i> UNDER INDIVIDUAL ENTRIES	
DITHIOPYR	164
DITHRANOL	58

DITIOCARB.....	91
DIUREDOSAN	206
DIURON.....	264
DIVIDED PREPARATION	4
DMA	
<i>See</i> 2,5-DIMETHOXYAMPHETAMINE	
DMHP	
<i>See</i> 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO- 6,6,9- TRIMETHYL-6H-DIBENZO (B,D) PYRAN	
DMT	
<i>See</i> N,N-DIMETHYLTRYPTAMINE	
DOB	
<i>See</i> 2,5-DIMETHOXY-4-BROMOAMPHETAMINE	
DOBUTAMINE.....	91
DOCETAXEL	91
DOCUSATE SODIUM-(DIOCTYL SODIUM SULFOSUCCINATE).....	264
N-(N-DODECYL)-2-PYRROLIDONE.....	4,173,175,206,283
DODINE.....	164,206
DOET	
<i>See</i> 2,5-DIMETHOXY-4-ETHYL-A-AMPHETAMINE	
DOFETILIDE.....	91
DOLASETRON.....	91
DOM	
<i>See</i> 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE	
DOMPERIDONE	91
DONEPEZIL	91
DOPAMINE	91
DOPEXAMINE.....	91
DORAMECTIN.....	164,206,237
DORNASE	91
DORZOLAMIDE	91
DOSAGE UNIT.....	4
DOTHIEPIN	91,335
DOXANTRAZOLE.....	91
DOXAPRAM	91
DOXAZOSIN	91
DOXEPIN.....	91,335
DOXORUBICIN	91
DOXYCYCLINE.....	91
DOXYLAMINE	43,58,91,335
2,2-DPA	264
DROMETRIZOLE TRISILOXANE	264
DRONABINOL	246,273,335
DROPERIDOL	91,335
DROSPIRENONE.....	91
DROSTANOLONE.....	92
DROTEBANOL	246
DROTECOGIN	92
DRUG.....	4

DRY CLEANING FLUID	25
DSMA.....	206,237
DUBOISIA LEICHHARDTII	44,92
DUBOISIA MYOPOROIDES.....	44,92
DULCIN	270
DULOXETINE.....	92,335
DUTASTERIDE.....	92
DYDROGESTERONE	92

E

ECGONINE.....	251
ECONAZOLE	44,58,92,206,311,326
ECOTHIOPATE.....	92
ECTYLUREA.....	92
EDETIC ACID	92
EDOXUDINE.....	92
EDROPHONIUM.....	92
EFALIZUMAB.....	92
EFAVIRENZ.....	92
EFLORNITHINE.....	92
ELECTRICAL ACCUMULATORS	256
ELECTRONIC COMPONENTS.....	256
ELETRIPTAN	92
ELTENAC	92
EMAMECTIN	164,207,237
EMEPRONIUM SALTS	93
EMETINE.....	93
EMODEPSIDE	164,207
EMTRICITABINE	93
ENALAPRIL	93
ENAMELLING PREPARATIONS.....	256
ENDOSULFAN.....	207,237
ENDOTHAL.....	207,237
ENDOTOXIN.....	262
ENDRIN	237
ENESTEBOL	93
ENFLURANE.....	93
ENFUVRTIDE.....	93
ENHANCING AGENTS.....	256
ENILCONAZOLE.....	164
ENOXACIN	93
ENOXAPARIN	93
ENOXIMONE	93
ENPROSTIL.....	93
ENROFLOXACIN	93
ENTACAPONE.....	93
ENTECAVIR.....	93
EPHEDRA	93
EPHEDRINE	93,273,311

EPICHLOROHYDRIN.....	237,311,331
EPICILLIN	93
EPIDERMAL GROWTH FACTOR.....	237,331
EPINASTINE	93
EPIRUBICIN.....	93
EPITIOSTANOL.....	93
EPLERENONE.....	93
EPOETINS	93,273
EPOPROSTENOL.....	93
EPOXICONAZOLE	164
EPOXY RESINS	16,153,164,283,311
EPRINOMECTIN.....	164,237
EPROSARTAN	93
EPSIPRANTEL	264
EPTC	207
EPTIFIBATIDE.....	94
ERGOMETRINE.....	94
ERGOT.....	94
ERGOTAMINE.....	94
ERGOTOXINE.....	94
ERLOTINIB	94
ERTAPENEM	94
ERYSIMUM.....	94,324
ERYTHRITYL TETRANITRATE.....	58
ERYTHROMYCIN	94
ERYTHROPOIETIN	94,273
ESBIOTHRIN.....	164,207
ESCITALOPRAM.....	94
ESFENVALERATE	207
ESMOLOL	94
ESOMEPRAZOLE.....	94
ESSENTIAL OILS	4,27,283
ESTRAMUSTINE.....	94
ESTROPIPATE	94
ERGOCALCIFEROL <i>See</i> VITAMIN D	
ETACONAZOLE	237,331
ETAFEDRINE.....	44
ETANERCEPT.....	94
ETHACRYNIC ACID.....	94
ETHAMBUTOL.....	94
ETHAMETSULFURON-METHYL.....	264
ETHAMIVAN	94
1,2-ETHANEDIAMINE POLYMER	164
ETHANOL	173
ETHANOLAMINE	94,164,207,311,312
ETHANOLAMINE	283
ETHCHLORVYNOL	94
ETHEPHON	207
ETHER	44,94,164,207,283,312

ETHINAMATE	94
ETHINYLOESTRADIOL	95
ETHIOFENCARB	207
ETHION	237
ETHIONAMIDE	95
ETHISTERONE	95
ETHOATE-METHYL	207
ETHOFUMESATE	164
ETHOGLUCID	95
ETHOHEPTAZINE	95
ETHOPABATE	264
ETHOPROPAZINE	95
ETHOPROPHOS	207,238
ETHOSUXIMIDE	95
ETHOTOIN	95
ETHOXYETHYLMERCURIC CHLORIDE	312
<i>See also</i> MERCURY	
ETHOXYQUIN	165
ETHOXYSULFURON	165
ETHOXZOLAMIDE	95
ETHYL	244
ETHYL ACETATE	264
ETHYL ALCOHOL	264
ETHYLAMPHETAMINE	246
ETHYL BROMIDE	207,283,312
ETHYLBUTYLACETYL-AMINOPROPIONATE	264
ETHYL BUTYRATE	264
ETHYL CHLORIDE	95
ETHYLDIENOLONE	95
ETHYLENE CHLOROXYDRIN	207,312
ETHYLENE DIBROMIDE	238,331
ETHYLENE DICHLORIDE	208
ETHYLENE GLYCOL	27,165,208,283,312
ETHYLENE GLYCOL MONOALKYL ETHER ACETATES	208
ETHYLENE GLYCOL MONOALKYL ETHERS	208,284,328
ETHYLENE OXIDE	238,284,312,332
ETHYL FORMATE	207
ETHYLHEXANEDIOL	95,270
ETHYL LACTATE	264
N-ETHYL MDA	
<i>See</i> N-ETHYL- α -METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE	
N-ETHYL- α -METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE	251
ETHYLMERCURIC CHLORIDE	312
<i>See also</i> MERCURY	
ETHYL METHACRYLATE	165
ETHYLMETHYLTHIAMBUTENE	251
ETHYLMORPHINE	44,95,246,335
ETHYLOESTRENOL	95
ETHYNODIOL	95
ETICYCLIDINE	251

ETIDOCAINE	95
ETIDRONIC ACID	95
ETILEFRIN	96
ETIPROSTON	96
ETODOLAC	96
ETOFENAMATE	45,96
ETONITAZENE	251
ETONOGESTREL	96
ETOPOSIDE	96
ETORICOXIB	96
ETORPHINE	251
ETOXAZOLE	264
ETOXERIDINE	251
ETRETINATE	34,96,272,312
ETRIDIAZOLE	165
ETRIMFOS	208
EUCALYPTUS OIL	27,208,284
EUGENOL	27,165,209,284,312
EUPATORIUM CANNABINUM	270
EVEROLIMUS	96
EXEMESTANE	96
EXPLOSIVES	256
EXTERNAL	5
EXTRACT OF LEMON EUCALYPTUS	165
EZETIMIBE	96

F

FAMCICLOVIR	96
FAMOTIDINE	45,96,312
FAMPHUR	209,238
FARFUGIUM	270
FEBANTEL	209
FELBINAC	45,96
FELODIPINE	96
FELYPRESSIN	96
FENAMIPHOS	209,238
FENARIMOL	165
FENAZAFLOR	209
FENBENDAZOLE	165
FENBUCONAZOLE	165
FENBUFEN	96
FENBUTATIN	210
<i>See also</i> TIN ORGANIC COMPOUNDS	
FENBUTATIN OXIDE	210
FENCAMFAMIN	96
FENCHLORAZOLE-ETHYL	165
FENCHLORPHOS	210
FENCLOFENAC	96
FENETYLLINE	251

FENFLURAMINE.....	96,335
FENFURAM.....	264
FENHEXAMID	264
FENITROTHION	210
FENOFIBRATE	96
FENOLDOPAM.....	96
FENOPROFEN.....	96
FENOPROP.....	165
FENOTEROL.....	96,312
FENOXACRIM.....	210,238
FENOXAPROP-ETHYL.....	165
FENOXAPROP-P-ETHYL.....	165
FENOXYCARB	264
FENPIPRAMIDE	97
FENPIPRANE	97
FENPROPOREX.....	97
FENPROSTALENE	97
FENPYROXIMATE.....	210
FENSON.....	165
FENSULFOTHION.....	238
FENTANYL	246
FENTHION	165,210,238
FENTHION-ETHYL.....	238
FENVALERATE.....	210
FERRICYANIDES	236
FERROCYANIDES	236
FEXOFENADINE.....	45,97
FIBRINOLYSIN.....	97
FILGRASTIM	97
FINASTERIDE.....	97
FIPRONIL	166,210
FIROCOXIB.....	97
FIRST SCHEDULE PAINT	5
FLAMPROP-M-METHYL.....	166
FLAMPROP-METHYL	166
FLAVOPHOSPHOLIPOL.....	71,191
FLAVOXATE	58
FLECAINIDE.....	97
FLEROXACIN	97
FLOCOUMAFEN	210,238
FLOCTAFENINE.....	97
FLORASULAM	166
FLORFENICOL	97
FLUANISONE	97
FLUAZIFOP-BUTYL	210
FLUAZIFOP-P-BUTYL.....	210
FLUAZINAM.....	210
FLUAZURON	166
FLUBENDAZOLE.....	166
FLUCHLORALIN.....	166
FLUCLOROLONE.....	97
FLUCLOXACILLIN	97
FLUCOFURON.....	210,238

FLUCONAZOLE	58,97,312,326
FLUCYTHRINATE	238
FLUCYTOSINE	97
FLUDARABINE	97
FLUDIOXONIL	166
FLUDROCORTISONE	97
FLUFENAMIC ACID	97
FLUFENOXURON	264
FLUMAZENIL	97
FLUMETHASONE	97
FLUMETHIAZIDE	97
FLUMETHRIN	166,210
FLUMETSULAM	264
FLUMICLORAC PENTYL	166
FLUMIOXAZIN	238
FLUNISOLIDE	98
FLUNITRAZEPAM	246,335
FLUNIXIN MEGLUMINE	98
FLUOCINOLONE	98
FLUOCINONIDE	98
FLUOCORTIN	98
FLUOCORTOLONE	98
FLUOMETURON	264
FLUORESCEIN	98,173
FLUORIDES	45,58,98,166,210,284,312
FLUOROACETAMIDE	33,238,332
FLUOROACETIC ACID	33,238,332
para-FLUOROFENTANYL	253
FLUOROMETHOLONE	98
FLUOROSILICATES	
<i>See</i> SILICOFLUORIDES	
FLUOROSILICIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
FLUOROURACIL	98
FLUOSILICIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
FLUOXETINE	98
FLUOXYMESTERONE	98
FLUPENTHIXOL	99,335
FLUPHENAZINE	99,335
FLUPROPANATE	211
FLUPROSTENOL	99
FLUQUINCONAZOLE	211
FLURANDRENOLONE	99
FLURAZEPAM	99,335
FLURBIPROFEN	45,99
FLUROXENE	99

FLUROXYPYR.....	264
FLUSILAZOL	211
FLUSPIRILENE.....	99
FLUTAMIDE	99
FLUTICASONE.....	46,99
FLUTOLANIL	264
FLUTRIAFOL.....	211
FLUVALINATE.....	167,211
FLUVASTATIN.....	99
FLUVOXAMINE	99
FOLIC ACID.....	46,99
FOLINIC ACID.....	46,99
FOLLICLE-STIMULATING HORMONE	99,324
FOLLITROPIN ALPHA	99,272
FOLLITROPIN BETA	99,272
FOLPET.....	238,332
FOMIVIRSEN	99
FONDAPARINUX.....	99
FOOD	256
FOOD ADDITIVES	256
FORCHLORFENURON	265
FORMALDEHYDE	46,211,284,312
FORMEBOLONE	99
FORMESTANE.....	99
FORMETANATE.....	238
FORMIC ACID	167,284,312
FORMOTEROL	99
FORMOTHION.....	211
FOSAMPRENAVIR.....	99
FOSCARNET	100
FOSFESTROL.....	100
FOSINOPRIL	100
FOSPHENYTOIN	100
FOSPIRATE	167,211
FOTEMUSTINE.....	100
FRAMYCETIN	100
FRITTED GLAZING	256
FRUSEMIDE.....	100
FULLERS EARTH.....	265
FULVESTRANT	100
FUMAGILLIN	211
FUNGAL PROTEASE	265
FURALAXYL	167
FURALTADONE.....	100
FURATHIOCARB	167,238
FURAZABOL	100
FURAZOLIDONE.....	100
FURETHIDINE	251
FUSIDIC ACID	100

G

GABAPENTIN	100,335
GALANTAMINE	100
GALANTHUS	100
GALLAMINE	100
GAMMA-CYHALOTHRIN	167,238
GAMMAHYDROXYBUTYRATE(GHB) <i>See</i> 4-HYDROXYBUTANOIC ACID	
GANCICLOVIR	100
GANIRELIX	100
GATIFLOXACIN	100
GEFITINIB	100
GELSEMIUM SEMPERVIRENS	46,324
GEMCITABINE	100,335
GEMEPROST	100
GEMFIBROZIL	100
GEMIFLOXACIN	100
GENTAMICIN	101
GENTIAN VIOLET <i>See</i> CRYSTAL VIOLET	
GERANIUM OIL	265
GESTODENE	101
GESTONORONE	101
GESTRINONE	101
GIBBERELIC ACID	265
GITALIN	101
GLASS	256
GLATIRAMER ACETATE	101
GLAZED POTTERY	256
GLAZING PREPARATIONS	313
GLIBENCLAMIDE	101
GLIBORNURIDE	101
GLICLAZIDE	101
GLIMEPIRIDE	101
GLIPIZIDE	101
GLISOXEPIDE	101
GLUCAGON	58,324
GLUCANASE	265
GLUFOSINATE-AMMONIUM	167
GLUTARALDEHYDE	46,167,211,284,313
GLUTATHIONE	101
GLUTETHIMIDE	101,273,335
GLYCERYL THIOGLYCOLLATE	212
GLYCERYL TRINITRATE	46,58,101,324
GLYCOLIC ACID	212,284,313
GLYCOPYRRONIUM	58,101
GLYMIDINE	101
GLYPHOSATE	167
GNRH VACCINE	101

GONADORELIN	101
GONADOTROPHIC HORMONES	101
GOSERELIN	101
GRAMICIDIN	102
GRANISETRON	102
GRAPHIC MATERIAL	5
GREPAFLOXACIN	102
GRISEOFULVIN	102
GROWTH HORMONE	138,324
GUAIPHENESIN	102
GUANABENZ	102
GUANACLINE	102
GUANETHIDINE	102
GUANIDINE	102
GUAZATINE	212

H

HACHIMYCIN	102
HAEMATIN	102
HAEMOPHILUS INFLUENZAE VACCINE	102
HALCINONIDE	102
HALOFANTRINE	102
HALOFENATE	102
HALOFUGINONE	102,239,332
HALOGENATED DIBENZODIOXINS	239,332
HALOGENATED DIBENZOFURANS	239,332
HALOPERIDOL	102,324,335
HALOSULFURON-METHYL	167
HALOTHANE	102
HALOXON	212
HALOXYFOP	212
HALQUINOL	
<i>See</i> CLIOQUINOL	
HARMALA ALKALOIDS	251
HCB	239,332
HEIGHT	5
HELIOTROPIUM	271
HEMEROCALLIS	102
HEMP AGRIMONY	
<i>See</i> EUPATORIUM CANNABINUM	
HEMP SEED OIL	5
HEPARINS	102
HEPATITIS A VACCINE	103
HEPATITIS B VACCINE	103
HEPTACHLOR	212
HEROIN	251
HETACILLIN	103
HEXACHLOROBENZENE	
<i>See</i> HCB	

HEXACHLOROPHANE.....	46,103,212,284,313
HEXACONAZOLE.....	167
HEXAFLUOROSILICATES	
<i>See</i> SILICOFLUORIDES	
HEXAFLUOROSILICIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
HEXAFLURON	265
HEXAMETHONIUM.....	103
HEXAMETHYLMELAMINE	
<i>See</i> ALTRETAMINE	
HEXAZINONE	167,212
HEXETIDINE	103
HEXOBENDINE.....	103
HEXOCYCLIUM	103
HEXOPRENALINE	103
HEXYL ACETATE.....	265
3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-	
DIBENZO(B,D)PYRAN	251
HEXYTHIAZOX.....	265
HISTAMINE	103
HOBBY FUELS	257
HOMATROPINE	103
HUMAN CHORIONIC GONADATROPHIN	103
HUMAN FOLLICLE-STIMULATING HORMONE	
<i>See</i> UROFOLLITROPHIN	
HUMAN OSTEOGENIC PROTEIN-1 (OP-1)	265
HYALURONIC ACID	103
HYDRALAZINE.....	103
HYDRAMETHYLNON	167,212
HYDRARGAPHEN	103
HYDRAZINE	212,284,313
HYDROCARBONS	4,16,27,284
HYDROCARBONS, LIQUID.....	x,25,168,239
HYDROCHLORIC ACID	27,168,212,284,313
HYDROCHLOROTHIAZIDE	104
HYDROCODONE.....	246,335
HYDROCORTISONE.....	46,58,104,313,326
HYDROCORTISONE ACETATE	46,58
HYDROCYANIC ACID	33,104,239,313,324
<i>See also</i> CYANIDES	
HYDROFLUMETHIAZIDE	104
HYDROFLUORIC ACID	168,212,239,284,313,332
HYDROFLUOSILICIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
HYDROGEN FLUORIDE	168,212
HYDROGEN HEXAFLUOROSILICATE	
<i>See</i> HYDROSILICOFLUORIC ACID	
HYDROGEN PEROXIDE	168,213,285,314
HYDROGEN SULFIDE.....	239
HYDROMORPHINOL.....	246

HYDROMORPHONE.....	246,335
HYDROPRENE.....	265
HYDROQUINONE.....	46,104,117,213,285,314
HYDROSILICOFLUORIC ACID.....	168,213,239,285,314,332
4-HYDROXYBUTANOIC ACID.....	251
HYDROXYCHLOROQUINE.....	104
HYDROXYEPHEDRINE.....	104
N-HYDROXY MDA	
<i>See</i> N-[ALPHA-METHYL-3,4-(METHYLENEDIOXY)	
PHENETHYL]HYDROXYLAMINE	
HYDROXYPETHIDINE.....	251
HYDROXYPHENAMATE.....	104
HYDROXYPROGESTERONE.....	104
HYDROXYPROPYL CELLULOSE.....	265
8-HYDROXYQUINOLINE.....	47,82,314
HYDROXYSTENOZOL.....	104
HYDROXYUREA.....	104
HYDROXYZINE.....	104,335
HYGROMYCIN.....	104
HYOSCINE.....	47,104,324
HYOSCINE BUTYLBROMIDE.....	47
HYOSCYAMINE.....	47,104,324
HYOSCYAMUS NIGER.....	48,104,324
HYPOTHALAMIC RELEASING FACTORS.....	104,324
HYPROMELLOSE.....	104

I

IBAFLOXACIN.....	105
IBANDRONIC ACID.....	105
IBRITUMOMAB.....	105
IBUFENAC.....	105
IBUPROFEN.....	48,59,105,314
IBUTEROL.....	105
IBUTILIDE.....	105
ICODEXTRIN.....	265
IDARUBICIN.....	105
IDOXURIDINE.....	105
IFOSFAMIDE.....	105
ILOPROST.....	105
IMATINIB.....	105
IMAZALIL.....	169
IMAZAMOX.....	169
IMAZAPIC.....	169
IMAZAPYR.....	169
IMAZETHAPYR.....	169
IMIDACLOPRID.....	169,213
IMIDAPRIL.....	105
IMIDOCARB.....	213
IMIGLUCERASE.....	105

IMINOCTADINE TRIALBESILATE.....	213
IMIPENEM.....	105
IMIPRAMINE	105,335
IMIPROTHRIN	169,213
IMIQUIMOD.....	105
IMMEDIATE CONTAINER.....	5
IMMEDIATE WRAPPER.....	5
IMMUNOGLOBULINS	105
IMMUNOSERA	68
INDANAZOLINE	48
INDAPAMIDE	105
INDINAVIR	105
INDOLE-3-ACETIC ACID.....	265
INDOMETHACIN	48,105,324
INDOPROFEN	106
INDORAMIN	106
INDOXACARB.....	169,213
INFLIXIMAB.....	106
INFLUENZA AND CORYZA VACCINES	106
INK ADDITIVES	258
INOSITOL NICOTINATE.....	59,106
INSULIN-LIKE GROWTH FACTORS	106,273
INSULINS	106
INTERFERONS	106
INTERLEUKINS.....	106
INTERNAL USE.....	5
INTRAOCULAR VISCOELASTIC PRODUCTS	257
IN VITRO DIAGNOSTIC PREPARATIONS	256
IODINE	48,213,214,285,300,314
IODOCARB	169,214
IODOMETHANE.....	239,332
IODOPHORS	48,213,214,285
3-iodo-2-propynyl butyl carbamate.....	169,214
IDOQUINOL	58,89,270
<i>See also</i> CLIOQUINOL	
IODOSULFURON-METHYL-SODIUM.....	169
IODOTHIOURACIL	106
IOXYNIL.....	214
IPECACUANHA.....	79
<i>See also</i> CEPHAELIS ACUMINATA and CEPHAELIS IPECACUANHA	
IPRATROPIUM	49,106,314
IPRIFLAVONE	106
IPRINDOLE	106
IPRODIONE.....	265
IPRONIAZID	106
IRBESARTAN	106
IRINOTECAN.....	106
IRON COMPOUNDS.....	49,106,169,214
ISOAMINILE.....	106
ISOAMYL NITRITE.....	106

ISOBUTYL NITRITE	106
ISOCARBOPHOS	239
ISOCARBOXAZID	107
ISOCONAZOLE	49,59,107,214
ISOCYANATES	285
ISOCYANATES, FREE ORGANIC	214,314
ISOETARINE	107
ISOEUGENOL	170,214
ISOFENPHOS	239
ISOFLURANE	107
ISOMETHADONE	252
ISOMETHEPTENE	107
ISONIAZID	107
ISOPHORONE	170,285
ISOPRENALINE	107,315
ISOPRENE ALCOHOL	265
ISOPRINOSINE	107
ISOPROPAMIDE	49,107
ISOPROTURON	239
ISOSORBIDE DINITRATE	59,107
ISOSORBIDE MONONITRATE	107
ISOSTEARYL ALCOHOL ETHOXYLATE	265
ISOTRETINOIN	34,107,272,315
ISOXABEN	170
ISOXAFLUTOLE	170
ISOXICAM	107
ISOXSUPRINE	107
ISRADIPINE	107
ITRACONAZOLE	107
IVERMECTIN	107,170,239

J

JASMOLONE	180
JEQUIRITY	
<i>See</i> ABRUS PRECATORIUS	
JUNIPERUS SABINE	271

K

KANAMYCIN	107
KAOLIN	265
KEROSENE	x,25,257,285
KETAMINE	246
KETANSERIN	107
KETAZOLAM	107
KETOBEMIDONE	252
KETOCONAZOLE	49,108
KETOPROFEN	59,108
KETORALAC TROMETAMOL	108
KETOROLAC	108

KETOTIFEN	59,326
K-HDO	
<i>See</i> N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM	
KHELLIN	108
KITASAMYCIN	108,170
KRESOXIM-METHYL.....	265
KUNZEA OIL	265
L	
LABEL	5,10
LABETALOL.....	108
LACIDIPINE.....	108
LAMBDA-CYHALOTHRIN	170,214,239
LAMIVUDINE.....	108
LAMOTRIGINE.....	108,335
LAMP OIL.....	25
LAMPS	256
LANATOSIDES.....	108
LANREOTIDE	108
LANSOPRAZOLE	108
LANTHANUM.....	108
LARONIDASE.....	108
LASALOCID.....	215
LATAMOXEF.....	108
LATANOPROST.....	109
LAUDEXIUM	109
LAURETH-9	
<i>See</i> LAUROMACROGOLS	
LAURIC ACID.....	265
LAUROMACROGOLS.....	109
LAURYL ALCOHOL (1-DODECANOL).....	265
LAURYLISOQUINOLINIUM BROMIDE.....	215,285
LAVANDIN OIL.....	265
<i>See also</i> CAMPHOR	
LAVENDER OIL	265
LEAD.....	19,23,109,226,317,327,328
LEAD CARBONATE	
<i>See</i> BASIC LEAD CARBONATE	
LEAD,METALLIC.....	265
LEAD COMPOUNDS.....	170,215,285,313,315
LEFETAMINE	109
LEFLUNOMIDE	34,109,315
LEMONGRASS OIL.....	265
LEMON OIL	170,285,315
LENOGRASTIM.....	109
LEPIDOPTEROUS SEX PHEROMONES	265
LEPIRUDIN	109
LEPTAZOL	109
LEPTOPHOS.....	239

LERCANIDIPINE	109
LETROZOLE	109
LEUPRORELIN	109
LEVALLORPHAN	109
LEVAMISOLE	109,171,215
LEVAMPHETAMINE	246
LEVETIRACETAM	109,335
LEVOBUNOLOL	109
LEVOBUPIVACAINE	109
LEVOCABASTINE	33,49,109,315,335
LEVOCETIRIZINE	
<i>See</i> CETIRIZINE	
LEVODOPA	109
LEVOMETHAMPHETAMINE	246
LEVOMETHORPHAN	8,252
LEVOMORAMIDE	246
LEVONORGESTREL	59,109
LEVOPHENACYLMORPHAN	252
LEVORPHANOL	246
LEVOSIMENDAN	110
LIDOFLAZINE	110
LIGHT MINERAL AND PARAFFIN OILS	
<i>See</i> HYDROCARBONS, LIQUID	
LIGNOCAINE	49,110
LIGULARIA	271
LIME OIL	171,285,315
LIMONENE	265
LINCOMYCIN	110
LINDANE	49,110,171,193,215
LINEZOLID	110
LINOLEIC ACID	265
LINSEED FATTY ACIDS	265
LINURON	265
LIOTHYRONINE	110
LIQUID HYDROCARBONS	
<i>See also</i> HYDROCARBONS, LIQUID	
LIQUORICE, DEGLYCYRRHISINISED	265
LISINAPRIL	110
LISURIDE	110
LITHIUM	50,110
LITHIUM PERFLUOROOCCTANE SULFONATE	239
LOBELIA INFLATA	50
LOBELINE	50
LODOXAMIDE	50,110
LOFEXIDINE	110
LOGIPARIN	110
LOMEFLOXACIN	110
LOMUSTINE	110
LOPERAMIDE	50,110,315
LOPINAVIR	111

LOPRAZOLAM.....	111
LORACARBEF.....	111
LORATADINE.....	50,111
LORAZEPAM.....	111,335
LORMETAZEPAM.....	111
LOSARTAN.....	111
LOXAPINE.....	111
LUBRICANTS.....	257
LUFENURON.....	171
LUMEFANTRINE.....	111
LUMIRACOXIB.....	111
LUTEINISING HORMONE.....	111,272
LYE WATER	
<i>See</i> ALKALINE SALTS, SODIUM HYDROXIDE OR POTASSIUM HYDROXIDE	
LYMECYCLINE.....	111
LYSERGIC ACID.....	252
LYSERGIDE.....	252
M	
MACROGOL 3350.....	59
MADURAMICIN.....	171,240,332
MAFENIDE.....	111,215
MAGNESIUM CHLORATE.....	171,285,315
MAGNESIUM FLUOSILICATE	
<i>See</i> FLUORIDES	
MAGNESIUM PHOSPHIDE	
<i>See</i> PHOSPHIDES, METALLIC	
MAIN LABEL.....	5
MALACHITE GREEN.....	171,240
MALATHION.....	59,215
<i>See</i> MALDISON	
MALDISON.....	172,215,286
MALEIC HYDRAZIDE.....	265
MANCOZEB.....	17,172
<i>See also</i> DITHIOCARBAMATES	
MANDRAGORA OFFICINARUM.....	111
MANGANESE DIOXIDE.....	265
MANNITYL HEXANITRATE.....	59
MANNOMUSTINE.....	111
MANUFACTURER.....	6
MAPROTILINE.....	111
MARBOFLOXACIN.....	111
MARJORAM OIL.....	28,172,286
MATCHES.....	257
MAZIDOX.....	240
MAZINDOL.....	111,335
MBDB	
<i>See</i> METHYLENEDIOXYBUTYLAMINE	
MCPA.....	172,216

MCPB	172
MDA	
<i>See</i> 3,4-METHYLENEDIOXYAMPHETAMINE	
MDMA	
<i>See</i> N,ALPHA-DIMETHYL-3,4-(METHYLENEDIOXY) PHENYLETHYLAMINE	
MEASLES VACCINE.....	111
MEASURE PACK.....	6
MEBANAZINE.....	111
MEBENDAZOLE	50,172,216
MEBEVERINE.....	111
MEBHYDROLIN.....	111,335
MEBOLAZINE	111
MEBUTAMATE	111
MECAMYLAMINE.....	112
MECARBAM.....	240
MECASERMIN.....	112
MECILLINAM.....	112
MECLOCYCLINE.....	112
MECLOFENAMATE.....	112
MECLOFENAMIC ACID.....	172
MECLOFENOXATE	112
MECLOQUALONE	252
MECLOZINE	50,112,335
MECOPROP.....	172,216
MECOPROP-P	216
MEDAZEPAM.....	112,335
MEDETOMIDINE.....	112
MEDICAL AND VETERINARY ADHESIVES	257
MEDICAL DEVICES	257
MEDIGOXIN (METHYLDIGOXIN)	112
MEDROXYPROGESTERONE	112
MEDRYSONE	112
MEFENAMIC ACID.....	50,112,315
MEFENOREX.....	112
MEFENPYR-DIETHYL.....	172
MEFLOQUINE	112
MEFLUIDIDE.....	216
MEFRUSIDE.....	112
MEGESTROL	112
MELAGATRAN	112
MELALEUCA OIL.....	28,216,286
MELATONIN.....	112
MELENGESTROL.....	112
MELENGESTROL ACETATE.....	216
MELIA AZEDARACH	271
MELOXICAM.....	112
MELPHALAN.....	112
MEMANTINE.....	112
MENAZON	216

MENINGOCOCCAL VACCINE.....	113
MENOTROPHIN	113
MEPACRINE	113
MEPENZOLATE	113
MEPHENESIN	113
MEPHENTERMINE	113
MEPINDOLOL	113
MEPIQUAT.....	172
MEPITIOSTANE	113
MEPIVACAINE.....	113
MEPROBAMATE.....	113,335
MEPYRAMINE.....	50,59,113,335
MEQUITAZINE.....	113
2-MERCAPTOETHANOL.....	216
MERCAPTOMERIN	113
MERCAPTOPURINE	113
MERCURIC CHLORIDE	240,286
MERCURIC IODIDE.....	286
MERCURIC NITRATE.....	286
MERCURIC OXIDE	113,216,286
MERCURIC POTASSIUM IODIDE	286
MERCURIC THIOCYANATE	286,315
MERCUROCHROME.....	217,286
MERCUROUS CHLORIDE.....	286
MERCURY.....	50,113,240,242,286,324,332
MERCURY,METALLIC.....	240,286
MEROPENEM	113
MERSALYL.....	113
MESABOLONE	113
MESALAZINE.....	113
MESCALINE	254
<i>See also 3,4,5-TRIMETHOXY-PHENYLETHYLAMINE</i>	
MESNA	113
MESOLSULFURON-METHYL	266
MESTANOLONE	113
MESTEROLONE	114
MESTRANOL.....	114
METACRESOLSULPHONIC ACID/FORMALDEHYDE CONDENSATION	217,315
METALAXYL	173,217
METALDEHYDE	173,217,286
METANDIENONE	114
METARAMINOL	114
METARHIZIUM ANISOPLIAE.....	266
METAZOCINE	252
METENOLONE	114
METERGOLINE.....	114
METFORMIN	114
METHABENZTHIAZURON.....	173
METHACHOLINE.....	114

METHACRIFOS	217,240,332
METHACYCLINE	114
METHADONE	246,335
METHADONE INTERMEDIATE	
<i>See</i> 4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYL BUTANE	
METHALLENOESTRIL	114
METHAM	217
METHAM SODIUM	
<i>See</i> METHAM	
METHAMIDOPHOS	240
METHANDRIOL	114
METHANOL	4,173,217,257,286,315
METHANTHELINIUM	114
METHAPYRILENE	240
METHAQUALONE	252
METHAZOLAMIDE	114
METHAZOLE	240
METHCATHINONE	252
METHDILAZINE	59,114,335
METHENOLONE	114
METHICILLIN	114
METHIDATHION	240
METHIMAZOLE	114
METHIOCARB	173,217,240
METHISAZONE	114
METHIXENE	114
METHOCARBAMOL	114,335
METHOHEXITONE	114
METHOIN	114
METHOMYL	217,240
METHOPRENE	266
METHOTREXATE	114
METHOTRIMEPRAZINE	114
METHOXAMINE	50,115,315
METHOXSALEN	115
5-METHOXY-METHYLTRYPTAMINE	252
METHOXY-PHENYLETHYLAMINE	254
METHOXYCHLOR	173
METHOXYETHYLMERCURIC ACETATE	240,332
METHOXYETHYLMERCURIC CHLORIDE	241,332
METHOXYFENOZIDE	266
METHOXYFLURANE	115
5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE	252
4-METHOXY-METHYLPHENYLETHYLAMINE	252
METHOXYPHENAMINE	50,254
METHOXYPHENETHYLAMINE	254
METHSUXIMIDE	115
METHYCLOTHIAZIDE	115
METHYL (2S,4AR,6AR,7R,9S,10AS,10BR)-9-ACETOX	252
N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE	252

N-[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE	252
METHYL ACETATE.....	266
METHYL AMINOLEVULINATE	115
4-METHYLAMINOREX	252
METHYLAMPHETAMINE	247
METHYLANDROSTANOLONE.....	115
METHYLATED SPIRIT(S)	25,28,173,286,315
METHYL BENZOQUATE.....	266
METHYL BROMIDE	241,332
METHYL CHLORIDE.....	316
METHYLCLOSTEBOL.....	115
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL.....	217,241
1-METHYLCYCLOPROPENE	266
METHYLDESORPHINE	252
METHYLDIHYDROMORPHINE.....	247
METHYLDOPA.....	115
4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA).....	241,332
METHYLENE BISTHIOCYANATE	217,316
METHYLENE BLUE.....	115,173,241
METHYLENE CHLORIDE.....	282,310,328
<i>See also</i> DICHLOROMETHANE	
METHYLENE DIANILINE.....	236,308,331
<i>See also</i> 4,4-DIAMINODIPHENYLMETHANE	
3,4-METHYLENEDIOXYAMPHETAMINE.....	252
3,4-METHYLENEDIOXY-N, α -DIMETHYLPHENYLETHYLAMINE	
<i>See</i> N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE	
DIMETHYLEPHEDRINE.....	50
METHYLERGOMETRINE	115
METHYL ETHYL KETONE.....	4,173, 286, 316
METHYL ETHYL KETONE PEROXIDE	173, 286, 316
METHYLEUGENOL.....	217,287,316
3-METHYLFENTANYL	252
METHYL ISOAMYL KETONE.....	4,173, 287,316
METHYL ISOBUTYL KETONE	4,173, 287,316
METHYL ISOTHIOCYANATE.....	217,316
METHYLMERCURY	115,324
2-METHYL-3-MORPHOLINO-1,1-DIPHENYLPROPANE CARBOXYLIC	
ACID (MORAMIDE INTERMEDIATE)	252
METHYL NEODECANAMIDE.....	217
METHYL P-HYDROXYBENZOATE.....	266
METHYLPENTYNOL.....	115
METHYLPHENIDATE	247
METHYLPHENOBARBITONE.....	115,335
<i>See also</i> BARBITURATE	
1-METHYL-4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID	
(PETHIDINE INTERMEDIATE)	247
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE.....	252
METHYLPREDNISOLONE.....	115
N-METHYL-2-PYRROLIDONE.....	4,164,173,175,217,287
METHYL SALICYLATE	28,173, 205,217,287

1-(β -METHYL SULPHONAMIDEETHYL)-2-AMINO-3-N,N-DIETHYLAMINO BENZENE	316
METHYLTESTOSTERONE.....	115
4-METHYLTHIOAMPHETAMINE.....	253
3-METHYLTHIOFENTANYL	253
2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPRROPYLAMINO-5- TRIAZINE.....	174
METHYLTHIOURACIL	115
METHYLTRIENOLONE.....	115
METHYPRYLONE.....	115
METHYSERGIDE	115
METIRAM	17,174
METOCLOPRAMIDE	59,115
METOLACHLOR	174
METOLAZONE	115
METOPON.....	253
METOPROLOL.....	115
METOSULAM.....	218
METRIBOLONE.....	115
METRIBUZIN.....	174
METRIFONATE	116
METRONIDAZOLE	116
METSULFURONMETHYL	266
METYRAPONE.....	116
MEVINPHOS	241
MEXILETINE	116
MEZLOCILLIN.....	116
MIANSERIN	116,335
MIBEFRADIL	116
MIBOLERONE	116
MICONAZOLE	50,60,116,218,316,326
MIDAZOLAM	116
MIDODRINE	116
MIGLITOL.....	116
MILBEMECTIN.....	174,218
MILBEMYCIN OXIME.....	174
MILRINONE.....	116
MINERAL OIL <i>See</i> HYDROCARBONS, LIQUID	
MINERAL TURPENTINE.....	25
MINOCYCLINE	116
MINOXIDIL.....	50,116
MIPAFOX	241
MIREX	241,332
MIRTAZAPINE	116,335
MISOPROSTOL.....	34,116,316
MITOBRONITOL.....	116
MITOMYCIN.....	116
MITOTANE	116
MITOXANTRONE	116

MITRAGYNA SPECIOSA	253
MITRAGYNINE	253
MIVACURIUM CHLORIDE.....	117
MMDA	
<i>See</i> 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE	
MOCA	
<i>See</i> 4,4'-METHYLENEBIS[2-CHLOROANILINE]	
MOCLOBEMIDE.....	117
MODAFINIL	117
MOLGRAMOSTIM	117
MOLINATE	241,332
MOLINDONE	117
MOMETASONE	51,117
MONENSIN	117,174,218
MONOBENZONE.....	46,117
MONOCLONAL ANTIBODIES	117
MONOCROTOPHOS.....	241
MONTELUKAST	117
MOPERONE	117
MORAMIDE	
<i>See</i> DEXTROMORAMIDE	
MORAMIDE INTERMEDIATE	
<i>See</i> 2-METHYL-3-MORPHOLINO-1,1-DIPHENYLPROPANE- CARBOXYLIC ACID (MORAMIDE INTERMEDIATE)	
MORANTEL	174,218
MORAZONE.....	117
MORICIZINE.....	117
MORPHERIDINE	253
MORPHINE	247,335
MORPHINE-N-OXIDE.....	247
MORPHINE METHOBROMIDE	247
MOTOR,HEATING AND FURNACE FUELS	257
MOTRAZEPAM	117
MOTRETINIDE	117
MOXIDECTIN	117,174,218,241
MOXIFLOXACIN.....	117
MOXONIDINE	117
MPPP	
<i>See</i> 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE	
MSMA	218,241
MUMPS VACCINE	117
MUPIROCIN.....	118
MURAGLITAZAR	118
MUROMONAB.....	118
MUSCIMOL.....	253
MUSTINE	118
MYCLOBUTANIL	174
MYCOPHENOLATE MOFETIL.....	118
MYCOPHENOLIC ACID	118
MYRISTIC ACID.....	266
MYROPHINE.....	253

N

NAA	174
NABILONE.....	247
NABUMETONE	118
NADOLOL.....	118
NADROPARIN	118
NAFARELIN.....	118
NAFTIDROFURYL	118
NALBUPHINE.....	118,335
NALED.....	174,218
NALIDIXIC ACID.....	118
NALORPHINE.....	118
NALOXONE.....	118
NALTREXONE.....	118
NAME AND ADDRESS.....	6
NANDROLONE.....	118
NAPHAZOLINE.....	51,316
NAPHTHALENE.....	23,30,218,287,316,324
NAPHTHALENEACETIC ACID	
<i>See</i> NAA	
NAPHTHALOPHOS.....	218,241
NAPROPAMIDE.....	266
NAPROXEN.....	51,118,316
NAPTALAM.....	174
NAPHTHYL ACETAMIDE	266
NARASIN	118,218
NARATRIPTAN	118
NATAMYCIN.....	118
NATEGLINIDE.....	118
NEBACUMAB.....	119
NEDOCROMIL.....	119
NEEM.....	269,280,305
NEFAZODONE.....	119
NEFOPAM.....	119
NELFINAVIR	119
NELFINAVIR MESYLATE	119
NEOMYCIN.....	119
NEOSTIGMINE.....	119
NERIUM OLEANDER	118, 119,319,324
<i>See also</i> OLEANDER	
NEROLI OIL.....	266
NESIRITIDE	119
NETILMICIN.....	119
NETOBIMIN.....	174,218
NEVIRAPINE	119
NIALAMIDE.....	119
NICABAZIN	266
NICARDIPINE.....	119
NICERGOLINE.....	119

NICKEL SULFATE	218
NICLOSAMIDE.....	51
NICOCODINE	253
NICODICODINE	253
NICOFURANOSE.....	119
NICOMORPHINE.....	253
NICORANDIL	119
NICOTINE	51,119,218,241,316,326,332
NICOTINIC ACID	60,120
NICOTINYL ALCOHOL.....	60
NICOUMALONE.....	120
NIFEDIPINE	120
NIFENAZONE	120
NIKETHAMIDE	120
NILUTAMIDE	120
NIMESULIDE.....	120
NIMIDANE	218,241
NIMODIPINE.....	120
NIMORAZOLE	120
NIRIDAZOLE	120
NISIN.....	68,266
NISOLDIPINE	120
NITENPYRAM	218
NITRAZEPAM.....	120,335
NITRENDIPINE.....	120
NITRIC ACID	175,219,287,317
NITROBENZENE.....	219,287,317
NITROFEN.....	241,332
NITROFURANTOIN	120
NITROFURAZONE	120
NITROGEN MUSTARD.....	118
NITROPHENOL	219,287,317
NITROPRUSSIDES	219,242,287,317
NITROSCANATE.....	175
NITROUS OXIDE.....	120
NITROXOLINE	120
NITROXYNIL.....	219
NIZATIDINE	51,120,317
NOMIFENSINE	120
NON-ACCESS PACKAGING	6
NON-VOLATILE CONTENT	6
NONOXINOL 9	175,219,287
NORACYMETHADOL	253
NORADRENALINE	120,317
19-NORANDROSTENEDIOL.....	121
19-NORANDROSTENEDIONE.....	121
NORANDROSTENOLONE	121
NORBOLETHONE.....	121
NORCLOSTEBOL.....	121

NORCODEINE	247
NORELGESTROMIN	121
NORETHANDROLONE	121
NORETHISTERONE	121
NORFLOXACIN	121
NORFLURAZON	266
NORGESTREL	121
NORLEVORPHANOL	253
NORMETHADONE	247,335
NORMETHANDRONE	121
NORMORPHINE	253
NORPIPANONE	253
NORTRIPTYLINE	121,335
NOSCAPINE	51,247,335
NOVALURON	266
NOVOBIOCIN	121
NOXIPTYLINE	121
NUCLEAR POLYHEDROSIS VIRUS	266
NUTMEG OIL	28,175,287
NUTRITION REPLACEMENT PREPARATIONS	257
NUX VOMICA	
<i>See</i> STRYCHNINE	
NYSTATIN	51,60,121,317,326

O

OCTAMYLAMINE	121
OCTATROPINE	121
1-OCTEN-3-OL	219
OCTHILINONE	219
<i>See also</i> 2-OCTYL-4-ISOTHIAZOLIN-3-ONE	
OCTREOTIDE	121
OCTYL ALCOHOLS	266
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE	175
2-OCTYL-4-ISOTHIAZOLIN-3-ONE (OCTHILINONE)	287
OCTYL NITRITE	121
N-(N-OCTYL)-2-PYRROLIDONE	175,219,287
OESTRADIOL	121,175,324
OESTRIOL	121
OESTROGENS	121
OESTRONE	121,324
OFLOXACIN	121
OLANZAPINE	122,335
OLAQUINDOX	220
OLEANDOMYCIN	122,176
OLEANDRIN	122
OLEIC ACID	266
N-OLEYL-1,3-DIAMINOPROPANE	220
OLMESARTAN	122
OLOPATADINE	122

OLSALAZINE	122
OMALIZUMAB.....	122
OMEPRAZOLE.....	122
OMETHOATE	176,220,242
ONDANSETRON	122
OPIPRAMOL	122
OPIUM	247,335
ORANGE OIL	176,287
ORANGE OIL (BITTER).....	176,317
ORANGE OIL,SWEET	266
ORBIFLOXACIN.....	122
ORCIPRENALINE.....	122,317
ORGANOPHOSPHORUS COMPOUND.....	16,122
ORGANO-TIN COMPOUNDS	
<i>See</i> TIN ORGANIC COMPOUNDS	
ORLISTAT	60,122,326
ORNIDAZOLE.....	122
ORNIPRESSIN.....	122
ORPHENADRINE	122
ORTHOPTERIN.....	122
OSELTAMIVIR	123
OUABAIN.....	123
OVANDROTONE.....	123
OXABETRINIL.....	266
OXABOLONE	123
OXACILLIN.....	123
OXADIARGYL.....	176
OXADIAZON	220
OXADIXYL	176
OXALATES,METALLIC	317
OXALIC ACID	220,287,317
OXALIPLATIN.....	123
OXAMYL.....	242
OXANDROLONE.....	123
OXANTEL EMBONATE	176
OXAPROZIN	123
OXAZEPAM	123,335
OXCARBAZEPINE	123
OXEDRINE.....	123
OXETACAINE.....	51,123
OXETHAZAINE.....	51,123
OXFENDAZOLE	176
OXIBENDAZOLE	176
OXICONAZOLE.....	60,123
OXITROPIUM	123
OXOLAMINE	123
OXOLINIC ACID	123
OXPENTIFYLLINE.....	123
OXPRENOLOL.....	123

OXYBUPROCAINE	123
OXYBUTYNIN	123
OXYCARBOXIN	176
OXYCLOZANIDE	220
OXYCODONE	247,336
OXYDEMETON METHYL	242
OXYFLUORFEN	266
OXYMESTERONE	123
OXYMETAZOLINE	51,317
OXYMETHOLONE	124
OXYMORPHONE	247
OXYPHENBUTAZONE	124
OXYPHENCYCLIMINE	124
OXYPHENISATIN	271
OXYPHENONIUM	124
OXYTETRACYCLINE	124,176
OXYTHIOQUINOX	176
OXYTOCIN	124,324

P

PACLITAXEL	124
PACLOBUTRAZOL	176
PAECILOMYCES LILACINUS STRAIN 251	220
PAINT	6,317
PALIFERMIN	124
PALIVIZUMAB	124
PALMAROSA OIL	266
PALMITIC ACID	266
PALONOSETRON	124
PAMAQUIN	124
PAMIDRONIC ACID	124
PANCREATIC ENZYMES	124
PANCURONIUM	124
PANTOPRAZOLE	60,124
PAPAVERETUM	336
PAPAVERINE	51,124,247,335
PAPER	257
PARACETAMOL	51,57,59,69,124,136,317
PARAFFIN OIL	
<i>See</i> HYDROCARBONS, LIQUID HYDROCARBONS, LIQUID	
PARAFORMALDEHYDE	52,220,284,288
PARAHEXYL	
<i>See</i> 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-	
TRIMETHYL-6H-DIBENZO(B,D)PYRAN*(PARAHEXYL)	
PARALDEHYDE	125
PARAMETHADIONE	125
PARAMETHASONE	125
PARAQUAT	14,32,242
PARATHION	242

PARATHION-METHYL	220,242
PARBENDAZOLE.....	220
PARECOXIB.....	125
PAROMOMYCIN.....	125
PAROXETINE	125
PATCHOULI OIL	266
PCBS	
<i>See</i> POLYCHLORINATED BIPHENYLS	
PCE	
<i>See</i> ETICYCLIDINE	
PCP	
<i>See</i> PENTACHLOROPHENOL or <i>see</i> PHENCYCLIDINE	
PCPY	
<i>See</i> ROLICYCLIDINE	
PDB	
<i>See</i> para-DICHLOROBENZENE	
PEBULATE.....	220
PECAZINE.....	125
PECTINASE.....	266
PEFLOXACIN	125
PEGAPTANIB	125
PEGFILGRASTIM.....	125
PEGINTERFERON.....	125
PEGVISOMANT.....	125
PEMETREXED.....	125
PEMOLINE	125
PEMPIDINE	125
PENBUTOLOL	125
PENCICLOVIR.....	52,125
PENCONAZOLE	176
PENCYCURON	266
PENDIMETHALIN.....	177
PENETHAMATE.....	125
PENICILLAMINE.....	125
PENNYROYAL OIL.....	28,220,288
PENTACHLORONITROBENZENE	
<i>See</i> QUINTOZENE	
PENTACHLOROPHENOL.....	220,242,317
PENTADECANOIC ACID	266
PENTAERYTHRITYL TETRANITRATE	125
PENTAGASTRIN	125
PENTAMETHONIUM.....	125
PENTAMIDINE	125
PENTAZOCINE.....	247,336
PENTHIENATE	125
PENTOBARBITONE.....	126,247,336
PENTOLINIUM	126
PENTOSAN POLYSULFATE SODIUM	126
PENTOXIFYLLINE.....	123

PEPAP	
<i>See</i> 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE	
PEPPERMINT OIL	266
PERACETIC ACID.....	177,221,288,318
PERFLUIDONE	221
PERGOLIDE	126
PERHEXILINE	126
PERICYAZINE	126,336
PERINDOPRIL	126
PERMANGANATES	221,288,318
PERMETHRIN.....	126,177,221
PERPHENAZINE.....	126,336
PERTUSSIS ANTIGEN	126
PESTICIDE	6
PETASITES.....	271
PETHIDINE	247,336
PETHIDINE INTERMEDIATE A	
<i>See</i> 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE	
PETHIDINE INTERMEDIATE B	
<i>See</i> 4-PHENYL-PIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER	
PETHIDINE INTERMEDIATE C	
<i>See</i> 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID	
PETROL	26,177,234,257,288
PETROLEUM OILS	
<i>See</i> HYDROCARBONS, LIQUID	
PHEDRAZINE	52
PHENACEMIDE.....	126
PHENACETIN	126
PHENADOXONE	253
PHENAGLYCODOL	126
PHENAMPROMIDE.....	253
PHENAZOCINE	253
PHENAZONE	52,126,177
PHENAZOPYRIDINE	126
PHENCYCLIDINE	253
PHENDIMETRAZINE.....	247
PHENELZINE.....	126,336
PHENETICILLIN.....	126
PHENFORMIN	126
PHENGLUTARIMIDE	126
PHENINDIONE	126
PHENIRAMINE.....	52,60,126,336
PHENISATIN.....	126
PHENISOPHAM.....	177
PHENMEDIPHAM	266
PHENMETRAZINE.....	247
PHENOBARBITONE	126,336
PHENOL	52,127,177,221,288,318
PHENOLPHTHALEIN	127

PHENOMORPHAN	253
PHENOPERIDINE	247,336
PHENOTHIAZINE	221
D-PHENOTHRIN	266
PHENOXYBENZAMINE	127
PHENOXYMETHYLPENICILLIN	127
PHENSUXIMIDE	127
PHENTERMINE	127,273
PHENTHIMENTONIUM	127
PHENTOLAMINE	127
PHENYL MERCURIC CHLORIDE	
<i>See</i> MERCURY	
PHENYLBUTAZONE	127
PHENYLENEDIAMINES	221,230,271,288,318
PHENYLEPHRINE	53,127,318
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE	253
PHENYLMERCURIC ACETATE	242,333
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-	
DIMETHANAMINE	193,288,318
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-	
DIMETHANAMINE	193,288,318
PHENYL METHYL KETONE	4,177,288
ortho-PHENYLPHENOL	177,288,318
PHENYLPHENOL	318
4-PHENYLPYPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER	247
PHENYLPROPANOLAMINE	127,318
PHENYLTOLOXAMINE	127,336
PHENYTOIN	127,318
PHOLCODINE	53,127,247,336
PHORATE	242
PHOSALONE	222
PHOSFOLAN	242
PHOSMET	222
PHOSPHIDES, METALLIC	242,333
PHOSPHINE	242,333
PHOSPHONIC ACID	177,289,318
PHOSPHORIC ACID	177,222,289,318
PHOSPHORUS	289
PHOSPHOROUS ACID	
<i>See</i> PHOSPHONIC ACID	
PHOSPHORUS (YELLOW)	242,318,324
PHOTOGRAPHIC PAPER OR FILM	257
PHOXIM	222
PHP	
<i>See</i> ROLICYCLIDINE	
ortho-PHTHALALDEHYDE	177,222,289,318
PHTHALALDEHYDE	318
PHTHALYLSULFATHIAZOLE	127
PHYSOSTIGMINE	127

PHYTASE	267
PICARIDIN	178
PICLORAM.....	267
PICOLINAFEN	267
PICRIC ACID.....	222,289,318
PICROTOXIN	127
PIGEON POX VACCINE	148
PIGMENTS	257
PILOCARPINE	127
PIMECROLIMUS	128
PIMELIC ACID.....	267
PIMINODINE.....	253
PIMOBENDAN.....	128
PIMOZIDE	128,336
PINACIDIL	128
PINDOLOL	128
PINDONE.....	222
PINE OIL.....	178,222
PINOXADEN.....	178,222
PIOGLITAZONE	128
PIPECURONIUM	128
PIPEMIDIC ACID.....	128
PIPENZOLATE.....	128
PIPERACILLIN.....	128
PIPERAZINE	53,178
PIPERIDINE.....	128
PIPERIDOLATE	128
PIPER METHYSTICUM	128
PIPERONYL BUTOXIDE	267
PIPEROPHOS	222
PIPOBROMAN	129
PIPOTHIAZINE	129
PIPRADROL	129
PIRACETAM	129
PIRBUTEROL.....	129
PIRENOXINE	129
PIRENZEPINE	129
PIRETANIDE.....	129
PIRFENOXONE SODIUM.....	129
PIRIMICARB	178,222
PIRIMIPHOS-ETHYL	223
PIRIMIPHOS-METHYL.....	223
PIRITRAMIDE.....	247
PIROXICAM.....	129
PIRPROFEN.....	129
PITUITARY	129
PIVAMPICILLIN	129
PIZOTIFEN	129,336
PLICAMYCIN	129

PMA

<i>See</i> 4-METHOXY-A-METHYLPHENYL-ETHYLAMINE	
PNEUMOCOCCAL VACCINE	129
PODOPHYLLIN	53,129,130,319,324
PODOPHYLLOTOXIN	53,60,129,319
PODOPHYLLUM EMODI	53,60,129
PODOPHYLLUM PELTATUM	53,60,130
PODOPHYLLUM RESIN	324
POISON	7,272,273,274
POLIDEXIDE	130
POLIHEXANIDE	178,319
POLIOMYELITIS VACCINE	130
POLIXETONIUM SALTS	178,223
POLOXALENE	267
POLY (GNRF) OVALBUMIN	267
POLY(OXY-1,2-ETHANEDIYL)	178
POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2- OXOETHYL]- ω -HYDROXY-,MONO-C13-15-ALKYL ETHERS	289,319
POLYACRYLAMIDE	130
POLYDADMAC	267
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE	267
POLYESTRADIOL	130
POLYETHANOXY	289
POLYETHANOXY (15) TALLOW AMINE	178,319
POLYHEDROSIS VIRUS	267
POLYLACTIC ACID	130
POLYMYXIN	130
POLYSORBATE 20	267
POLYSULFATED GLYCOSAMINOGLYCANS	130
POLYTHIAZIDE	130
POPPY STRAW CONCENTRATE	
<i>See</i> CONCENTRATE OF POPPY STRAW	
PORACTANT ALPHA	130
PORCELAIN	258
PORCINE SOMATOTROPHIN	267
POSACONAZOLE	130
POTASSIUM AZELOYL DIGLYCINATE	223
POTASSIUM BICARBONATE	267
POTASSIUM BROMATE	223,289
POTASSIUM BROMIDE	130
POTASSIUM CARBONATE	
<i>See</i> ALKALINE SALTS	
POTASSIUM CHLORATE	53,178,289
POTASSIUM CHROMATE	x
POTASSIUM CHLORIDE	130
POTASSIUM CYANATE	223,289
POTASSIUM HYDROXIDE	28,178,223,289,319
POTASSIUM METABISULPHITE	178,289,320
POTASSIUM NITRITE	178,223,242,289,320
POTASSIUM PERCHLORATE	131

POTASSIUM PERMANGANATE	
<i>See</i> PERMANGANATES	
POTASSIUM PEROXOMONOSULFATE.....	289
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT	179,223
POTASSIUM PERSULFATE	224,290,320
POTASSIUM PHOSPHATE	
<i>See</i> ALKALINE SALTS	
POTASSIUM SILICATE	
<i>See</i> ALKALINE SALTS	
POTASSIUM SORBATE.....	267
POTASSIUM SULFIDE	179,290,320
POULTRY VACCINES	148
PRACTOLOL.....	131
PRALIDOXIME.....	131
PRALLETHRIN	179,224
PRAMIPEXOLE	131
PRAMOCAINE.....	131
PRAMPINE	131
PRASTERONE.....	131
PRAVASTATIN.....	131
PRAZEPAM	131,336
PRAZQUANTEL	131,267
PRAZOSIN.....	131
PREDNISOLONE	131
PREDNISONONE	131
PREGABALIN	131,336
PREGNENOLONE	131
PRENALTEROL.....	131
PRENYLAMINE.....	131
PRILOCAINE.....	53,131
PRIMAQUINE	131
PRIMARY PACK.....	7
PRIMIDONE	131
PRINTING INKS	258,329
PROBENECID	131
PROBUCOL	131
PROCAINAMIDE.....	131
PROCAINE	131
PROCAINE PENICILLIN.....	132,224
PROCARBAZINE.....	132
PROCHLORAZ.....	224
PROCHLORPERAZINE.....	60,132,336
PROCYCLIDINE	53,132
PROCYMIDONE	242
PROFENOFOS	224
PROFOXYDIM	179
PROGESTERONE	132,179,324
PROGESTOGENS	132
PROGLUMIDE	132

PROGUANIL	132
PROHEPTAZINE.....	253
PROHEXADIONE CALCIUM	179
PROLINTANE	132
PROMACYL	224
PROMAZINE.....	132,336
PROMETHAZINE	53,60,132,336
PROMETRYN.....	179
PROMOXOLANE.....	132
PROPACHLOR.....	224
PROPAFENONE.....	132
PROPAMIDINE.....	267
PROPAMOCARB	179
PROPANIDID	132
PROPANIL.....	179
PROPANTHELINE.....	132
PROPAQUIZAFOP.....	179
PROPARGITE.....	224
PROPENTOFYLLINE.....	132
PROPERIDINE	254
PROPETAMPHOS	224
PROPETANDROL.....	132
PROPICONAZOLE.....	179,224
PROPINEB	17,224
<i>See also</i> DITHIOCARBAMATES	
PROPIONIBACTERIUM ACNES.....	132
PROPIONIC ACID.....	179,224,290,320
PROPIRAM.....	248
PROPOFOL.....	132
PROPOXUR	179,180,224
PROPRANOLOL	132,324
PROPYL ACETATES.....	267
PROPYLENE GLYCOL	267
2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER	267
PROPYLENE OXIDE.....	242
PROPYLHEXEDRINE	132
PROPYLTHIOURACIL.....	132
PROPYPHENAZONE.....	132
PROPYZAMIDE.....	180
PROQUAZONE	132
PROSCILLARIDIN.....	133
PROSTAGLANDINS.....	133
PROSTIANOL	133
PROSULFOCARB	224
PROTAMINE.....	133
PROTHIOCONAZOLE.....	267
PROTHIOFOS.....	224
PROTHIONAMIDE	133
PROTHIPENDYL	133
PROTIRELIN.....	133

PROTOVERATRINES.....	133
PROTRIPTYLINE.....	133,336
PROXYMETACAINE	133
PSEUDOEPHEDRINE.....	60,133,326
PSEUDOMONAS FLUORESCENS.....	267
PSILOCINE.....	250,254
<i>See also 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE</i>	
PSILOCYBINE	254
PSILOTSIN	250,254
<i>See also 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE</i>	
PTERIDIUM.....	271
D-PULEGONE	28,225,290
PULMONARIA.....	271
PYMETROZINE	180
PYRACLOFOS	225
PYRACLOSTROBIN.....	180
PYRAFLUFEN-ETHYL	180
PYRANTEL	54
PYRAZINAMIDE.....	133
PYRAZOPHOS	225
PYRETHRIC ACID ESTERS	180
PYRETHRINS.....	180
PYRETHROLONE.....	180
PYRIDABEN	180,225
PYRIDALYL.....	225
PYRIDATE.....	225
PYRIDINOLCARBAMATE	133
PYRIDOSTIGMINE	133
PYRIDOXAL	133
PYRIDOXAMINE.....	133
PYRIDOXINE.....	133
PYRIFENOX.....	180
PYRIMETHAMINE.....	133
PYRIMETHANIL	267
PYRINURON	242,333
PYRIPROXYFEN	267
PYRITHIOBAC SODIUM.....	180
PYRITHIONE COPPER	225
PYRITHIONE ZINC	54,225,290
PYROVALERONE	133
PYRVINIUM.....	133

Q

QUASSIA.....	267
QUATERNARY AMMONIUM COMPOUNDS.....	16,180,225,290
QUAZEPAM.....	133
QUETIAPINE.....	133,336
QUINAGOLIDE.....	134
QUINALBARBITONE	248,336

QUINAPRIL.....	134
QUINBOLONE.....	134
QUINCLORAC.....	180
QUINETHAZONE.....	134
QUINIDINE.....	134
QUININE.....	134,180,242
QUINISOCAINE.....	134
QUINOXYFEN.....	267
QUINTOZENE.....	180
QUINUPRISTIN.....	134
QUIZALOFOP-P-ETHYL.....	180,225
QUIZALOFOP ETHYL (D+ ISOMER)	
<i>See also</i> QUIZALOFOP ETHYL	
QUIZALOFOP-P-TEFURYL.....	225
QUIZALOFOP ETHYL.....	225

R

RABEPRAZOLE.....	134
RABIES VACCINE.....	134
RACEMETHORPHAN.....	254
RACEMORAMIDE.....	248
RACEMORPHAN.....	254
RACTOPAMINE.....	134,181
RADIOGRAPHIC CONTRAST MEDIA.....	258
RADIOISOTOPES.....	258
RADIOPAQUES	
<i>See also</i> RADIOGRAPHIC CONTRAST MEDIA	
RALOXIFENE.....	134
RALTITREXED.....	134
RAMIPRIL.....	134
RANITIDINE.....	54,134,320
RAPACURONIUM.....	134
RASAGILINE.....	134
RASBURICASE.....	134
RAUWOLFIA SERPENTINA.....	134
RAUWOLFIA VOMITORIA.....	134
RAZOXANE.....	134
REBOXETINE.....	134
REDUCERS.....	25
REMIFENTANIL.....	248
REMOXIPRIDE.....	134
REPAGLINIDE.....	135
REQUIRED ADVISORY STATEMENTS FOR MEDICINE LABELS.....	7
RESERPINE.....	135
RESMETHRIN.....	181,225
RESTRICTED FLOW INSERT.....	7
RETEPLASE.....	135
RIBAVIRIN.....	135
RIFABUTIN.....	135

RIFAMPICIN	135
RIFAMYCIN.....	135
RIFAPENTINE.....	135
RILUZOLE.....	135
RIMITEROL.....	135
RIMSULFURON.....	181
RISEDRONIC ACID.....	135
RISPERIDONE	135,336
RITODRINE.....	135
RITONAVIR	135
RITUXIMAB.....	135
RIVASTIGMINE.....	135
RIZATRIPTAN	135
ROBENIDINE.....	181
ROCURONIUM.....	135
ROFECOXIB.....	135
ROLICYCLIDINE.....	254
ROLITETRACYCLINE	135
ROMIFIDINE.....	135
RONIDAZOLE.....	135
ROPINIROLE.....	135
ROPIVACAINE	135
ROSEMARY OIL.....	267
<i>See</i> CAMPHOR CINEOLE	
ROSIGLITAZONE.....	136
ROSOXACIN	136
ROSUVASTATIN.....	136
ROTENONE.....	226
ROXIBOLONE	136
ROXITHROMYCIN	136
RUBELLA VACCINE	136
S	
SABADILLA.....	136
SAFROLE	226,271,290,320
SAGE OIL	28,156,196,226,290
SAGE OIL (SPANISH).....	267
<i>See also</i> CAMPHOR	
SALBUTAMOL	61,136,320
SALCATONIN.....	136
SALICYLAMIDE	54,69,124,136,320
SALICYLANILIDE	181
SALICYLIC ACID.....	61
SALINOMYCIN	136,226
SALMETEROL.....	136
SALVIA DIVINORUM.....	254
SANTONIN.....	61
SAQUINAVIR	136
SASSAFRAS OIL	226,290,320

SAVIN	271
S-BIOALLETHRIN	
<i>See</i> BIOALLETHRIN	
SCABBY MOUTH VACCINE	148
SCHOENOCAULON OFFICINALE	136
SCHRADAN	243
SCOPOLIA CARNIOLICA	136
SEAWEED & UNFRACTIONED SEAWEED-EXTRACTS	267
SECBUTOBARBITONE	248,336
SECOND SCHEDULE PAINT	7
SEEDS	258
SELAMECTIN	181
SELECTED CONTAINER.....	7
SELEGILINE	136
SELENIUM	54,61,136,226,243,320,325,328
SELENIUM COMPOUNDS	290,320
SEMDURAMICIN	227,243
SENECIO	271
SERMORELIN.....	137
SERTINDOLE.....	137
SERTRALINE.....	137
SETHOXYDIM.....	181
SEVELAMER	137
SEVOFLURANE.....	137
SEX HORMONES	137
SHUI OIL	
<i>See</i> CAMPHOR	
SIBUTRAMINE.....	137
SIDURON	181
SILANDRONE.....	137
SILDENAFIL	137
SILICOFLUORIC ACID	
<i>See</i> HYDROSILICOFLUORIC ACID	
SILICOFLUORIDES.....	181,227,290,312
SILICONES.....	137,271
SILVER	320
SILVER NITRATE	227
SILVER SALTS	54,290
SILVER SULFADIAZINE.....	137
SIMAZINE	267
SIMVASTATIN	137
SINBIOALLETHRIN.....	181,227
SINGLE-USE TUBES.....	258
SIROLIMUS.....	137
SISOMICIN.....	137
SLIMICIDES.....	256
SMELLING SALTS	304
SODIUM ALUMINATE	227,290,320
SODIUM BICARBONATE	267
SODIUM BROMATE	228,290

SODIUM BROMIDE	137
SODIUM CARBONATE	
<i>See</i> ALKALINE SALTS	
SODIUM CELLULOSE PHOSPHATE	137
SODIUM CHLORATE	181,290,320
SODIUM CLODRONATE.....	82
SODIUM CROMOGLYCAT.....	54,138
SODIUM DIACETATE	181,290
SODIUM DICHLOROISOCYANURATE	290
SODIUM 2,2-DICHLOROPROPIONATE	
<i>See</i> 2,2-DPA	
SODIUM DODECYLBENZENE SULFONATE.....	181,291,320
SODIUM FLUORIDE	321
SODIUM HYDROGEN SULFATE	181,291,321
SODIUM HYDROSULFITE.....	181,291,321
SODIUM HYDROXIDE	28,181,228,291,321
SODIUM HYPOCHLORITE	
<i>See</i> ALSO CHLORINATING COMPUNDS	
SODIUM LAURETH-6 CARBOXYLATE	182,291,321
SODIUM METABISULPHITE.....	182,291,321
SODIUM MORRHUATE	138
SODIUM NITRITE	54,182,228,243,291,321
SODIUM NITROPRUSSIDE.....	138
SODIUM OXALATE.....	x
SODIUM OXYBATE	
<i>See</i> 4-HYDROXYBUTANOIC ACID	
SODIUM PERCARBONATE	182,228,291
SODIUM PERSULFATE	228,291,321
SODIUM PHOSPHATE.....	61,138
<i>See also</i> ALKALINE SALTS	
SODIUM PICOSULFATE	61
SODIUM POLYSTYRENE SULPHONATE.....	138,182
SODIUM PROPIONATE	267
SODIUM SALICYLATE	138
SODIUM SILICATE(S)	
<i>See</i> ALKALINE SALTS	
SODIUM STANNATE.....	182,291
SODIUM SULFIDE	182,228,291,321
SODIUM TETRADECYLSULFATE	138
SODIUM TRICHLOROACETATE.....	291
SOLASODINE	138
SOLID	7
SOLIFENACIN	138
SOMATOSTATIN	138
SOMATOTROPIN,EQUINE	138,268
SOMATROPIN	138,273
SONTOQUINE.....	138
SOTALOL	138
SPARFLOXACIN	138
SPARTEINE.....	138

SPECTINOMYCIN	138
SPINOSAD	182
SPIRAMYCIN	138
SPIRAPRIL	138
SPIRONOLACTONE	138
SPIROXAMINE	228
SQUILL	54
S,S,S-TRIBUTYLPHOSPHOROTRITHIOATE	
<i>See</i> TRIBUFOS	
STABAXOL	
<i>See</i> 2,2',6,6'-TETRAISOPROPYLDIPHENYLCARBODIIMIDE	
STANOLONE	138
STANOZOLOL	138
STAPHISAGRIA	42
STAR ANISE OIL	182
STAVUDINE	138
STENBOLONE	139
STERIC ACID	268
STEROID HORMONES	139
STILBOESTROL	139
STP	
<i>See</i> 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE	
STRAMONIUM	42,85
STREPTODORNASE	139
STREPTOKINASE	139
STREPTOMYCIN	139
STRONTIUM RANELATE	139
STROPHANTHINS	139
STROPHANTHUS	139,325
STRYCHNINE	33,139,243,291,325,333
STRYCHNOS SPP	139,325
STYRAMATE	139
STYRENE	4,182,291,321
SUCRALFATE	268
SUFENTANIL	248
SULBACTAM	139
SULCOFURON	243,291,333
SULCONAZOLE	54,139
SULESOMAB	268
SULFACETAMIDE	61,139,183
<i>See also</i> SULFONAMIDES	
SULFADIAZINE	139,183
SULFADIMETHOXINE	139
SULFADIMIDINE	139,183
SULFADOXINE	139
SULFAFURAZOLE	139
SULFAGUANIDINE	139
SULFAMERAZINE	139
SULFAMETHIZOLE	139
SULFAMETHOXAZOLE	140

SULFAMETHOXYDIAZINE.....	140
SULFAMETHOXYPYRIDAZINE.....	140
SULFAMETROLE.....	140
SULFAMIC ACID.....	183,228,291,321
SULFAMONOMETHOXINE.....	140
SULFAMOXOLE.....	140
SULFAPHENAZOLE.....	140
SULFAPYRIDINE.....	140
SULFAQUINOXALINE.....	140,183
SULFASALAZINE.....	140
SULFATHIAZOLE.....	140,183
SULFATROXAZOLE.....	140
SULFINPYRAZONE.....	140
SULFLURAMID.....	228
SULFOMETURON-METHYL.....	183
SULFOMYXIN.....	140
SULFONAL.....	140
SULFONAMIDES.....	140
SULFONMETHANE.....	140
SULFOSULFURON.....	268
SULFOTEP.....	243
SULFURIC ACID.....	229,291,321
SULFURYL FLUORIDE.....	229
SULINDAC.....	140
SULPHANILAMIDE	
<i>See</i> SULFONAMIDES	
SULPHATED POLYSACCHARIDES.....	268
SULPROFOS.....	229
SULTAMICILLIN.....	140
SULTHIAME.....	140
SUMATRIPTAN.....	140
SUPROFEN.....	140
SUTILAINS.....	141
SUXAMETHONIUM.....	140,141
SUXETHONIUM.....	141
SYMPHYTUM.....	183,190,271,321

T

2,4,5-T.....	229
T-CELL RECEPTOR ANTIBODY.....	141
TACRINE.....	141
TACROLIMUS.....	141
TADALAFIL.....	141
TALLOW ALKYLAMINE ACETATES.....	229
N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE.....	229
TAMOXIFEN.....	141
TAMSULOSIN.....	141
TANACETUM VULGARE.....	141
TANNIC ACID.....	268

TANNIC ACID/BENZYL ALCOHOL-PRODUCT	268
TANSY OIL	141
TAR	
<i>See</i> PHENOL	
TAR ACIDS	229
TASONERMIN	141
TAZAROTENE	141,322
TAZOBACTAM.....	141
2,3,6-TBA.....	183
TBTO	
<i>See</i> TRI-ALKYL TIN COMPOUNDS/SALTS	
TCMTB	229
TCP	
<i>See</i> TENOCYCLIDINE	
TDE (1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE).....	183,229
TEA-TREE OIL	
<i>See</i> MELALEUCA OIL	
TEBUCONAZOLE	183
TEBUFENOZIDE	183
TEBUFENPYRAD.....	229
TEBUTHIURON.....	229
TEFLUTHRIN.....	183,243
TEGAFUR.....	141
TEGASEROD.....	141
TEICOPLANIN	141
TELITHROMYCIN.....	141
TELMISARTAN	141
TEMAZEPAM	141,336
TEMEPHOS	183,229
TEMOZOLOMIDE	141
TENECTEPLASE	141
TENIPOSIDE	141
TENOCYCLIDINE	254
TENOFOVIR.....	141
TENOXICAM	142
TEPOXALIN.....	142
TEPP.....	244
TEPRALOXYDIM.....	183
TERAZOSIN	142
TERBACIL.....	268
TERBINAFINE	54,142
TERBUCONAZOLE	
<i>See</i> TEBUCONAZOLE	
TERBUFOS	244
TERBUTALINE.....	142,322
TERBUTALINESALBUTAMOL.....	61
TERBUTHYLAZINE.....	229
TERBUTRYN	183
TERFENADINE.....	142,322
TERIPARATIDE.....	142,272

TERLIPRESSIN	142
TERMITE BARRIERS.....	258
TERODILINE.....	142
TEROPTERIN	142
TERPENES.....	291
TERPENES,CHLORINATED	229,322
TESTOLACTONE	142
TESTOSTERONE	142,229,325
TETANUS ANTITOXIN	142
TETANUS TOXOID	142
TETRABENAZINE.....	142
TETRACHLOROETHANE	244,292,322,333
TETRACHLOROETHYLENE	4,55,184,229,292,322
TETRACHLORVINPHOS.....	184
TETRACONAZOLE	184,229
TETRACOSACTRIN	142
TETRACYCLINE	142,184
TETRADIFON	229
TETRAETHYLAMMONIUM	142
TETRAHYDROCANNABINOLS	254
TETRAHYDROZOLINE	55,322
2,2',6,6' -TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE.....	230,244,333
TETRAMETHRIN	184
TETRAMISOLE.....	230
TETRAPION	
<i>See</i> FLUPROPANATE	
TETROXOPRIM	142
THALIDOMIDE	34,142,272,322
THALLIUM	33,244,333
THALLIUM SULFATE	
<i>See</i> THALLIUM	
THAUMATIN	268
THEBACON.....	248
THEBAINE	248
THENYLDIAMINE	55,61,142,143,336
THEOPHYLLINE	143
THERAPEUTIC USE.....	7
THEVETIA PERUVIANA.....	143
THEVETIN.....	143
THIABENDAZOLE	55,184
THIACETARSAMIDE.....	143
THIACLOPRID	230
THIAMBUTOSINE.....	143
THIAMETHOXAM	184,230
THIAZAFLURON.....	230
THIAZOPYR.....	184
THIAZOSULFONE.....	143
THIDIAZURON	268
THIETHYLPERAZINE	143,336
THIFENSULFURON	184

THINNERS.....	25
THIOACETAZONE.....	143
THIOBENCARB.....	184
THIOCARLIDE.....	143
2-(THIOCYANOMETHYLTHIO)BENZOTHAZOLE	
<i>See</i> TCMTB	
THIODICARB.....	184,230
THIOFANOX.....	244
THIOFENTANYL.....	254
THIOGUANINE.....	143
THIOMESTERONE.....	143
THIOMETON.....	230
THIOPENTONE.....	143
THIOPROPAZATE.....	143,336
THIOPROPERAZINE.....	143
THIORIDAZINE.....	143,336
THIOSTREPTON.....	143
THIOTEPA.....	143
THIOTHIXENE.....	143,336
THIOURACIL.....	143
THIOUREA.....	143,230, 292,322
THIRAM.....	17,225
<i>See also</i> DITHIOCARBAMATES	
THIRAM.....	17,230
THIRD SCHEDULE PAINT.....	7
THUJONE.....	28,230,292
THYME OIL.....	28,184,292
THYMOXAMINE.....	143
THYROID.....	143
THYROID STIMULATING HORMONE	
<i>See</i> THYROTROPHIN	
THYROTROPHIN.....	143
THYROTROPHIN RELEASING FACTOR	
<i>See</i> PROTIRELIN	
THYROXINE.....	144
THYROXINE SODIUM.....	325
TIAGABINE.....	144
TIAMULIN.....	144
TIAPROFENIC ACID.....	144
TIARAMIDE.....	144
TIBOLONE.....	144
TICARCILLIN.....	144
TICLOPIDINE.....	144
TIEMONIUM.....	144
TIENILIC ACID.....	144
TIGECYCLINE.....	144
TIGLOIDINE.....	144
TILETAMINE.....	144
TILIDINE.....	248
TILMICOSIN.....	144

TILUDRONIC ACID	144
TIMBER	258
TIMOLOL	144
TINIDAZOLE	144
TIN ORGANIC COMPOUNDS	244
TINTER	8
TINZAPARIN	144
TIOCARBAZIL	185
TIOCONAZOLE	55,61,144
TIOMESTERONE	143
TIOTROPIUM	144
TIPEPIDINE	144
TIPRANAVIR	144
TIRILAZAD	145
TIROFIBAN	145
TMA	
<i>See</i> 3,4,5-TRIMETHOXY-A-METHYLPHENYLETHYLAMINE	
TOBRAMYCIN	145
TOCAINIDE	145
TOLAZAMIDE	145
TOLAZOLINE	145
TOLBUTAMIDE	145
TOLCAPONE	145
TOLCLOFOS-METHYL	185
TOLFENAMIC ACID	145
ortho-TOLIDINE	244,292,333
TOLMETIN	145
TOLONIUM	145
TOLPROPAMINE	145
TOLRESTAT	145
TOLTERODINE	145
TOLTRAZURIL	185
TOLUENE	26,230,232, 292,322,328
TOLUENEDIAMINE	271, 292,322
TOLYLFLUANID	231
TOPICAL USE	8
TOPIRAMATE	145
TOPOTECAN	145
TORASEMIDE	145
TOREMIFENE	145
TOXOIDS	145
TOY	8
TOY FUELS	257
TRALKOXYDIM	185
TRAMADOL	145,336
TRAMAZOLINE	55,322
TRANDOLAPRIL	145
TRANEXAMIC ACID	61,145,322,326
TRANSDERMAL USE	8
TRANSFLUTHRIN	231

TRANLYCYPROMINE.....	145,336
TRASTUZUMAB	146
TRAVOPROST	146
TRAZODONE.....	146
TRENBOLONE.....	146,185
TREOSULPHAN.....	146
TREPROSTINIL	146
TRESTOLONE.....	146
TRETAMINE	146
TRETINOIN	34,146,273,322
TRI-ALKYL TIN COMPOUNDS.....	244
TRI-ALLATE.....	17,185
TRI-PHENYL TIN COMPOUNDS	244
TRACETYLOLEANDOMYCIN.....	146
TRIADIMEFON.....	185,231
TRIADIMENOL.....	185
TRIAMCINOLONE	55,62,146,322
TRIAMIPHOS.....	244
TRIAMTERENE	146
TRIASULFURON	268
TRIAZBUTIL.....	244
TRIAZQUONE	146
TRIAZOLAM.....	146
TRIBENURON-METHYL.....	185
TRIBUFOS.....	244
TRICHLORFON	231
TRICHLORMETHIAZIDE.....	146
TRICHLOROACETATES,ALKALINE SALTS	185
TRICHLOROACETIC ACID.....	146,185,231, 292,322
1,1,1-TRICHLOROETHANE	4,154,185, 271,292,323
TRICHLOROETHENE	
<i>See</i> TRICHLOROETHYLENE	
TRICHLOROETHYLENE.....	146,231, 292,323
TRICHLOROISOCYANURIC ACID	292,333
<i>See also</i> CHLORINATING COMPOUNDS	
TRICHLOROPHENOL.....	231,323
TRICHLORPHON	
<i>See</i> TRICHLORFON	
TRICHODERMA HARZIANUM.....	268
TRICHODESMA.....	271
TRICLABENDAZOLE	231
TRICLOFOS.....	146
TRICLOPYR	231
TRICOSENE	268
TRICYCLAMOL.....	146
TRIDEMORPH	231
TRIDIHEXETHYL	146
TRIDIPHANE	186
TRIENBOLONE	146

TRIENOLONE	146
TRIETAZINE	186
TRIETHANOLAMINE	186, 292,323
TRIETHYLENE GLYCOL	268
TRIETHYLENE THIOPHOSPHORAMIDE	
<i>See</i> THIOTEPA	
TRIETHYL PHOSPHATE	231, 292,323
TRIETHYL TIN ACETATE	
<i>See</i> TIN ORGANIC COMPOUNDS	
TRIFLOXYSTROBIN	186
TRIFLOXYSULFURON	268
TRIFLUMIZOLE	186
TRIFLUMURON	186
TRIFLUOPERAZINE	146,336
TRIFLUOROMETHANE	292
TRIFLUOROMETHANESULFONIC ACID	231,323
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE	254
TRIFLUPERIDOL	146
TRIFLUPROMAZINE	147
TRIFLURALIN	268
TRIFORINE	268
TRIIODOTHYRONINE	
<i>See</i> LIOTHYRONINE SODIUM	
TRIIISOPROPANOLAMINE LAURYL ETHER SULFATE	186,292,323
TRIMEPERIDINE	254
TRIMEPRAZINE	55,62,147,336
TRIMETAPHAN	147
TRIMETHOPRIM	147
3,4,5-TRIMETHOXY-METHYLPHENYLETHYLAMINE	254
3,4,5-TRIMETHOXYPHENETHYLAMINE	254
1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBTANE	254
TRIMETHYL TIN CHLORIDE	
<i>See</i> TIN ORGANIC COMPOUNDS	
TRIMETHYL TIN COMPOUNDS	244
TRIMIPRAMINE	147,336
TRIMUSTINE	147
TRINEXAPAC-ETHYL	186
TRIOXAUNDECANEDIOIC ACID	186
3,6,9-TRIOXAUNDECANEDIOIC ACID	323
TRIOXYSALEN	147
TRIPARANOL	271
TRIPLENNAMINE	147
TRIPLE ANTIGEN VACCINE	147
TRIPROLIDINE	55,62,147,336
TRIPROPYL TIN COMPOUNDS	
<i>See</i> TIN ORGANIC COMPOUNDS	
TRIPTORELIN	147
TRISODIUM NITRILOTRIACETATE	232
TRITICONAZOLE	186
TROGLITAZONE	147

TROMETAMOL	147
TROPICAMIDE	147
TROPISETRON	147
TROVAFLOXACIN	147
TROXIDONE	147
TRYPTOPHAN	147
TSH	
<i>See</i> THYROTROPHIN	
TUAMINOHEPTANE	55
TUBOCURARINE	147
TULATHROMYCIN	147
TULOBUTEROL	147
TURPENTINE.....	292
TURPENTINE (MINERAL)	168
TURPENTINE (VEGETABLE).....	28,186
TURPENTINE OIL	293
TUSSILAGO	271
TYLOSIN	148,187
TYMAZOLINE	55,323
TYPHOID VACCINE	148

U

ULOCLADIUM OUDEMANSII.....	268
UNICONAZOLE-P	198
UNOPROSTONE	148
URACIL	148
URAPIDIL.....	148
13C-UREA	268
UREA	268
URETHANE.....	148
UROFOLLITROPIN	148,272
UROKINASE	148
URSODEOXYCHOLIC ACID	148

V

VACCINES	148
VACCINES,VETERINARY LIVE VIRUS	148
VALACICLOVIR	148
VALDECOXIB	148
VALGANCICLOVIR.....	149
VALNOCTAMIDE	149
VALPROIC ACID.....	149
VALSARTAN	149
VAMIDOTHION.....	232
VANCOMYCIN.....	149
VARDENAFIL.....	149
VARICELLA VACCINE	149
VASOPRESSIN	149
VECURONIUM	149

VEDAPROFEN	149
VENLAFAXINE	149
VERAPAMIL	149
VERATRUM.....	149
VERNOLATE	187
VERTEPORFIN	149
VETIVER OIL.....	268
VIDARABINE	149
VIGABATRIN	149
VILOXAZINE.....	149
VINBLASTINE.....	149
VINCA ALKALOIDS	
<i>See</i> UNDER INDIVIDUAL ENTRIES	
VINCAMINE	149
VINCLOZOLIN	244,323
VINCRISTINE	149
VINDESINE	149
VINORELBINE.....	149
VINYL CHLORIDE.....	244,333
VINYL ETHER	149,268
VIPRYNIUM	
<i>See</i> PYRVINIUM	
VIRGINIAMYCIN.....	150,187
VISNADINE.....	150
VITAMIN A	150
VITAMIN D	150
VITAMIN K	268
VITREOUS ENAMELS	258
VORICONAZOLE	150
W	
WALLBOARD.....	258
WARFARIN	150,187,232
WHITE LEAD	
<i>See</i> BASIC LEAD CARBONATE	
WHITE PETROLEUM SPIRIT.....	25
<i>See also</i> HYDROCARBONS, LIQUID	
WHITE SPIRIT	293
<i>See also</i> HYDROCARBONS, LIQUID	
WHOLE BLOOD AND BLOOD COMPONENTS	258
WRITING	8
WRITING CORRECTION FLUIDS.....	185
WRITING CORRECTION PENS	258
X	
XAMOTEROL	150
XANTHINOL NICOTINATE.....	150
XANTHOPHYLL.....	268
XIMELAGATRAN	150

XIPAMIDE.....	150
XYLANASE.....	268
XYLAZINE.....	150
XYLENE.....	26,230,232,293,323,328
XYLENOLS.....	177,221,293
<i>See also</i> PHENOL	
XYLOMETAZOLINE.....	55,323

Y

YLANG YLANG OIL.....	268
YOHIMBINE.....	150

Z

ZAFIRLUKAST.....	150
ZALCITABINE.....	150
ZALEPLON.....	150
ZANAMIVIR.....	150
ZERANOL.....	151,232
ZETA-CYPERMETHRIN.....	232,244
ZIDOVUDINE.....	151
ZILPATEROL.....	151
ZIMELDINE.....	151
ZINC CHLORIDE.....	55,232,293,323
ZINC COMPOUNDS.....	151
ZINC NAPHTHENATE.....	268
ZINC P-PHENOLSULFONATE.....	232
ZINC PHOSPHIDE	
<i>See</i> PHOSPHIDES, METALLIC	
ZINC SULFATE.....	232,293,323
ZINEB.....	17,187
<i>See also</i> DITHIOCARBAMATES	
ZIPRASIDONE.....	151,336
ZIRAM.....	17,232
<i>See also</i> DITHIOCARBAMATES	
ZOLAZEPAM.....	151
ZOLEDRONIC ACID.....	151
ZOLMITRIPTAN.....	151
ZOLPIDEM.....	151,336
ZOPICLONE.....	151,336
ZOXAZOLAMINE.....	151
ZUCLOPENTHIXOL.....	151

**Part 2 – Standard for the
Uniform Scheduling of Drugs
and Poisons No. 22,
Consolidated Amendment**

**STANDARD
FOR THE
UNIFORM SCHEDULING
OF
DRUGS AND POISONS**

No. 22

CONSOLIDATED AMENDMENT

**(including Amendment No.2 and an
unchanged reprint of Amendment No.1)**



Australian Government

Department of Health and Ageing

Effective Date – Part A: 1 September 2007 (Amendment
No.1)

Part B: 1 October 2007 (Amendment No.1)

Part C: 1 January 2008 (Amendment No.2)

Part D: 1 January 2009 (Amendment No.2)

© Commonwealth of Australia 2007

ISBN 1-74186-481-X

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the:

Commonwealth Copyright Administration
Attorney-General's Department
Robert Garran Offices
National Circuit
CANBERRA ACT 2600
or at <http://www.ag.gov.au/cca>

Published by the Australian Government under the *Therapeutic Goods Act 1989*.

Publication approval number: P3-2918



Australian Government
Department of Health and Ageing

The amendments listed in this document in Parts A and B (i.e. Amendment No.1) were finalised at the February and June 2007 meetings of the National Drugs and Poisons Schedule Committee (NDPSC) except where separately specified. The amendments listed in this document in Parts C and D (i.e. Amendment No.2) were finalised at the June and October 2007 meetings of the NDPSC except where separately specified. **Please note that this consolidated amendment, incorporating both Amendment No.1 and Amendment No.2 of SUSDP 22 in a single publication, is a once off and in no way alters the standard NDPSC procedure of publishing a separate amendment after each of its meetings.**

The basis of the amendments listed in this document can be found in the 'Record of the Reasons', which can be accessed from the NDPSC website:

www.tga.gov.au/ndpsc/records.htm

Further inquiries should be directed to:

The Secretary
National Drugs and Poisons Schedule Committee
GPO Box 9848
CANBERRA ACT 2601

Or by email: NDPSC@health.gov.au

Media Liaison Unit
Australian Government Department of Health and Ageing

TABLE OF CONTENTS

PART A – EFFECTIVE DATE 1 SEPTEMBER 2007	1
PRINCIPLES OF SCHEDULING	1
PART 4 – THE SCHEDULES	2
SCHEDULE 2 – NEW ENTRIES	2
SCHEDULE 2 – AMENDMENTS	2
SCHEDULE 3 – AMENDMENTS	6
SCHEDULE 4 – NEW ENTRIES	7
SCHEDULE 4 – AMENDMENTS	7
SCHEDULE 5 – NEW ENTRY	9
SCHEDULE 5 – AMENDMENTS	9
SCHEDULE 6 – NEW ENTRIES	10
SCHEDULE 6 – AMENDMENTS	10
SCHEDULE 7 – NEW ENTRY	11
SCHEDULE 7 – AMENDMENT	11
PART 5 – APPENDICES	11
APPENDIX C – NEW ENTRY	11
APPENDIX E – PART 2 – NEW ENTRY	11
APPENDIX E – PART 2 – AMENDMENT	11
APPENDIX F – PART 3 – NEW ENTRIES	11
APPENDIX H – AMENDMENTS	12
EDITORIAL AMENDMENTS AND ERRATA	12
SCHEDULE 3 – AMENDMENT	12
SCHEDULE 4 – AMENDMENTS	12
SCHEDULE 5 – AMENDMENTS	12
SCHEDULE 6 – AMENDMENTS	13
APPENDIX H – AMENDMENT	13
PART B – EFFECTIVE DATE 1 OCTOBER 2007	14
APPENDIX H – AMENDMENT	14
PART C – EFFECTIVE DATE 1 JANUARY 2008	15
PRINCIPLES OF SCHEDULING	15
PART 1 – INTERPRETATION	16
PART 4 – THE SCHEDULES	17
SCHEDULE 2 – NEW ENTRIES	17
SCHEDULE 2 – AMENDMENT	17
SCHEDULE 3 – AMENDMENTS	18
SCHEDULE 4 – NEW ENTRIES	18
SCHEDULE 4 – AMENDMENTS	19
SCHEDULE 5 – NEW ENTRIES	20
SCHEDULE 5 – AMENDMENT	20
SCHEDULE 6 – NEW ENTRY	20
SCHEDULE 6 – AMENDMENT	21
PART 5 – APPENDICES	21
APPENDIX A – NEW ENTRY	21
APPENDIX B – AMENDMENTS	21
APPENDIX D, PART 6 – NEW ENTRY	21
APPENDIX K – NEW ENTRY	21
EDITORIAL AMENDMENTS AND ERRATA	22
SCHEDULE 2 – AMENDMENT	22

SCHEDULE 3 – AMENDMENT	22
SCHEDULE 4 – AMENDMENT	22
SCHEDULE 5 – AMENDMENT	23
APPENDIX B – AMENDMENT	23
APPENDIX F, PART 3 – AMENDMENTS	23
PART D – EFFECTIVE DATE 1 JANUARY 2009	24
PART 2 – LABELS AND CONTAINERS	24

PART A – EFFECTIVE DATE 1 SEPTEMBER 2007

Amendments to the Standard for the Uniform Scheduling of Drugs and Poisons

The National Drugs and Poisons Schedule Committee directs that the amendments below be applied to the Standard for the Uniform Scheduling of Drugs and Poisons No.22 and recommends that these amendments be adopted by the States and Territories with effect from 1 September 2007 unless otherwise stated. The amendments arise from decisions made by the Committee at its February 2007 meeting and confirmed at the June 2007 meeting except where separately specified.

PRINCIPLES OF SCHEDULING

READING THE SCHEDULES – Amend section to read:

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are now scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are being revised and replaced by individual entries as time permits although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry these have been emphasised by printing the word “except” in bold type.

Where the schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation such as pesticide registration may apply.

Where a poison has been included in more than one Schedule the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Interpretation PART 1 [paragraph 1(2)]).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a Scheduled poison relies on a balanced consideration of factors to decide if a substance

has a similar nature (e.g. structurally, pharmacologically, toxicologically) to a Scheduled poison or is readily converted (either physically or chemically) to a Scheduled poison. However, a substance is only considered a derivative of a Scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a Scheduled poison, the same scheduling requirements as the Scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using the Standard to determine the scheduling status of a poison it may be necessary to search each relevant Schedule as well as Appendices A, B and C and the Index. In this process if the poison is not found under its “approved name” it may be shown under a group term such as:

Group	Example
the parent acid of salts	“oxalic acid” to find sodium oxalate
the radical of a salt	“chromates” to find potassium chromate
the element	“arsenic” to find arsenic trioxide
a chemical group with similar toxicological or pharmacological activity	“hydrocarbons, liquid” to find kerosene
a pharmacological group	“anabolic steroidal agents” to find “androsterone”

PART 4 – THE SCHEDULES

SCHEDULE 2 – NEW ENTRIES

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.

SCHEDULE 2 – AMENDMENTS

BENZYDAMINE – amend entry to read:

BENZYDAMINE in preparations for topical use, **except** in preparations for dermal use.

BROMPHENIRAMINE – amend entry to read:

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

CHLORPHENIRAMINE – amend entry to read:

CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

DEXCHLORPHENIRAMINE – amend entry to read:

DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE – amend entry to read:

DIPHENHYDRAMINE in oral preparations:

- (a) in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
- (b) when combined with one or more other therapeutically active substances when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

DOXYLAMINE – amend entry to read:

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

(The following entry for hydrocortisone and hydrocortisone acetate was varied at the June 2007 meeting)

HYDROCORTISONE AND HYDROCORTISONE ACETATE – amend entry to read:

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human dermal use containing 0.5 per cent or less of hydrocortisone in packs containing 30 g or less of such preparations containing:

- (a) no other therapeutically active substance; or
- (b) an antifungal as the only other therapeutically active substance.

PHENIRAMINE – amend entry to read:

PHENIRAMINE:

- (a) in eye drops; or
- (b) when combined with one or more other therapeutically active substances in oral preparations when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

PROMETHAZINE – amend entries to read:

PROMETHAZINE in oral preparations:

- (a) in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
- (b) when combined with one or more other therapeutically active substances when:
 - (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 - (ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

PYRITHIONE ZINC – amend entry to read:

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

(The following entry for ranitidine was varied at the June 2007 meeting)

RANITIDINE – amend entry to read:

RANITIDINE in preparations supplied in the manufacturer's original pack containing not more than 14 days supply **except** in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 14 dosage units.

SELENIUM – amend entry to read:

SELENIUM in preparations for human therapeutic use **except**:

- (a) for topical use containing 3.5 per cent or less of selenium sulfide;
- (b) when included in Schedule 4; or
- (c) for oral use with a recommended daily dose of 150 micrograms or less.

TRIMEPRAZINE – amend entry to read:

TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

- (b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE – amend entry to read:

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

- (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
- (b) in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

SCHEDULE 3 – AMENDMENTS

(The following entry for hydrocortisone and hydrocortisone acetate was varied at the June 2007 meeting)

HYDROCORTISONE AND HYDROCORTISONE ACETATE – amend entry to read:

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations containing 1 per cent or less of hydrocortisone:

- (a) for human dermal use, in packs containing 30 g or less of such preparations; and
 - (i) containing no other therapeutically active substance; or
 - (ii) containing an antifungal but no other therapeutically active substance; or
- (b) for human rectal use, when combined with a local anaesthetic but no other therapeutically active substance **except** unscheduled astringents:
 - (i) in undivided preparations, in packs of 35 grams or less; or
 - (ii) in packs containing 12 or less suppositories,

except when included in Schedule 2.

SELENIUM – Delete entry.

TRANEXAMIC ACID – Delete entry.

SCHEDULE 4 – NEW ENTRIES

ADRAFINIL.

EXENATIDE.

GHRH INJECTABLE PLASMID.

IVABRADINE.

MEPTAZINOL.

METHYL SALICYLATE in preparations for internal therapeutic use.

NATALIZUMAB.

SITAGLIPTIN.

SORAFENIB.

SUNITINIB.

TELBIVUDINE.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

VARENICLINE.

SCHEDULE 4 – AMENDMENTS

BENZYDAMINE – amend entry to read:

BENZYDAMINE except:

- (a) when included in Schedule 2; or
- (b) in preparations for dermal use.

(The following entry for hydrocortisone was varied at the June 2007 meeting)

HYDROCORTISONE – amend entry to read:

HYDROCORTISONE:

- (a) for human use **except** when included in Schedule 2 or 3; or
- (b) for the treatment of animals.

NICOTINE – amend entry to read:

NICOTINE in preparations for human therapeutic use **except:**

- (a) when included in Schedule 2; or
- (b) for use as an aid in withdrawal from tobacco smoking in chewing gum, lozenges, or preparations for sublingual or transdermal use.

PARACETAMOL – amend entry to read:

PARACETAMOL:

- (a) when combined with aspirin, caffeine or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;
- (b) in slow release tablets or capsules containing more than 665 mg of paracetamol;
- (c) in non-slow release tablets or capsules containing more than 500 mg of paracetamol; or
- (d) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol.

PROTIRELIN – amend entry to read:

PROTIRELIN.

(The following entry for ranitidine was varied at the June 2007 meeting)

RANITIDINE – amend entry to read:

RANITIDINE **except**:

- (a) when included in Schedule 2; or
- (b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer's original pack containing not more than 14 dosage units.

(The following entry for selenium was varied at the June 2007 meeting)

SELENIUM – amend entry to read:

SELENIUM:

- (a) for human oral use with a recommended daily dose of more than 300 micrograms; or
- (b) for the treatment of animals **except**:
 - (i) when included in Schedule 6 or 7;

- (ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;
- (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;
- (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
- (v) in feeds containing 1 g/tonne or less of selenium.

TRANEXAMIC ACID – amend entry to read:

TRANEXAMIC ACID.

(The following entry for vitamin A was varied at the June 2007 Meeting)

VITAMIN A – amend entry to read:

VITAMIN A for human therapeutic or cosmetic use **except**:

- (a) in preparations for topical use containing 1 per cent or less of vitamin A;
- (b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of vitamin A per daily dose; or
- (c) in preparations for parenteral nutrition replacement.

SCHEDULE 5 – NEW ENTRY

DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.

SCHEDULE 5 – AMENDMENTS

BETACYFLUTHRIN – amend entry to read:

BETACYFLUTHRIN:

- (a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin;
or
- (b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.

METHYL SALICYLATE – amend entry to read:

METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate **except**:

- (a) in preparations for therapeutic use; or

- (b) in preparations containing 5 per cent or less of methyl salicylate.

PYRETHRINS – amend entry to read:

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids **except**:

- (a) in preparations for human therapeutic use; or
- (b) in preparations containing 10 per cent or less of such substances.

SCHEDULE 6 – NEW ENTRIES

† 5,6-DIHYDROXYINDOLINE.

† METHYL METHACRYLATE (excluding its derivatives) **except** in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

TRINITROPHENOL (excluding its derivatives) **except**:

- (a) in preparations for human therapeutic use; or
- (b) in preparations containing 5 per cent or less of trinitrophenol.

SCHEDULE 6 – AMENDMENTS

BIFENTHRIN – amend entry to read:

BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin **except** in preparations containing 0.5 per cent or less of bifenthrin.

METHYL SALICYLATE – amend entry to read:

METHYL SALICYLATE **except**:

- (a) when included in Schedule 5;
- (b) in preparations for therapeutic use; or
- (c) in preparations containing 5 per cent or less of methyl salicylate.

PYRITHIONE ZINC – amend entry to read:

PYRITHIONE ZINC **except**:

- (a) when included in Schedule 2;
- (b) in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the

	Statement	Directions
Methyl methacrylate.....	28	4,9,23
5,6-Dihydroxyindoline	21,28	

APPENDIX H – AMENDMENTS

Clobetasone – Delete entry.

Tranexamic acid – Delete entry.

EDITORIAL AMENDMENTS AND ERRATA

SCHEDULE 3 – AMENDMENT

NICOTINIC ACID – amend entry to read:

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit **except:**

- (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
- (b) nicotinamide.

SCHEDULE 4 – AMENDMENTS

DROTECOGIN – amend entry to read:

DROTRECOGIN.

METHYLANDROSTANOLONE – amend entry to read:

METHYLANDROSTANOLONE.

ORGANOPHOSPHORUS COMPOUNDS – amend entry to read:

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use **except:**

- (a) when separately specified in these Schedules; or
- (b) in preparations containing 2 per cent or less of malathion for external use.

SCHEDULE 5 – AMENDMENTS

INDOXACARB – amend entry to read:

INDOXACARB (Includes the R and S enantiomers) in preparations containing 1 per cent or less of indoxacarb.

MALDISON – amend entry to read:

MALATHION in preparations containing 10 per cent or less of malathion **except**:

- (a) for human therapeutic use; or
- (b) in dust preparations containing 2 per cent or less of malathion.

SCHEDULE 6 – AMENDMENTS

(The following Basic Orange 31 editorial amendment was a decision of the February 2007 meeting but was deferred for incorporation into SUSDP 22 Amendment 1 to come into effect on 1 Septemeber 2007)

BASIC ORANGE 31 – amend entry to read:

† BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except** in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN;

If in eyes wash out immediately with water; and

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

MALDISON – amend entry to read:

MALATHION **except**:

- (a) when included in Schedule 5;
- (b) for human therapeutic use; or
- (c) in dust preparations containing 2 per cent or less of malathion.

APPENDIX H – AMENDMENT

Nicotine – Delete entry.

PART B – EFFECTIVE DATE 1 OCTOBER 2007

Amendments to the Standard for the Uniform Scheduling of Drugs and Poisons

The National Drugs and Poisons Schedule Committee directs that the amendment below be applied to the *Standard for the Uniform Scheduling of Drugs and Poisons* No. 22 and recommends that these amendments be adopted by the States and Territories with effect from **1 October 2007**. The following amended entry for orlistat arose from a decision made by the Committee at its February 2007 meeting, originally with an effective date of 1 September 2007. The June 2007 meeting confirmed the February 2007 decision but agreed to vary the implementation date to 1 October 2007.

APPENDIX H – AMENDMENT

Orlistat – Delete entry.

PART C – EFFECTIVE DATE 1 JANUARY 2008

Amendments to the Standard for the Uniform Scheduling of Drugs and Poisons

The National Drugs and Poisons Schedule Committee directs that the amendments below be applied to the Standard for the Uniform Scheduling of Drugs and Poisons No.22 and recommends that these amendments be adopted by the States and Territories with effect from 1 January 2008 unless otherwise stated. The amendments arise from decisions made by the Committee at its June 2007 meeting and confirmed at the October 2007 meeting except where separately specified.

PRINCIPLES OF SCHEDULING

READING THE SCHEDULES – amend section to read:

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are now scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are being revised and replaced by individual entries as time permits although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry these have been emphasised by printing the word “except” in bold type.

Where the schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation such as pesticide registration may apply.

Where a schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption ('reverse scheduling'), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Interpretation PART 1 [paragraph 1(2)]).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a Scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, toxicologically) to a Scheduled poison or is readily converted (either physically or chemically) to a Scheduled poison. However, a substance is only considered a derivative of a Scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a Scheduled poison, the same scheduling requirements as the Scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using the Standard to determine the scheduling status of a poison it may be necessary to search each relevant Schedule as well as Appendices A, B and C and the Index. In this process if the poison is not found under its “approved name” it may be shown under a group term such as:

Group	Example
the parent acid of salts	“oxalic acid” to find sodium oxalate
the radical of a salt	“chromates” to find potassium chromate
the element	“arsenic” to find arsenic trioxide
a chemical group with similar toxicological or pharmacological activity	“hydrocarbons, liquid” to find kerosene
a pharmacological group	“anabolic steroidal agents” to find “androsterone”

PART 1 – INTERPRETATION

Paragraph 1.(3) – amend section to read:

- (3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a schedule or an appendix to this Standard in respect of a substance:
- (a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and
 - (b) the expression “one per cent” means:
 - (i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or

- (ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram of the substance per 100 grams of the preparation; and
 - (iii) any expression of greater or lesser percentages shall have a corresponding meaning; and
- (c) in the case of codeine such concentration, strength or quantity is calculated as anhydrous codeine.

PART 4 – THE SCHEDULES

SCHEDULE 2 – NEW ENTRIES

PROPAMIDINE for ophthalmic use.

DIBROMOPROPAMIDINE for ophthalmic use.

SCHEDULE 2 – AMENDMENT

(The following entry for paracetamol was varied at the October 2007 meeting)

PARACETAMOL – amend entry to read:

PARACETAMOL for therapeutic use **except:**

- (a) when included in Schedule 4;
- (b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when:
 - (i) enclosed in a primary pack that contains not more than 12 such powders or sachets of granules;
 - (ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
 - (iii) not labelled for the treatment of children 6 years of age or less; and
 - (iv) not labelled for the treatment of children under 12 years of age when combined with phenylephrine; or
- (c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when:
 - (i) packed in blister or strip packaging or in a container with a child-resistant closure;

- (ii) in a primary pack containing not more than 25 tablets or capsules;
- (iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
- (iv) not labelled for the treatment of children 6 years of age or less; and
- (v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.

SCHEDULE 3 – AMENDMENTS

(The following entry for promethazine was varied at the October 2007 meeting)

PROMETHAZINE – amend entry to read:

PROMETHAZINE in oral preparations **except**:

- (a) when included in Schedule 2; or
- (b) in preparations for the treatment of children under 2 years of age.

(The following entry for trimeprazine was varied at the October 2007 meeting)

TRIMEPRAZINE – amend entry to read:

TRIMEPRAZINE:

- (a) in solid oral preparations **except** when included in Schedule 2; or
- (b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL,

except in preparations for the treatment of children under 2 years of age.

SCHEDULE 4 – NEW ENTRIES

ABATACEPT.

ALISKIREN.

DARUNAVIR.

DASATINIB.

(The following entry for dibromopropamide was varied at the October 2007 meeting)

DIBROMOPROPAMIDINE for therapeutic use **except** when included in Schedule 2.

FOSAPREPITANT.

GALSULFASE.

LAPATINIB.

NEPAFENAC.

NILOTINIB.

PALIPERIDONE.

PARICALCITOL.

(The following entry for propamidine was varied at the October 2007 meeting)

PROPAMIDINE for therapeutic use **except** when included in Schedule 2.

RANIBIZUMAB.

RIMEXOLONE.

RIMONABANT.

RUBOXISTAURIN.

SITAXENTAN.

TRILOSTANE.

VILDAGLIPTIN.

SCHEDULE 4 – AMENDMENTS

LANTHANUM – amend entry to read:

LANTHANUM for therapeutic use.

MERCURIC OXIDE – delete entry.

PARACETAMOL – amend entry to read:

PARACETAMOL:

- (a) when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;
- (b) in tablets or capsules containing more than 665 mg of paracetamol; or
- (c) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol.

POTASSIUM CHLORIDE – amend entry to read:

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

- (a) when containing less than 550 mg of potassium chloride per dosage unit;
- (b) in preparations for oral rehydration therapy;
- (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
- (d) in preparations for enteral feeding.

SCHEDULE 5 – NEW ENTRIES

CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin.

PYRASULFOTOLE.

SCHEDULE 5 – AMENDMENT

HYDROCARBONS, LIQUID – amend entry to read:

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

- (a) toluene and xylene when included in Schedule 6;
- (b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;
- (c) food grade and pharmaceutical grade white mineral oils;
- (d) in solid or semi-solid preparations;
- (e) in preparations containing 25 per cent or less of designated solvents;
- (f) in preparations packed in pressurised spray packs;
- (g) in adhesives packed in containers each containing 50 grams or less of adhesive;
- (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or
- (i) in other preparations when packed in containers with a capacity of 2 mL or less.

SCHEDULE 6 – NEW ENTRY

PYRIPROLE.

SCHEDULE 6 – AMENDMENT

CLOTHIANIDIN – amend entry to read:

CLOTHIANIDIN **except** when included in Schedule 5.

PART 5 – APPENDICES

APPENDIX A – NEW ENTRY

DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as
plasma substitutes/ blood volume expanders.

APPENDIX B – AMENDMENTS

DIBROMPROPAMIDINE – delete entry.

PROPAMIDINE – delete entry.

APPENDIX D, PART 6 – NEW ENTRY

SITAXENTAN for human use.

APPENDIX K – NEW ENTRY

Paliperidone

EDITORIAL AMENDMENTS AND ERRATA

SCHEDULE 2 – AMENDMENT

HYDROCORTISONE AND HYDROCORTISONE ACETATE – amend entry to read:

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:

- (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
- (b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:
 - (i) in undivided preparations in packs of 35 g or less; or
 - (ii) in packs containing 12 or less suppositories.

SCHEDULE 3 – AMENDMENT

HYDROCORTISONE AND HYDROCORTISONE ACETATE – amend entry to read:

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:

- (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
- (b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:
 - (i) in undivided preparations, in packs of 35 g or less; or
 - (ii) in packs containing 12 or less suppositories,

except when included in Schedule 2.

SCHEDULE 4 – AMENDMENT

DIENOESTROL – amend entry to read:

DIENESTROL.

SCHEDULE 5 – AMENDMENT

LEVAMISOLE – amend entry to read:

LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals **except:**

- (a) when included in Schedule 4; or
- (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

APPENDIX B – AMENDMENT

AMINACRINE – delete entry.

APPENDIX F, PART 3 – AMENDMENTS

ETRETINATE – amend entry to read:

POISON	WARNING SAFETY STATEMENTS DIRECTIONS
---------------	---

Etretinate	7,62,76
------------------	---------

FORMIC ACID – amend entry to read:

POISON	WARNING SAFETY STATEMENTS DIRECTIONS
---------------	---

Formic acid.....	1,4,8
------------------	-------

PART D – EFFECTIVE DATE 1 JANUARY 2009

Amendments to the Standard for the Uniform Scheduling of Drugs and Poisons

The National Drugs and Poisons Schedule Committee directs that the amendment below be applied to the *Standard for the Uniform Scheduling of Drugs and Poisons* No. 23 and recommends that these amendments be adopted by the States and Territories with effect from **1 January 2009**. The following amended entry for Part 2, Paragraph 8.(2) arose from a decision made by the Committee at its June 2007 meeting.

PART 2 – LABELS AND CONTAINERS

Paragraph 8.(2) – amend section to read:

- (2) if the poison is for a purpose or purposes other than human therapeutic use and:
 - (a) if the poison is in a pressurised spray aerosol preparation, as the mass of the poison per stated mass of the preparation;
 - (b) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;
 - (c) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;
 - (d) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;
 - (e) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
 - (f) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;
 - (g) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;
 - (h) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;